Please select a day:
10.10.2012
11.10.2012
12.10.2012
13.10.2012
Search

Personal programme
Please enter your email address here in order to bring up your personal programme






Search result

Search Result: Session Chair

Wednesday, October 10, 2012

08:30 - 10:00 Auditorium Pasteur
Teaching Course 1: Meet the Professors: A case-based approach to diagnosis and management of MS
A. Miller (New York, US)
D. Bates (Newcastle, GB)
08:30 - 10:00 Salle Rhône 3
Teaching Course 2: Body fluid biomarkers
C. Teunissen (Amsterdam, NL)
J. Kuhle (Basel, CH)
08:30 - 10:00 Amphitheatre
Teaching Course 3: Disease-modifying therapy in MS - current and emerging treatment
H. Wiendl (Münster, DE)
C. Lubetzki (Paris, FR)
08:30 - 10:00 Forum 2 & 3
Teaching Course 4: Neuroinflammation, neurodegeneration, and tissue repair - in RRMS, SPMS, PPMS
W. Brück (Göttingen, DE)
C. Lucchinetti (Rochester, US)
08:30 - 10:00 Salon Pasteur
Teaching Course 5: Quantitating tissue and functional changes in MS
M. Filippi (Milan, IT)
A. Rovira (Barcelona, ES)
08:30 - 10:00 Auditorium Lumičre
Teaching Course 6: From dreams to reality: antigen-specific and stem cell therapy in MS?
K. Selmaj (Lodz, PL)
A. Uccelli (Genoa, IT)
08:30 - 10:00 Salle Rhône 2
Teaching Course 7: Molecular mechanisms of tissue injury in MS lesions
H. Lassmann (Vienna, AT)
J. van Horssen (Amsterdam, NL)
10:30 - 12:00 Auditorium Pasteur
Teaching Course 8: Issues in MS clinical trials: study design and results interpretation
M.P. Sormani (Genoa, IT)
F. Lublin (New York, US)
10:30 - 12:00 Forum 2 & 3
Teaching Course 9: Paediatric MS
B. Banwell (Toronto, CA)
C. Hemingway (London, GB)
10:30 - 12:00 Amphitheatre
Teaching Course 10: MRI in the diagnosis of MS and related disorders
N. De Stefano (Siena, IT)
M. Wattjes (Amsterdam, NL)
10:30 - 12:00 Auditorium Lumičre
Teaching Course 11: NMO: a practical approach
D. Wingerchuk (Scottsdale, US)
J. Palace (Oxford, GB)
10:30 - 12:00 Salon Pasteur
Teaching Course 12: Gender differences in MS
H. Harbo (Oslo, NO)
M. Tintoré (Barcelona, ES)
10:30 - 12:00 Salle Rhône 3
Teaching Course 13: Controversies in the natural history of multiple sclerosis
C. Confavreux (Lyon, FR)
A. Scalfari (London, GB)
12:30 - 14:00 Amphitheatre
Parallel Session 14: Late Breaking News I
T. Olsson (Stockholm, SE)
D. Laplaud (Nantes, FR)
14:00 - 15:30 Forum 2 & 3
Young Scientific Investigators’ Session I
P. Calabresi (Baltimore, US)
J. de Sčze (Strasbourg, FR)
16:00 - 17:15 Forum 2 & 3
Young Scientific Investigators’ Session II
J. Stadelmann (Göttingen, DE)
A. Siva (Istanbul, TR)
17:15 - 18:15 Amphitheatre
Satellite Symposium: Merck Serono S.A.: Get on track, stay on track: patient journeys in MS
D. Bates (Newcastle upon Tyne, GB)
P. Vermersch (Lille, FR)
N. Blanc (patients advocate) (Geneva, CH)
18:30 - 19:30 Amphitheatre
Satellite Symposium: Novartis Pharma AG: Growing global experience with once-daily oral fingolimod in MS
J. Pelletier (Marseille, FR)
M. Duddy (Newcastle, GB)

Thursday, October 11, 2012

08:30 - 10:00 Amphitheatre
Plenary Session 1: Welcome Address and ECTRIMS Lecture
M. Clanet (Toulouse, FR)
C. Confavreux (Lyon, FR)
10:30 - 12:00 Amphitheatre
Parallel Session 1: From environment to MS
G. Ebers (Oxford, GB)
M. Debouverie (Nancy, FR)
10:30 - 12:00 Auditorium Lumičre
Parallel Session 3: Adaptative and innate immunity in MS
R. Gold (Bochum, DE)
R. Liblau (Toulouse, FR)
12:45 - 13:45 Amphitheatre
Satellite Symposium: Genzyme, a Sanofi Company: MS pathophysiology and implications for treatment
C. Confavreux (Lyon, FR)
14:00 - 15:30 Forum 2 & 3
Parallel Session 4: Neurons and oligodendrocytes in MS
H. Lassmann (Vienna, AT)
P.-O. Couraud (Paris, FR)
14:00 - 15:30 Amphitheatre
Parallel Session 5: From inflammation to neurodegeneration
W. Brück (Göttingen, DE)
P. Giraudon (Lyon, FR)
14:00 - 15:30 Auditorium Lumičre
Parallel Session 6: Biology of recovery
N. Scolding (Bristol, GB)
S. Chandran (Edinburgh, GB)
15:30 - 17:00
Poster Session 1: Grey matter damage in MS
15:30 - 17:00
Poster Session 1: Economic burden
15:30 - 17:00
Poster Session 1: Pregnancy and MS
15:30 - 17:00
Poster Session 1: Databases and Pharmacoepidemiology
15:30 - 17:00
Poster Session 1: Epidemiology
15:30 - 17:00
Poster Session 1: Paediatric MS
15:30 - 17:00
Poster Session 1: Devic’s NMO spectrum
15:30 - 17:00
Poster Session 1: Diagnosis and differential diagnosis
15:30 - 17:00
Poster Session 1: MS and infections
15:30 - 17:00
Poster Session 1: Neuropsychology and fatigue
15:30 - 17:00
Poster Session 1: Immunomodulation
15:30 - 17:00
Poster Session 1: Risk management for disease modifying treatments
15:30 - 17:00
Poster Session 1: Tools for detecting therapeutic response
15:30 - 17:00
Poster Session 1: Adaptative and Innate immunology
15:30 - 17:00
Poster Session 1: Experimental models
15:30 - 17:00
Poster Session 1: Comprehensive care and rehabilitation
17:00 - 17:45 Auditorium Lumičre
Hot Topic 3: Temporal changes in MS epidemiology
P. De Jager (Boston, US)
M. Pugliatti (Sassari, IT)
17:00 - 17:45 Amphitheatre
Hot Topic 1: Devic's neuromyelitis optica spectrum
J. Palace (Oxford, GB)
D. Wingerchuk (Scottsdale, US)
17:00 - 17:45 Forum 2 & 3
Hot Topic 2: PML and IRIS
T. Weber (Hamburg, DE)
H. Wiendl (Münster, DE)
18:00 - 19:00 Auditorium Lumičre
Satellite Symposium: Almirall:
MS spasticity symptoms management.
Endocannabinoid system modulator data beyond clinical trials
M. Trojano (Bari, IT)
19:15 - 20:15 Amphitheatre
Satellite Symposium: Teva Pharmaceutical Industries: New concepts in MS pathology shed light on MS treatment approaches
R. Gold (Bochum, DE)

Friday, October 12, 2012

09:15 - 10:15 Auditorium Lumičre
Free Communications III: Platform presentation of selected abstracts on fatigue and cognition
E. Havrdová (Prague, CZ)
D. Karussis (Jerusalem, IL)
09:15 - 10:15 Forum 2 & 3
Free Communications II: Platform presentation of selected abstracts on MS disease evolution
J. Hillert (Stockholm, SE)
M. Tintoré (Barcelona, ES)
09:15 - 10:15 Amphitheatre
Free Communications I: Platform presentation of selected abstracts on therapy and clinical trials
J. Wolinsky (Houston, US)
E. Wassmer (Birmingham, GB)
10:45 - 12:15 Auditorium Lumičre
Parallel Session 9: From databases and cohorts to pharmaco-epidemiology
M. Trojano (Bari, IT)
M. Clanet (Toulouse, FR)
10:45 - 12:15 Forum 2 & 3
Parallel Session 8: From natural to treated history
J. Rio (Barcelona, ES)
P. Soelberg Sorensen (Copenhagen, DK)
10:45 - 12:15 Amphitheatre
Parallel Session 7: Beyond clinical monitoring of progression in MS
C. Pozzilli (Rome, IT)
F. Cotton (Lyon, FR)
12:45 - 13:45 Forum 2 & 3
Satellite Symposium: Bayer HealthCare: Novel performance measures for early and long-term gains
P. Vermersch (Lille, FR)
14:00 - 15:30 Auditorium Lumičre
Parallel Session 10: Pregnancy
J. Nogales (Santiago, CL)
H. Tremlett (Vancouver, CA)
14:00 - 15:30 Amphitheatre
Parallel Session 12: Disease-modifying treatments
G. Comi (Milan, IT)
G. Edan (Rennes, FR)
15:30 - 17:00
Poster Session 2: Tools for detecting therapeutic response
15:30 - 17:00
Poster Session 2: Diagnosis and differential diagnosis
15:30 - 17:00
Poster Session 2: Devic’s NMO spectrum
15:30 - 17:00
Poster Session 2: Paediatric MS
15:30 - 17:00
Poster Session 2: Epidemiology
15:30 - 17:00
Poster Session 2: Databases and Pharmacoepidemiology
15:30 - 17:00
Poster Session 2: Pregnancy and MS
15:30 - 17:00
Poster Session 2: Economic burden
15:30 - 17:00
Poster Session 2: Grey matter damage in MS
15:30 - 17:00
Poster Session 2: Experimental models
15:30 - 17:00
Poster Session 2: Adaptative and Innate immunology
15:30 - 17:00
Poster Session 2: MS and infections
15:30 - 17:00
Poster Session 2: Neuropsychology and fatigue
15:30 - 17:00
Poster Session 2: Immunomodulation
15:30 - 17:00
Poster Session 2: Risk management for disease modifying treatments
15:30 - 17:00
Poster Session 2: Comprehensive care and rehabilitation
17:00 - 17:45 Amphitheatre
Hot Topic 6: Symptomatic treatments
B. Brochet (Bordeaux, FR)
A. Thompson (London, GB)
17:00 - 17:45 Forum 2 & 3
Hot Topic 5: Paediatric MS
M. Tardieu (Paris, FR)
A. Ghezzi (Gallarate, IT)
17:00 - 17:45 Auditorium Lumičre
Hot Topic 4: Imaging and cognition
A. Feinstein (Toronto, CA)
F. Fazekas (Graz, AT)
18:00 - 19:00 Amphitheatre
Satellite Symposium: Biogen Idec: Committed to MS
C. Confavreux (Lyon, FR)


Search Result: Abstracts

Wednesday, October 10, 2012

08:30 - 10:00 Meet the Professors: A case-based approach to diagnosis and management of MS (Auditorium Pasteur)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 Body fluid biomarkers (Salle Rhône 3)
Future use of biomarkers in daily clinical practice 4
F. Sellebjerg (Copenhagen, DK)
08:30 - 10:00 Disease-modifying therapy in MS - current and emerging treatment (Amphitheatre)
First-line therapies (ABCR drugs) 5
H. Wiendl (Münster, DE)
08:30 - 10:00 Disease-modifying therapy in MS - current and emerging treatment (Amphitheatre)
Monoclonal antibodies 6
C. Lubetzki (Paris, FR)
08:30 - 10:00 Disease-modifying therapy in MS - current and emerging treatment (Amphitheatre)
Oral drugs 7
L. Kappos (Basel, CH)
08:30 - 10:00 Neuroinflammation, neurodegeneration, and tissue repair - in RRMS, SPMS, PPMS (Forum 2 & 3)
Inflammation and degeneration in MS 10
W. Brück (Göttingen, DE)
08:30 - 10:00 Quantitating tissue and functional changes in MS (Salon Pasteur)
Fibre tracts and functionality 12
O. Ciccarelli (London, GB)
08:30 - 10:00 From dreams to reality: antigen-specific and stem cell therapy in MS? (Auditorium Lumičre)
Antigen specific therapy of MS 14
K. Selmaj (Lodz, PL)
08:30 - 10:00 From dreams to reality: antigen-specific and stem cell therapy in MS? (Auditorium Lumičre)
Autologous haematopoetic stem cells for the treatment of MS 16
D. Karussis (Jerusalem, IL)
08:30 - 10:00 Molecular mechanisms of tissue injury in MS lesions (Salle Rhône 2)
Interplay of free radicals and mitochondrial dysfunction in MS 18
J. van Horssen (Amsterdam, NL)
08:30 - 10:00 Molecular mechanisms of tissue injury in MS lesions (Salle Rhône 2)
Amplification of oxidative damage in MS brain by iron 19
H. Lassmann (Vienna, AT)
08:30 - 10:00 Body fluid biomarkers (Salle Rhône 3)
Basic introduction on biomarkers in body fluids 2
C. Teunissen (Amsterdam, NL)
08:30 - 10:00 Meet the Professors: A case-based approach to diagnosis and management of MS (Auditorium Pasteur)
A case-based approach to diagnosis and management of MS 1
A. Miller, D. Bates (New York, US; Newcastle, GB)
08:30 - 10:00 Body fluid biomarkers (Salle Rhône 3)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 Disease-modifying therapy in MS - current and emerging treatment (Amphitheatre)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 Molecular mechanisms of tissue injury in MS lesions (Salle Rhône 2)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 From dreams to reality: antigen-specific and stem cell therapy in MS? (Auditorium Lumičre)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 Quantitating tissue and functional changes in MS (Salon Pasteur)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 Neuroinflammation, neurodegeneration, and tissue repair - in RRMS, SPMS, PPMS (Forum 2 & 3)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 Controversies in the natural history of multiple sclerosis (Salle Rhône 3)
Relapses and long-term disability accumulation 35
A. Scalfari (London, GB)
10:30 - 12:00 Gender differences in MS (Salon Pasteur)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 MRI in the diagnosis of MS and related disorders (Amphitheatre)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 Paediatric MS (Forum 2 & 3)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 Issues in MS clinical trials: study design and results interpretation (Auditorium Pasteur)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 Issues in MS clinical trials: study design and results interpretation (Auditorium Pasteur)
Statistical issues and results interpretation in MS clinical trials 20
M.P. Sormani (Genoa, IT)
10:30 - 12:00 Issues in MS clinical trials: study design and results interpretation (Auditorium Pasteur)
Surrogate outcomes for immunomodulation and neuroprotection 22
J. Wolinsky (Houston, US)
10:30 - 12:00 Paediatric MS (Forum 2 & 3)
Environmental and genetic factors in paediatric MS 23
B. Banwell (Toronto, CA)
10:30 - 12:00 Paediatric MS (Forum 2 & 3)
Relapse severity, recovery and progression in paediatric MS 24
E. Waubant (San Francisco, US)
10:30 - 12:00 Paediatric MS (Forum 2 & 3)
Acute disseminated encephalomyelitis in children and MS 25
C. Hemingway (London, GB)
10:30 - 12:00 MRI in the diagnosis of MS and related disorders (Amphitheatre)
Lesion characteristics in MS: brain and spinal cord 26
M. Wattjes (Amsterdam, NL)
10:30 - 12:00 MRI in the diagnosis of MS and related disorders (Amphitheatre)
The ''Radiologically Isolated Syndrome'' 27
N. De Stefano (Siena, IT)
10:30 - 12:00 Controversies in the natural history of multiple sclerosis (Salle Rhône 3)
Emerging concepts from natural history studies: an overview 37
C. Confavreux (Lyon, FR)
10:30 - 12:00 NMO: a practical approach (Auditorium Lumičre)
Pathogenesis of NMO 29
K. Fujihara (Sendai, JP)
10:30 - 12:00 NMO: a practical approach (Auditorium Lumičre)
NMO diagnostic criteria: are they really so distinct in clincal practice? 30
D. Wingerchuk (Scottsdale, US)
10:30 - 12:00 Gender differences in MS (Salon Pasteur)
Genetic aspects and gender differences in disease onset and progression 32
H. Harbo (Oslo, NO)
10:30 - 12:00 Gender differences in MS (Salon Pasteur)
Effects of sex hormones, the menstrual cycle and pregnancy on MS 33
M. Tintoré (Barcelona, ES)
10:30 - 12:00 Gender differences in MS (Salon Pasteur)
Gender differences in the immune system and response to immunotherapy 34
R. Gold (Bochum, DE)
10:30 - 12:00 Controversies in the natural history of multiple sclerosis (Salle Rhône 3)
Age, prognosis and the MS disease course 36
H. Tremlett (Vancouver, CA)
10:30 - 12:00 MRI in the diagnosis of MS and related disorders (Amphitheatre)
Pitfalls in diagnosing ''active MS'' 28
C. Enzinger (Graz, AT)
10:30 - 12:00 Controversies in the natural history of multiple sclerosis (Salle Rhône 3)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 NMO: a practical approach (Auditorium Lumičre)
Please download the Teaching Course Manuscript here by clicking on this link
12:30 - 12:45 Late Breaking News I (Amphitheatre)
The MS-STAT trial: high dose simvastatin demonstrates neuroprotection without immune-modulation in secondary progressive multiple sclerosis (SPMS) – a phase II trial 38a
J. Chataway, A. Alsanousi, D. Chan, D. MacManus, K. Hunter, J. Foster, C. Bangham, D. Wilkie, J. Nicholas, S. Clegg, C. Nielsen, N. Scheurer, V. Calder, J. Greenwood, C. Frost, R. Nicholas (London, Brighton, GB)
12:45 - 13:00 Late Breaking News I (Amphitheatre)
Induction of immune tolerance by autologous peptide-coupled cells – a phase I trial in relapsing-remitting and secondary-progressive multiple sclerosis patients 38b
A. Lutterotti, S. Yousef, A. Sputtek, K.H. Stürner, J.-P. Stellmann, P. Breiden, S. Reinhardt, C. Schulze, M. Bester, C. Heesen, S. Schippling, S. Miller, M. Sospedra, R. Martin (Innsbruck, AT; Hamburg, Hamburg-Eppendorf, DE; Zurich, CH; Chicago, US)
13:00 - 13:15 Late Breaking News I (Amphitheatre)
Defective sphingosine-1-phosphate receptor 1 (S1PR_1) internalization exacerbates autoimmune neuroinflammation by enhancing Stat3-mediated Th17 polarization 39a
C.S. Garris, S. Acharya, R. Axtell, D. Lewis, R.A. Sobel, L. Steinman, T. Hla, M.H. Han (Stanford, US)
13:15 - 13:30 Late Breaking News I (Amphitheatre)
A novel autoantigen in neuromyelitis optica spectrum disorders 39b
J.S. Tzartos, C. Stergiou, K. Kilintireas, P. Zisimopoulou, T. Thomaidis, S.J. Tzartos (Athens, Patras, GR)
13:30 - 13:45 Late Breaking News I (Amphitheatre)
Association of MRI metrics and clinical relapses to explain long-term disability changes in relapsing multiple sclerosis 40a
A. Giorgio, M.P. Sormani, M.L. Stromillo, M.L. Bartolozzi, F. Rossi, M. Battaglini, A. De Leucio, L. Guidi, P. Maritato, E. Portaccio, M.P. Amato, A. Federico, N. De Stefano (Siena, Genoa, Empoli, Florence, IT)
13:45 - 14:00 Late Breaking News I (Amphitheatre)
Gene expression profiling study in multiple sclerosis patients responders and non-responders to treatment with glatiramer acetate 40b
M. Comabella, N. Fissolo, R. Nurtdinov, J. Río, C. Tur, J. Sastre-Garriga, X. Montalban (Barcelona, ES)
14:00 - 14:15 Young Scientific Investigators’ Session I (Forum 2 & 3)
Multi-contrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical grey matter with 3D fluid-attenuated inversion recovery 42
I.D. Kilsdonk, W.L. de Graaf, A. Lopez Soriano, J.J. Zwanenburg, F. Visser, J.P.A. Kuijer, J.J.G. Geurts, P.J.W. Pouwels, C.H. Polman, J.A. Castelijns, P.R. Luijten, F. Barkhof, M.P. Wattjes (Amsterdam, Utrecht, NL)
14:15 - 14:30 Young Scientific Investigators’ Session I (Forum 2 & 3)
Neuromyelitis optica spectrum disorder and multiple sclerosis can be distinguished on the basis of MRI brain lesion characteristics 43
L.A.E. Matthews, R. Marasco, M. Jenkinson, W. Kuker, M.I. Leite, A. Giorgio, N. De Stefano, S. Luppe, N. Robertson, H. Johansen-Berg, N. Evangelou, J. Palace (Oxford, GB)
14:30 - 14:45 Young Scientific Investigators’ Session I (Forum 2 & 3)
Rodent models of neuromyelitis optica based on pathogenicity of engineered anti-aquaporin-4 ‘NMO superantibodies’ with enhanced effector functions 44
J. Ratelade, N. Asavapanumas, P. W. Phuan, S. Wemlinger, A. Ritchie, J. L. Bennett, A. S. Verkman (San Francisco, Aurora, US)
14:45 - 15:00 Young Scientific Investigators’ Session I (Forum 2 & 3)
A novel retinal phenotype in multiple sclerosis is predictive of inflammatory disease activity and disability progression 45
S. Saidha, E. Sotirchos, M. Ibrahim, J. Gelfand, Y. Sepah, J. Ratchford, J. Oh, M. Seigo, S. Newsome, L. Balcer, E. Frohman, C. Crainiceanu, A. Green, Q. Nguyen, P. Calabresi (Baltimore, San Francisco, Philadelphia, Dallas, US)
15:00 - 15:15 Young Scientific Investigators’ Session I (Forum 2 & 3)
Impaired decision-making in MS and grey matter diffusion orientational complexity 46
N. Muhlert, V. Sethi, M. Ron, L. Cipolotti, G. Parker, H. Haroon, T.A. Yousry, C.A. Wheeler-Kingshott, D.H. Miller, D.T. Chard (London, Manchester, GB)
15:15 - 15:30 Young Scientific Investigators’ Session I (Forum 2 & 3)
Relation of cerebellar volume to performance in cognitive tests in patients with multiple sclerosis 47
K. Weier, I.K. Penner, S. Magon, M. Amann, Y. Naegelin, N. Mueller-Lenke, A. Beck, M. Andelova, T. Derfuss, E.-W. Radue, C. Stippich, L. Kappos, T. Sprenger (Basel, CH; Langenfeld, DE)
16:00 - 16:15 Young Scientific Investigators’ Session II (Forum 2 & 3)
Axonal damage in inflammatory demyelinating lesions of paediatric patients 48
S. Pfeifenbring, R.F. Bunyan, I. Metz, C.F. Lucchinetti, W. Brück (Göttingen, DE; Dammam, SA; Rochester, US)
16:15 - 16:30 Young Scientific Investigators’ Session II (Forum 2 & 3)
Analysis of HLA classical alleles and derived amino acids identifies independent effects in several DRB1 and non-DRB1 classical alleles 49
N.A. Patsopoulos, L. Barcellos, C. Schaefer, R.Q. Hintzen, P.L. De Jager, P.I.W. de Bakker on behalf of ANZgene, GeneMSA, IMSGC
16:30 - 16:45 Young Scientific Investigators’ Session II (Forum 2 & 3)
Role of the chemokine CCL2 in T-cell tolerance and protection from experimental autoimmune encephalomyelitis 50
O. Cédile, M. Lřbner, H. Toft-Hansen, T. Owens (Odense, DK)
16:45 - 17:00 Young Scientific Investigators’ Session II (Forum 2 & 3)
MCAM is expressed by IL-17-producing T-lymphocytes and regulates their entry in the CNS 51
C. Larochelle, J. Alvarez, H. Kebir, M.-A. Lécuyer, R. Cayrol, O. Saint-Laurent, J. Poirier, P. Duquette, N. Arbour, A. Prat (Montreal, CA)
17:00 - 17:15 Young Scientific Investigators’ Session II (Forum 2 & 3)
Endoplasmatic reticulum stress responses: mechanisms of oligodendrocyte stress in the cuprizone model for multiple sclerosis 52
J. Goldberg, M. Victor, B. Krauspe, S. Diederichs, S. Amor, P. van der Valk, T. Clarner, C. Beyer, M. Kipp (Aachen, DE; Amsterdam, NL)
17:20 - 17:35 Merck Serono S.A.: Get on track, stay on track: patient journeys in MS (Amphitheatre)
Starting on the right track 53
M.S. Freedman (Ottawa, CA)
17:35 - 17:55 Merck Serono S.A.: Get on track, stay on track: patient journeys in MS (Amphitheatre)
Staying the course: benefits of long-term therapy adherence 54
V. Devonshire (Vancouver, CA)
17:55 - 18:10 Merck Serono S.A.: Get on track, stay on track: patient journeys in MS (Amphitheatre)
Tracking outcomes: new imaging techniques 55
P. Gallo (Padua, IT)
18:30 - 19:30 Novartis Pharma AG: Growing global experience with once-daily oral fingolimod in MS (Amphitheatre)
Initiating treatment with fingolimod 56
B. Singer (St. Louis, US)
18:30 - 19:30 Novartis Pharma AG: Growing global experience with once-daily oral fingolimod in MS (Amphitheatre)
Growing evidence for the benefit–risk profile of treatment with fingolimod 57
H.-P. Hartung (Düsseldorf, DE)
18:30 - 19:30 Novartis Pharma AG: Growing global experience with once-daily oral fingolimod in MS (Amphitheatre)
The evolving role of fingolimod in MS treatment 58
M. Duddy (Newcastle, GB)

Thursday, October 11, 2012

08:30 - 09:00 Welcome Address and ECTRIMS Lecture (Amphitheatre)
Welcome 60
Welcome to Lyon
F.-N. Gilly, Lyon (FR)
President of Claude Bernard Lyon 1 University

Welcome to Lyon
C. Confavreux (Lyon, FR)

The ECTRIMS Society
M. Clanet (Toulouse, FR)

09:00 - 10:00 Welcome Address and ECTRIMS Lecture (Amphitheatre)
ECTRIMS Lecture
Biotherapies in MS: hopes and threats
61
H.-P. Hartung (Düsseldorf, DE)
10:30 - 10:50 Adaptative and innate immunity in MS (Auditorium Lumičre)
The effects of Vitamin D on the adaptive immune system (T and B cells) in relation to clinical manifestations in MS 72
R.M. Hupperts, J. Smolders, J. Damoiseaux (Sittard-Geleen, NL)
10:30 - 10:50 From environment to MS (Amphitheatre)
From infections to MS 62
R. Du Pasquier (Lausanne, CH)
10:30 - 10:50 From genetics to MS (Forum 2 & 3)
From the genes to MS 67
J.S. Sawcer (Cambridge, GB)
10:50 - 11:10 From environment to MS (Amphitheatre)
From physico-chemical agents exposure to MS 63
S. Ramagopalan (London/Oxford, GB)
10:50 - 11:10 From genetics to MS (Forum 2 & 3)
Expectations from omics in MS 68
D. Brassat (Toulouse, FR)
10:50 - 11:10 Adaptative and innate immunity in MS (Auditorium Lumičre)
Microglia and monocytes: kith or kin? 73
R.M. Ransohoff (Cleveland, US)
11:10 - 11:25 From genetics to MS (Forum 2 & 3)
Genetic differences relating to oligoclonal band status in multiple sclerosis 69
I.-L. Mero, M. W. Gustavsen, H. Sćther, S. Flĺm, H.B. Sřndergaard, P.E.H. Jensen, T. Berge, A. Bjřlgerud, A. Muggerud, J.H. Aarset, K.-M. Myhr, E.G. Celius, F. Sellebjerg, J. Hillert, L. Alfredsson, T. Olsson, A.B. Oturai, I. Kockum, B.A. Lie, B. Kulle, H.F. Harbo (Oslo, NO; Copenhagen, DK; Bergen, NO; Stockholm, SE)
11:10 - 11:25 From environment to MS (Amphitheatre)
An age at exposure effect in the association between sun exposure and the risk of MS in Norway and Italy. The EnvIMS study 64
K. Bjřrnevik, T. Riise, K. Wesnes, E. Granieri, I. Casetta, J. Drulovic, K.M. Myhr, K. Lauer, M. Kampman, S. Magalhaes, T. Pekmezovic, T. Holmřy, A.M. Landtblom, C. Wolfson, M. Pugliatti (Bergen, NO; Ferrara, IT; Belgrade, RS; Griesheim, DE; Tromsř, NO; Montreal, CA; Oslo, NO; Linköping, SE; Sassari, IT)
11:10 - 11:25 Adaptative and innate immunity in MS (Auditorium Lumičre)
The potassium channel KIR4.1 as an immune target in multiple sclerosis 74
R. Srivastava, M. Aslam, R Kalluri, L. Schirmer, D. Buck, B. Tackenberg, V. Rothhammer, A. Chan, R. Gold, A. Berthele, J. Bennett, T. Korn, B. Hemmer (Munich, Marburg, Bochum, DE; Denver, US)
11:25 - 11:40 From genetics to MS (Forum 2 & 3)
ICAM3 expression level integrates the effects of six MS susceptibility alleles: dissecting a molecular cascade relevant to MS susceptibility 70
T. Raj, M. Kuchroo, B. Keenan, L. Ottoboni, X. Hu, S. Raychaudri, P. De Jager (Boston, US)
11:25 - 11:40 Adaptative and innate immunity in MS (Auditorium Lumičre)
Immune reconstitution after autologous haematopoietic stem cell transplantation for aggressive relapsing-remitting MS 75
J. Burman, J. Fagius, T.H. Tötterman, M. Fransson, S.M. Mangsbo, A.S.I. Loskog (Uppsala, SE)
11:25 - 11:40 From environment to MS (Amphitheatre)
Smoking is a potentially modifiable risk factor for all causes of mortality in patients with multiple sclerosis 65
A. Manouchehrinia, M. Weston, C. Constantinescu (Nottingham, GB)
11:40 - 11:55 From genetics to MS (Forum 2 & 3)
A pharmacogenetic study on Italian, US and French MS patients reveals an SLC9A9 variant as a novel marker of response to interferon-beta 71
F. Esposito, E. Lim, M. Romeo, M. Rodegher, M. Sorosina, P. Brambilla, N.A. Patsopoulos, B. Keenan, V. Martinelli, D. Brassat, G. Comi, F. Martinelli Boneschi, P.L. De Jager (Milan, IT; Boston, US; Toulouse, FR)
11:40 - 11:55 From environment to MS (Amphitheatre)
Cytomegalovirus seropositivity is associated with lower multiple sclerosis risk 66
E. Sundqvist, T. Bergström, H. Daialhosein, P. Sundström, J. Hillert, L. Alfredsson, I. Kockum, T. Olsson (Stockholm, Gothenburg, Umeĺ, SE)
11:40 - 11:55 Adaptative and innate immunity in MS (Auditorium Lumičre)
Encephalitogenic and non-encephalitogenic T-Cell epitopes of aquaporin-4 76
P. Nelson, M. Varrin-Doyer, C. Spencer, S. Sagan, R. Sobel, J. Bennett, S. Zamvil (San Francisco, Palo Alto, Denver, US)
12:50 - 13:05 Genzyme, a Sanofi Company: MS pathophysiology and implications for treatment (Amphitheatre)
Role of lymphocytes in the pathogenesis of MS 77
H. Wiendl (Münster, DE)
13:05 - 13:35 Genzyme, a Sanofi Company: MS pathophysiology and implications for treatment (Amphitheatre)
MS immunomodulation: experiences with B- & T-lymphocyte targeting agents 78
G. Comi, G. Giovannoni (Milan, IT; London, GB)
14:00 - 14:20 Neurons and oligodendrocytes in MS (Forum 2 & 3)
Neurons in MS 79
D. Mahad (Edinburgh, GB)
14:00 - 14:20 From inflammation to neurodegeneration (Amphitheatre)
From focal inflammation to neurodegeneration 84
F. Zipp (Mainz, DE)
14:00 - 14:20 Biology of recovery (Auditorium Lumičre)
Sodium channels in MS 89
M. Craner (Oxford, GB)
14:20 - 14:40 Neurons and oligodendrocytes in MS (Forum 2 & 3)
Oligodendrocytes in MS 80
T. Kuhlmann (Münster, DE)
14:20 - 14:40 From inflammation to neurodegeneration (Amphitheatre)
From diffuse inflammation to neurodegeneration 85
D. Merkler (Geneva, CH)
14:20 - 14:40 Biology of recovery (Auditorium Lumičre)
Remyelination 90
C. Lubetzki (Paris, FR)
14:40 - 14:55 Biology of recovery (Auditorium Lumičre)
Dosing regimen impacts in vitro effects of FTY720 on human astrocyte proliferation, IL1b-induced Ca2+ mobilisation, and miRNA-155 expression 91
C. Wu, C.S. Moore, S. Leong, T.A. Johnson, T.E. Kennedy, P. Séguéla, A. Bar-Or, J.P. Antel (Montreal, CA)
14:40 - 14:55 Neurons and oligodendrocytes in MS (Forum 2 & 3)
Differential roles for the small heat shock protein Alpha B-Crystallin in cuprizone-induced de- & remyelination 81
H.F. Kuipers, J. Yoon, J. Vister, T.D. Palmer, L. Steinman (Stanford, US)
14:40 - 14:55 From inflammation to neurodegeneration (Amphitheatre)
Periplaques form extensive lesions in multiple sclerosis spinal cords 86
A. Lhuillier, M. Chanal, G. Androdias, R. Reynolds, C. Confavreux, S. Nataf (Lyon, FR; London, GB)
14:55 - 15:10 Biology of recovery (Auditorium Lumičre)
New enhancers of endogenous remyelination: an extensive in vitro and ex vivo screening 92
C. Eleuteri, C. Veroni, R. Umeton, V. Annibali, G. Ristori, M. Salvetti, C. Agresti (Rome, IT)
14:55 - 15:10 Neurons and oligodendrocytes in MS (Forum 2 & 3)
Early disruption of astrocytic connexins in multiple sclerosis, Baló’s disease and neuromyelitis optica 82
K. Masaki, S.O. Suzuki, T. Matsushita, T. Matsuoka, M. Suzuki, T. Suenaga, T. Tabira, T. Iwaki, J. Kira (Fukuoka, Hamamatsu, Tenri, Tokyo, JP)
14:55 - 15:10 From inflammation to neurodegeneration (Amphitheatre)
Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions 87
T. Clarner, F. Diederichs, K. Berger, B. Denecke, L. Gan, P. van der Valk, C. Beyer, S. Amor, M. Kipp (Aachen, DE; Amsterdam, NL)
15:10 - 15:25 Neurons and oligodendrocytes in MS (Forum 2 & 3)
Heterogeneity of cortical remyelination in multiple sclerosis 83
E.M.M. Strijbis, E.J. Kooi, P. van der Valk, C.H. Polman, J.J.G. Geurts (Amsterdam, NL)
15:10 - 15:25 From inflammation to neurodegeneration (Amphitheatre)
Preventing neurodegeneration in neuroinflammation – an in vivo two-photon imaging approach 88
V. Siffrin, R. Gollan, J. Birkenstock, M. Paterka, F. Zipp (Mainz, DE)
15:10 - 15:25 Biology of recovery (Auditorium Lumičre)
Krüppel-like factor-6 is required for oligodendrocyte maturation and CNS myelination 93
L. Asp, E. Kramer, Y.-M. Lee, J. Zhang, X. Pedre, A.T. Argaw, J. Liu, D. Dutta, E. Zaslavsky, D. Braun, T. Pham, G. Narla, C. Raine, P. Casaccia, S. Friedman, G. John (New York, Bronx, US)
15:30 - 17:00 Paediatric MS
Safety of adult doses of subcutaneous interferon-beta-1a in children and adolescents with multiple sclerosis: results of the REPLAY study P 220
A. Ghezzi, D. Pohl, B. Banwell, L.B. Krupp, A. Boyko, M. Meinel, L. Lehr, M. Stam Moraga, S. Tenembaum on behalf of the REPLAY Study Group
15:30 - 17:00 Comprehensive care and rehabilitation
ALLIANCE: evaluation of interruption to care in multiple sclerosis P 581
C. Donzé, L. Malapel, A. Kwiatkowski, B. Lenne, P. Louchard, V. Neuville, P. Hautecoeur (Lomme, Lille, Dunkerque, Maubeuge, FR)
15:30 - 17:00 Devic’s NMO spectrum
The characteristics of Sjögren’s syndrome in patients with anti-aquaporin4-antibody positive neuromyelitis optica spectrum disorder P 210
D.K. Lee, J.H. Min, B.J. Kim, M.S. Park, S.J. Lee, J.H. Park, K.H. Lee (Seoul, KR)
15:30 - 17:00 Immunomodulation
Siponimod (BAF312) treatment leads to early MRI benefits in relapsing-remitting multiple sclerosis patients: results from a phase 2 study P 494
D.K.B. Li, B. Hemmer, O. Stüve, H.-P. Hartung, M.S. Freedman, P. Rieckmann, X. Montalban, L. Zhang-Auberson, H. Pohlmann, E. Wallström, K. Selmaj, L. Kappos (Vancouver, CA; Munich, DE; Dallas, US; Düsseldorf, DE; Ottawa, CA; Bamberg, DE; Barcelona, ES; Basel, CH; Lodz, PL)
15:30 - 17:00 Comprehensive care and rehabilitation
Cerebellar-parietal dysfunctions in multiple sclerosis patients with cerebellar signs P 580
G. Mangone, A. Cerasa, P. Valentino, R. Nisticň, D. Pirritano, M.C. Gioia, C. Chiriaco, P. Perrotta, V. Vaiti, M. Trotta, T. Talarico, G. Bilotti, A. Quattrone (Catanzaro, IT)
15:30 - 17:00 Diagnosis and differential diagnosis
The comparison of McDonald 2005, McDonald 2010 and Swanton criteria for prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis P 187
B. Piri Cinar, S. Ozakbas (Izmir, TR)
15:30 - 17:00 Diagnosis and differential diagnosis
MRI parameters of cortical pathology identify patients at high risk of conversion to MS and increase the specificity of the new diagnostic criteria P 181
M. Calabrese, C. Romualdi, V. Poretto, D. Seppi, A. Favaretto, M. Puthenparampil, S. Alessio, P. Perini, P. Gallo (Padua, IT)
15:30 - 17:00 Risk management for disease modifying treatments
Efficacy analysis of disease-modifying treatments in more than 9000 German patients with MS P 544
M. Mäurer, P. Knorn, G. Niemczyk, P. Schickmaier, K. Rehberg-Weber, C. Wernsdörfer, S. Schwab for the TYPIC Study
15:30 - 17:00 Biomarkers
Decreased circulating miRNAs in patients with multiple sclerosis P 614
C. Fenoglio, E. Ridolfi, C. Cantoni, M. De Riz, A. Pietroboni, M. Serpente, C. Villa, R. Bonsi, N. Bresolin, L. Piccio, A.H. Cross, D. Galimberti, E. Scarpini (Milan, IT; St. Louis, US)
15:30 - 17:00 Databases and Pharmacoepidemiology
Fingolimod (Gilenya®) compassionate use in patients with relapsing-remitting multiple sclerosis in France in 2011 - Population description P 259
K. Rerat, C. Gerbeau, F. Heintzmann, I. Bourdeix, M.-S. Behier on behalf of the fingolimod ATU GROUP FRANCE
15:30 - 17:00 Risk management for disease modifying treatments
Utilization of JC-virus antibody testing in clinical practice P 546
T. Berger on behalf of CETAB (Central European Tysabri Advisory Board)
15:30 - 17:00 Comprehensive care and rehabilitation
Effects of 24 weeks progressive resistance training in comparison to core and stability training performed in groups on muscle performance, balance and spasticity in people with multiple sclerosis P 578
C. Jolk, R. Alcantara, L. Bernhardt, P. Platen, M. Marziniak, K. Weßling (Münster, Bochum, DE)
15:30 - 17:00 Neuroprotection
BG-12 is neuroprotective in the murine cuprizone/rapamycin model of demyelination and neurodegeneration P 504
R.H. Scannevin, B. Bai, R. Huang, S. Medicetty, B. Trapp, K.J. Rhodes (Weston, Cleveland, US)
15:30 - 17:00 Epidemiology
A new method to identify multiple sclerosis patients with a high risk for secondary progression P 254
H. Tedeholm, B. Skoog, B. Runmarker, A. Oden, O. Andersen (Gothenburg, SE)
15:30 - 17:00 Risk management for disease modifying treatments
Immunomodulatory treatment of relapsing-remitting multiple sclerosis – the ASSET (AVONEX Assessment in Multiple Sclerosis-Therapy)-study, an observational study in 1343 patients P 547
M. Marziniak, T. Graf, G. Niemczyk, K. Rehberg-Weber, C. Wernsdörfer for the ASSET Study Group
15:30 - 17:00 Diagnosis and differential diagnosis
Study of cerebrospinal fluid in neuromyelitis optica. Analysis and correlation with multiple sclerosis in a series of cases of Rio de Janeiro, Brazil P 192
V. Carvalho Neri, C.O. Brandao, M. Papais Alvarenga, C. Cristina Ferreira Vasconcelos, S. Camargo, E. Baptista, R.M. Papais Alvarenga (Rio de Janeiro, BR)
15:30 - 17:00 Imaging
Increased microglial activation in the brain of secondary progressive multiple sclerosis patients - a [11C]PK11195 PET study P 424
E. Rissanen, J. Tuisku, T. Paavilainen, S. Helin, R. Parkkola, J.O. Rinne, L. Airas (Turku, FI)
15:30 - 17:00 Neuropsychology and fatigue
Alexithymia in multiple sclerosis is associated with callosal atrophy P 444
F. Reuter, N. Moll, W. Zaaraoui, A. Rico, I. Malikova, P. Cozzone, J.P. Ranjeva, B. Audoin, J. Pelletier (Marseille, FR)
15:30 - 17:00 Neuro-ophthalmology
Uveitis in patients with multiple sclerosis P 595
E. Shugaiv, M. Kurtuncu, M. Mutlu, G. Akman-Demir, I. Tugal-Tutkun, E. Tuzun, M. Eraksoy (Istanbul, TR)
15:30 - 17:00 Epidemiology
The epidemiology of MS in Iceland, 1900 – 2000 P 251
S. Sveinbjornsdottir, H. Magnusson, J. Benedikz (Chelmsford, GB; Oslo, NO; Reykjavik, IS)
15:30 - 17:00 Treatment of specific symptoms
Effectiveness of Sativex® in multiple sclerosis spasticity. First data from a large observational study in Germany P 568
U. Zettl, T. Henze, C. Pfiffner, C. Vila Silvan, P. Flachenecker (Rostock, Nittenau, Munich, DE; Barcelona, ES; Bad Wildbad, DE)
15:30 - 17:00 Neurobiology
Neurodegeneration in the retina precedes manifest experimental optic neuritis P 377
R. Fairless, S.K. Williams, D.B. Hoffmann, A. Stojic, S. Hochmeister, F. Schmitz, M.K. Storch, R. Diem (Heidelberg, Homburg/Saar, DE; Graz, AT)
15:30 - 17:00 Immunomodulation
Natalizumab exerts direct signalling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis P 474
T.F. Benkert, L. Dietz, E.M. Hartmann, E. Leich, A. Rosenwald, E. Serfling, M. Buttmann, F. Berberich-Siebelt (Würzburg, DE)
15:30 - 17:00 Imaging
Six-year follow-up of a case-series with non-communicating syringomyelia in multiple sclerosis P 417
K. Weier, Y. Naegelin, M. Amann, S. Magon, M. Andelova, N. Mueller-Lenke, E.W. Radue, L. Kappos, C. Stippich, A. Gass, T. Sprenger (Basel, CH)
15:30 - 17:00 Risk management for disease modifying treatments
Progressive desensitization of the heart prevents first dose effects: guinea pig study with ponesimod, a selective S1P1 receptor modulator P 543
B. Steiner, M. Rey, P. Hess (Allschwil, CH)
15:30 - 17:00 Natural history
Does multiple sclerosis in Korea differ from that in the Caucasian populations? P 232
S.-H. Kim, W. Kim, S.-Y. Huh, S.J. Lee, A.-R. Joung, H. J. Kim (Goyangsi, KR)
15:30 - 17:00 MS and infections
qPCR versus two-step ELISA to detect JC virus in natalizumab-treated patients P 364
M.I. Domínguez-Mozo, M. García-Montojo, V. De las Heras, M.A. García-Martínez, A. Arias-Leal, I. Casanova, R. Arroyo, R. Álvarez-Lafuente (Madrid, ES)
15:30 - 17:00 Neuro-ophthalmology
Microcystic macular oedema in neuromyelitis optica P 599
J.M. Gelfand, B.A. Cree, P. Calabresi, E. Frohman, L. Balcer, R. Nolan, A.J. Green (San Francisco, Baltimore, Dallas, Philadelphia, US)
15:30 - 17:00 Neuropsychology and fatigue
Anxiety and depression in MS: short-term evolution and relationship with cognitive and clinical variables P 448
T. Olivares, Y. Pérez, M. Betancort, A. Nieto, J. Barroso, M. González-Platas, M.A. Hernández (La Laguna, ES)
15:30 - 17:00 Biomarkers
The effects of intrathecal rituximab on biomarkers in MS P 617
J. Topping, E. Evdoshenko, R. Dobson, S. Lapin, A. Maslyanskiy, G. Giovannoni (London, GB; Saint-Petersburg, RU)
15:30 - 17:00 Immunomodulation
Plasma exchange in acute central nervous system inflammatory demyelinating diseases P 495
J. Chateauraynaud, M. Deloire, A. Ruet, B. Brochet, J.C. Ouallet (Bordeaux, FR)
15:30 - 17:00 Long-term treatment monitoring
Baseline predictors of mortality in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS-15 study P 521
P. Cornelisse, L. Lehr, F. Baldinetti (Geneva, CH)
15:30 - 17:00 Neuropsychology and fatigue
Multivariate analysis of clinical, behavioural and psychological influences on fatigue and cognition in patients with relapsing-remitting multiple sclerosis P 436
H. Schreiber, C. Lang, K. Kiltz, M. Lang, P. Flachenecker, H. Meissner, M. Freidel, H. Herbst, E. Scholz, W. Hofmann, E. Schlegel, W. Elias, K. Gehring, U. Eckhardt, A. Bergmann, G. Reifschneider, S. Ries, C. Ring, S. Schlegel on behalf of the NTD Study Group on Multiple Sclerosis
15:30 - 17:00 Neuropsychology and fatigue
Neuroimaging, psychosocial, and demographic determinants of subjective and objective cognitive function in MS P 452
H.E. Hulst, K. Gehring, B.M.J. Uitdehaag, L.H. Visser, C.H. Polman, F. Barkhof, M.M. Sitskoorn, J.J.G. Geurts (Amsterdam, Tilburg, NL)
15:30 - 17:00 Natural history
Male MS patients fare worse! P 230
K.A. Ribbons, P. McElduff, S. Vetere, C. Boz, M. Trojano, C. Zwanikken, A. Lugaresi, G. Izquierdo, P. Duquette, M. Girard, F. Grand'Maison, P. Grammond, C. Oreja-Guevara, R. Hupperts, T. Petersen, R. Bergamaschi, G. Guiliani, M. Barnett, V. Van Pesch, M.P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, E. Cristiano, R. Fernandez-Bolanos, M.L. Saladino, M.E. Rio, W. Oleschko Arruda, J. Cabrera-Gomez, M. Paine, N. Vella, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, H. Butzkueven, J.S. Lechner-Scott on behalf of the MS Base Group
15:30 - 17:00 Diagnosis and differential diagnosis
Comparison of McDonald 2005 and 2010 criteria in a cohort of clinically isolated syndrome patients P 183
A. Enderle, H. Zephir, J. Salleron, O. Outteryck, A.S. Berteloot, M. Giroux, P. Vermersch (Lille, FR)
15:30 - 17:00 Immunomodulation
Efficacy, safety and tolerability of Atorvastatin in patients with Relapsing-remitting multiple sclerosis in treAtment with INterferoN-betA (ARIANNA): a multicentre, randomised, double-blind, placebo-controlled, parallel-group-study P 477
V. Brescia Morra, B. Alfano, R. Lanzillo, M. Quarantelli, M. Comerci, S. Marini, G. Vacca, M.P. Amato, M. Trojano, A. Brunetti, C. Pozzilli (Naples, Rome, Florence, Bari, IT)
15:30 - 17:00 MS symptoms
Spasticity in MS patients: prevalence and demographics in Australia P 270
C. Taylor, D. Silva, C. Skulina, H. Butzkueven on behalf of the MS Base Australian Investigators
15:30 - 17:00 Comprehensive care and rehabilitation
Improved autonomy and self-efficacy in people with multiple sclerosis after Can Do Training with Partners P 573
P. Jongen, R. Ruimschotel, M. Heerings, L. Duyverman, L. Visser, J. Vissers, H. Wolper, A. Hussaarts, M. van Droffelaar, G. Borm, A. Van der Zande (Nijmegen, Rotterdam, Maassluis, Tilburg, NL)
15:30 - 17:00 Imaging
Brain lesion location and cognitive impairment in relapsing multiple sclerosis P 403
F. Rossi, A. Giorgio, M. Battaglini, M.L. Stromillo, E. Portaccio, B. Goretti, B. Hakiki, A. Federico, M.P. Amato, N. De Stefano (Siena, IT)
15:30 - 17:00 Clinical assessment tools
Quick screening of cognitive function in MS patients using 5 min Montreal cognitive assessment subtests: a pilot study P 284
G. Kumar, D. Kaur, A.K. Singh (New Delhi, Patna, IN)
15:30 - 17:00 Immunosuppression
Rituximab in secondary-progressive MS: a two-year retrospective analysis P 499
C. Ionete, C. Perrone, B. Barton, M. Diiulio, P. Riskind (Worcester, US)
15:30 - 17:00 Neuro-ophthalmology
Bedside tested ocular movement disorders in multiple sclerosis patients P 597
G. Servillo, S. Bastide, D. Renard, P. Labauge, M. Zorzon, G. Castelnovo (Trieste, IT; Nimes, Montpellier, FR)
15:30 - 17:00 Long-term treatment monitoring
Phase III FREEDOMS study extension: long-term safety of fingolimod (FTY720) in relapsing-remitting multiple sclerosis P 523
P. O'Connor, C. Polman, R. Hohlfeld, K. Selmaj, T. Olsson, C. Agoropoulou, F. Holdbrook, L. Zhang-Auberson, P. von Rosenstiel, L. Kappos (Toronto, CA; Amsterdam, NL; Munich, DE; Lodz, PL; Stockholm, SE; Basel, CH)
15:30 - 17:00 Biology of recovery
BLBP-expression in astrocytes is an important variable for endogenous remyelination P 381
M. Kipp, R. Bazinet, G. Eckert, S. Gingele (Aachen, DE; Toronto, CA; Frankfurt, DE)
15:30 - 17:00 Long-term treatment monitoring
The switch from interferon-beta to natalizumab treatment is more effective in patients with relapsing forms of multiple sclerosis when administered early during the disease course P 515
A. Lourbopoulos, V. Giantzi, E. Chatzikyriakou, E. Liaptsi, N. Tascos, N. Grigoriadis (Thessaloniki, GR)
15:30 - 17:00 Immunomodulation
Multicentre clinical trial phase I/II randomised, placebo-controlled study to evaluate safety and feasibility of therapy with two different doses of autologous mesenchymal stem cells in patients with SPMS who do not respond to treatment P 493
O. Fernandez, G. Izquierdo, M. Guerrero, G. Navarro, A. Leon, M.J. Pinto-Medel, M.D. Paramo, D. Pozo, L. Leyva, P. Galvez (Malaga, Sevilla, ES)
15:30 - 17:00 Biomarkers
BG-12 pharmacodynamic responses have distinct temporal profiles and are dose dependent P 615
M.N. Shackett, H. Patel, M.Y. Jung, S. Ryan, M. Lukashev, P. Bista, K.J. Rhodes, R.H. Scannevin (Weston, US)
15:30 - 17:00 Diagnosis and differential diagnosis
Are the clinically isolated syndrome days over? P 189
B. Canneti, I. Palmí, V. Meca Lallana, J. Vivancos (Madrid, ES)
15:30 - 17:00 Biomarkers
Proteomic analysis: identification of candidate protein biomarkers in the CSF and serum samples of patients with clinically different multiple sclerosis subtypes P 607
T. Avsar, U. Uygunoglu, M. Tütüncü, N.O. Demirci, S. Saip, A. Siva, E. Tahir Turanli (Istanbul, TR)
15:30 - 17:00 Tools for detecting therapeutic response
Cerebrospinal fluid biomarkers as outcome measures in clinical trials of MS: The significance of post lumbar puncture headaches P 550
A. Davis, R. Dobson, M. Espasandin, G. Giovannoni, K. Schmierer (London, GB)
15:30 - 17:00 Quality of life
Subcutaneous interferon-beta-1a discontinuation rates are diminished for treatment-naive patients using RebiSmart P 591
K. Giles, J. Morin, G. Stoyanov, P. Moriarty (Cambridge, Mississauga, CA)
15:30 - 17:00 Quality of life
Health-related quality of life in elderly patients with MS P 590
M.B. Buhse, W.B. Banker, L.C. Clement (Stony Brook, Honeoye Falls, US)
15:30 - 17:00 Immunomodulation
Relapses requiring intravenous steroid use and MS-related hospitalisations: findings from the phase 3 DEFINE and CONFIRM studies P 490
E. Havrdova, R. Gold, R.J. Fox, L. Kappos, M. Kita, M. Yang, R. Zhang, K.T. Dawson, V. Viglietta, S.I. Sheikh, G. Giovannoni (Prague, CZ; Bochum, DE; Cleveland, US; Basel, CH; Seattle, Weston, US; London, GB)
15:30 - 17:00 Treatment of specific symptoms
PR-fampridine and improvement of walking: it’s clinically meaningful in daily practice P 572
M. Prugger, T. Berger (Innsbruck, AT)
15:30 - 17:00 Genetics / transcriptomics
Association of genetic markers with the presence of cerebrospinal fluid oligoclonal bands in the Italian population P 342
N. Barrizzone, M.A. Leone, F. Esposito, A. Lucenti, H.F. Harbo, A. Goris, I. Kockum, A.B. Oturai, E.G. Celius, I.L. Mero, B. Dubois, T. Olsson, H.B. Sřndergaard, D. Cusi, S. Lupoli, F. Guerini, D. Galimberti, M. Salvetti, G. Liberatore, V. Martinelli, P. Naldi, K.-M. Myhr, R. Bergamaschi, G. Comi, F. Martinelli Boneschi, S. D'Alfonso (Novara, Milan, IT; Oslo, NO; Leuven, BE; Stockholm, SE; Copenhagen, DK; Rome, IT; Bergen, NO; Pavia, IT)
15:30 - 17:00 Tools for detecting therapeutic response
Effects of BG-12 on a marker of Nrf2 pathway activation: pharmacodynamic results from the phase 3 DEFINE and CONFIRM studies P 554
L. Amaravadi, S. Gopal, R. Gold, R.J. Fox, A. Mikulskis, M. Lukashev, J. Kong, M. Stephan, K.T. Dawson (Weston, US; Bochum, DE; Cleveland, US)
15:30 - 17:00 Quality of life
Measurement of quality of life in patients with relapsing forms of multiple sclerosis: the CoMPaRe study P 589
L. Lee, F. Moore, B. Vickrey, K. Fortin (Toronto, Montreal, CA; Los Angeles, US)
15:30 - 17:00 Adaptative and Innate immunology
Antibodies against native myelin oligodendrocyte glycoprotein in adult multiple sclerosis patients P 354
N. Sanderson, M. Ricklin, C. Pfaff, Y. Naegelin, P. de Jager, T. Sprenger, J. Kuhle, K. Dornmair, R.L.P. Lindberg, L. Kappos, T. Derfuss (Basel, CH; Boston, US; London, GB; Munich, DE)
15:30 - 17:00 Epidemiology
Significant increase in prevalence of multiple sclerosis in Iran, review of literatures and report of new rates P 246
S. Izadi, A. Nikseresht, M. Sharifian Dorche, A. Rezaianzadeh (Shiraz, IR)
15:30 - 17:00 Imaging
Diffusion tensor imaging evidence of abnormal white matter integrity in very early onset paediatric MS P 418
M. Sonkin, M.A. Rocca, E. Pagani, M. Copetti, M. Absinta, B. Banwell, J.G. Sled, D.L. Arnold, S. Narayanan, D.L. Collins, M. Filippi (Toronto, CA; Milan, Foggia, IT; Montreal, CA)
15:30 - 17:00 Grey matter damage in MS
The grey matter basis of disability progression in multiple sclerosis P 319
M. Calabrese, V. Poretto, A. Favaretto, D. Seppi, S. Alessio, F. Rinaldi, P. Perini, P. Gallo (Padua, IT)
15:30 - 17:00 Biomarkers
Antiphospholipid antibodies in multiple sclerosis: a pathogenetic or epiphenomenal role? P 612
T. Koudriavtseva, P. Cordiali-Fei, G. D'Agosto, E. Onesti, E. Sbardella, E. Trento, F. Ensoli (Rome, IT)
15:30 - 17:00 Devic’s NMO spectrum
Aquaporin-4-specific T-cells in neuromyelitis optica exhibit a Th17 bias and recognise Clostridium ABC transporter P 202
M. Varrin-Doyer, C.M. Spencer, U. Schulze-Topphoff, P.A. Nelson, R.M. Stroud, B.A.C. Cree, S.S. Zamvil (San Francisco, US)
15:30 - 17:00 Epidemiology
The low prevalence of multiple sclerosis in Maori is not responsible for the latitude gradient in New Zealand P 245
S. Alla, J. Pearson, G. Clarke, B. Taylor, D. Mason (Christchurch, NZ; Tasmania, AU)
15:30 - 17:00 Neuropsychology and fatigue
Low-contrast visual acuity and near visual acuity is associated with cognitive and physical performance in relapsing-remitting and secondary-progressive multiple sclerosis P 434
T. Feaster (Wayne, US)
15:30 - 17:00 Immunomodulation
Clinical response to glatiramer acetate correlates with an increase in activated and memory CD45RA-Foxp3+CD4+ T-cells P 492
S. Dhib-Jalbut, S. Boppana, R. Valenzuela, O. Khan, K. Ito (New Brunswick, Detroit, US)
15:30 - 17:00 Imaging
Early diffuse brain tissue injury predicts disability ten years later in RRMS patients P 423
A. Ruet, M. Deloire, J.C. Ouallet, V. Dousset, B. Brochet (Bordeaux, FR)
15:30 - 17:00 Clinical assessment tools
Detection and quantification of efficiency and quality of gait impairment in multiple sclerosis through foot path analysis P 295
R. Phan-Ba, S. Pierard, G. Moonen, M. Vandroogenbroeck, S. Belachew (Ličge, BE)
15:30 - 17:00 Diagnosis and differential diagnosis
Impaired cerebrovascular reactivity in multiple sclerosis measured with hypercapnia perfusion magnetic resonance imaging P 179
Y. Ge, Y. Zhou, H. Lu, F. Xu, I. Kister, H. Jaggi, J. Herbert, R. Grossman (New York City, Dallas, US)
15:30 - 17:00 MS symptoms
Gabapentin for spasticity in multiple sclerosis – lack of efficacy data using the Wartenburg’s Pendulum test P 267
B. Waddell, K. Grieve, P. Walker, J. O'Riordan (Dundee, GB)
15:30 - 17:00 Clinical assessment tools
Speed of recovery after multiple sclerosis relapses P 282
K. Kannel, H. Maamägi, K. Taalfeld, M. Toots, M. Siiro, K. Kallaste, L. Vahter, T. Saarup, K. Rohulaid, I. Zopp, A. Aaso, A. Reitsnik, U. Sorro, K. Gross-Paju (Tallinn, EE)
15:30 - 17:00 MS symptoms
Hidden symptoms of multiple sclerosis increase with patient age P 265
G.H. Kraft, D. Amtmann, K. Johnson, V. Weir, A. Verrall (Seattle, US)
15:30 - 17:00 Neuropsychology and fatigue
Long-term effects of cognitive rehabilitation in multiple sclerosis: 12-month follow-up P 440
A. Altinkaya, I. Guclu, E. Kurt, A. Bingol, A. Soysal, D. Yandim-Kuscu, D. Kirbas, B. Topcular (Istanbul, TR)
15:30 - 17:00 MS and infections
Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial P 362
L. Kappos, D. Li, P. Calabresi, P. O’Connor, A. Bar-Or, F. Barkhof, C. Wells, D. Leppert, D. Masterman, J. Tinbergen, S.L. Hauser (Basel, CH; Vancouver, CA; Baltimore, US; Toronto, Montreal, CA; Amsterdam, NL; Welwyn Garden City, GB; San Francisco, US)
15:30 - 17:00 Risk management for disease modifying treatments
Asymptomatic non-tuberculous mycobacteriosis as an opportunistic infection in a subject treated with natalizumab for relapsing-remitting multiple sclerosis – case report P 535
P. Hradilek, I. Tudik, O. Zapletalova, I. Woznicova, D. Zeman (Ostrava, Jablunkov, CZ)
15:30 - 17:00 Neurophysiology
Altered functional connectivity in multiple sclerosis is related to thalamus atrophy, cognition and clinical status P 427
P. Tewarie, M.M. Schoonheim, C.J. Stam, M.L. van der Meer, B.W. van Dijk, F. Barkhof, C.H. Polman, A. Hillebrand (Amsterdam, NL)
15:30 - 17:00 Pathology
Local T-cell infiltration is associated with subpial cortical demyelination and retinal ganglion cell activation in marmosets with experimental autoimmune encephalomyelitis P 310
C. Wegner, K. Neid, M. Ton, E. Fuchs, W. Brück (Göttingen, DE)
15:30 - 17:00 Databases and Pharmacoepidemiology
The “Immunomodulation and Multiple Sclerosis Epidemiology” (IMSE II) study; A Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of fingolimod (Gilenya®) P 261
N. Nordin, C. Holmen, J. Hillert, T. Olsson (Stockholm, SE)
15:30 - 17:00 Genetics / transcriptomics
Polymorphisms in TRAIL and TRAIL receptor genes and response to IFN-beta P 345
C. Lopez-Gomez, A. Pino-Angeles, J.A. García-León, M.J. Pinto-Medel, B. Oliver-Martos, J. Ortega-Pinazo, M. Suardíaz, L. García-Trujillo, C. Marín-Bańasco, T. Órpez-Zafra, R. Maldonado-Sánchez, C. Guijarro-Castro, J. Varadé, E. Urcelay, Ó. Fernández, L. Leyva (Málaga, Madrid, ES)
15:30 - 17:00 Immunomodulation
Effects on heart rate of three different up-titration regimens of ponesimod, a selective S1P1 receptor modulator, and of re-initiation of treatment in healthy male and female subjects P 468
P. Brossard, D. D'ambrosio, M. Ipak, J. Dingemanse (Allschwil, CH; Berlin, DE)
15:30 - 17:00 Long-term treatment monitoring
Long-term comparison of fingolimod with interferon-beta-1a: results of 4.5-year follow-up from the extension phase III TRANSFORMS study P 517
X. Montalban, F. Barkhof, G. Comi, H.-P. Hartung, L. Kappos, B. Khatri, J. Pelletier, K. Tiel-Wilck, F. Holdbrook, E. Kornyeyeva, T. Stites, P. von Rosenstiel, J. Cohen (Barcelona, ES; Amsterdam, NL; Milan, IT; Düsseldorf, DE; Basel, CH; Milwaukee, US; Marseille, FR; Berlin, DE; East Hanover, US; Cleveland, US)
15:30 - 17:00 Experimental models
Maternal neurofascin-specific autoantibodies have no long term effect on CNS development P 326
S. Hochmeister, T. Pekar, M. Kitic, M.K. Storch, F. Fazekas, C. Linington (Graz, Vienna, AT; Glasgow, GB)
15:30 - 17:00 Pathology
Megalin receptor: an important player in the pathogenesis of multiple sclerosis and blood-brain barrier abnormalities P 308
M.C. Ortega, D. Clemente, F. de Castro (Toledo, ES)
15:30 - 17:00 Neuro-ophthalmology
Cholesterol affects retinal nerve fibre layer thickness in MS patients with optic neuritis P 598
A. Kardys, B. Weinstock-Guttman, M. Dillon, M. Masud, N. Weinstock, N. Mahfooz, J. Lang, A. Weinstock, N. Lincoff, R. Zivadinov, M. Ramanathan (Buffalo, US)
15:30 - 17:00 MS symptoms
Early cognitive impairment in multiple sclerosis P 269
F. Gampourou, P. Clavelou (Clermont-Ferrand, FR)
15:30 - 17:00 MS symptoms
The burden of multiple sclerosis-related spasticity on indirect costs and requirement for non-professional care: results of a cross-sectional study in the USA P 263
R. Schapiro, D. Wynn, D. Lissin, A. AL-Sabbagh, E. Jones, J. Pike (Eagle, Northbrook, Santa Clara, US; Macclesfield, GB)
15:30 - 17:00 Neuropsychology and fatigue
Speed of presentation affects recall of medication and disease information in relapsing-remitting multiple sclerosis P 447
S. LLoyd, E. Silber, D. Langdon (London, GB)
15:30 - 17:00 Grey matter damage in MS
Classification by location of cortical grey matter lesions studied using phase sensitive inversion recovery P 314
V Sethi, T. Yousry, N. Muhlert, M. Ron, X. Golay, C. Wheeler-Kingshott, D. Miller, D. Chard (London, GB)
15:30 - 17:00 Epidemiology
Patient reports of unmet needs in multiple sclerosis P 250
M. Ponzio, S. Traversa, V. Berio, M. Messmer Uccelli, M.A. Battaglia (Genoa, Siena, IT)
15:30 - 17:00 MS symptoms
Onset of multiple sclerosis-related spasticity and its impact on health-related quality of life as measured by EQ-5D and HAQUAMS P 264
D. Wynn, R. Schapiro, A. AL-Sabbagh, D. Lissin, E. Jones, J. Pike (Northbrook, Eagle, Santa Clara, US; Macclesfield, GB)
15:30 - 17:00 Imaging
Improving the detection of spinal cord atrophy in multiple sclerosis: evaluation of methodologies at six-month follow-up P 394
H. Kearney, M.C. Yiannakas, K. Abdel-Aziz, C.A.M. Wheeler-Kingshott, O. Ciccarelli, D.H. Miller (London, GB)
15:30 - 17:00 Economic burden
Impact of the frequency of multiple sclerosis relapses on the direct and indirect cost burden of family caregivers P 303
H. Parisé, F. Laliberté, P. Lefebvre, M.S. Duh, E. Kim, N. Agashivala, S. Abouzaid, B. Weinstock-Guttman (Montréal, CA; Boston, East Hanover, Buffalo, US)
15:30 - 17:00 MS symptoms
Sustained improvement in urinary incontinence and quality of life with onabotulinumtoxin A regardless of baseline EDSS score in MS patients with neurogenic detrusor overactivity P 273
M. Tullman, P. Denys, B. Jenkins, AJ Joshi, J. Zhou, I. Yushmanova, C. Fowler (St. Louis, US; Garches, FR; Irvine, US; London, GB)
15:30 - 17:00 Adaptative and Innate immunology
CD6 expression on lymphocytes correlates with MRI gadolinium-enhancing lesions in multiple sclerosis patients P 358
A. Jurewicz, K. Zaleski, B. Szymanska, K. Wodz, M. Domowicz, H. Cwiklinska, K. Selmaj (Lodz, PL)
15:30 - 17:00 Clinical assessment tools
Multiple sclerosis associated retrovirus proviral load is elevated in multiple sclerosis patients P 290
M. Garcia-Montojo, M.I. Dominguez-Mozo, A. Arias-Leal, M.A. Garcia-Martinez, V. De las Heras, I. Casanova, R. Faucard, N. Gehin, A. Madeira, R. Arroyo, F. Curtin, R. Alvarez-Lafuente, H. Perron (Madrid, ES)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Endovascular treatment of chronic cerebro-spinal venous insufficiency in multiple sclerosis: a retrospective study P 629
R. Alroughani, S. Lamdhade (Kuwait, KW)
15:30 - 17:00 Neuroprotection
Neurogenic effects of fingolimod in mice P 501
P. Efstathopoulos, I. Charalampopoulos, A. Gravanis (Heraklion, GR)
15:30 - 17:00 Experimental models
Partial deprivation of the DC-poietin FLT3L protects animals from experimental autoimmune encephalomyelitis P 336
P.H. Lalive, N.L. Tran, M. Benkhoucha, G. Schneiter, M.-L. Santiago-Raber (Geneva, CH)
15:30 - 17:00 Neuroprotection
Laquinimod treatment reduces cuprizone-induced pathology in a dose-dependent manner P 510
R. Pförtner, N. Kramann, W. Brück, C. Wegner (Göttingen, DE)
15:30 - 17:00 Immunomodulation
Efficacy and safety of the S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis: results of a 26-week, double-blind, placebo-controlled, phase II trial (DreaMS) P 482
F. Zipp, T.L. Vollmer, K.W. Selmaj, A. Bar-Or on behalf of the DreaMS Study Group
15:30 - 17:00 Clinical assessment tools
Taking therapeutic decisions in interferon-treated patients with multiple sclerosis: an evidence-based analysis based on clinical and magnetic resonance imaging activity P 293
M.P. Sormani, F. Baldinetti, P. Cornelisse, B. Stubinski, N. De Stefano (Genoa, IT; Geneva, CH; Siena, IT)
15:30 - 17:00 Immunomodulation
Early effect of fingolimod on clinical and MRI related outcomes in relapsing multiple sclerosis P 459
P.S. Chin, P.A. Calabresi, Y. Zhang, P. von Rosenstiel, L. Kappos (East Hanover, Baltimore, US; Basel, CH)
15:30 - 17:00 Neuropsychology and fatigue
Improvement of MS-related fatigue also significantly improves quality of life in patients treated with natalizumab: results from the TYNERGY trial P 445
I.K. Penner, E. Gulowsen Celius, K. Schreiber, S. Fuchs, E. Falk, S. Berkö, J. Sun, A. Svenningsson (Basel, CH; Oslo, NO; Copenhagen, DK; Graz, AT; Stockholm, SE; Weston, US; Umeĺ, SE)
15:30 - 17:00 Neuropsychology and fatigue
Detecting cognitive dysfunction in patients with multiple sclerosis: assessing the validity of a computerized battery P 431
H. Lapshin, P. O'Connor, K.L. Lanctôt, A. Feinstein (Toronto, CA)
15:30 - 17:00 Biology of recovery
Complement C3 in neural stem cell development P 382
Y. Song, J. Zhong, L. Weiner (Los Angeles, US)
15:30 - 17:00 MS symptoms
Association of MS relapse symptoms with changes in cognition, fatigue, and work and usual activities P 271
H. Zwibel, B. Cohen, M. Tullman, T. Leist, P.K. Coyle, M. Lage on behalf of the TOP MS Study Steering Committee
15:30 - 17:00 Pregnancy and MS
Gene expression in the spinal cord in MBP-EAE in pregnant and post-partum rats: implications for the effects of MS in pregnancy P 277
H. Inglis, J. Greer, P. McCombe (Brisbane, AU)
15:30 - 17:00 Neuroprotection
Natalizumab improves MRI markers suggestive of irreversible tissue damage in RRMS P 513
C. Oreja-Guevara, A. Royo, S. Noval, L. Rodriguez de Antonio, B. Chamorro, J. Moreno, E. Diez-Tejedor, J. Alvarez-Linera (Madrid, ES)
15:30 - 17:00 Environmental risk factors
Month of birth is a latitude-dependent risk factor for multiple sclerosis in Norway P 370
N. Grytten Torkildsen, O. Torkildsen, J. Aarseth, E. Benjaminsen, E. Gulowsen Celius, O. Dahl, T. Holmoey, K. Loeken-Amsrud, R. Midgard, K.-M. Myhr, G. Risberg, A. Vatne, M. Kampman (Bergen, Bodř, Oslo, Namsos, Lillehammer, Molde, Kristiansand, Tromsř, NO)
15:30 - 17:00 Immunomodulation
Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor agonist, in healthy adult volunteers P 457
J. Hartung, R. Peach, M. Boehm, H. Rosen, H. Smith, C. Pan, J. Brooks, G. Timony, S. Gujrathi (San Diego, US)
15:30 - 17:00 Imaging
Evaluation of microstructural brain white matter damage in patients with neuromyelitis optica and multiple sclerosis P 392
C. Pires, F. Rueda, T. Doring, G. Gutfilen, N. Ventura, S. Aves-Leon, E. Gasparetto (Rio de Janeiro, BR)
15:30 - 17:00 Epidemiology
Do patient-reported symptom changes indicate increased risk for a future relapse in multiple sclerosis? P 240
A. Salter, T. Tyry, S. Cofield, D. Belletti, R.A. Marrie, R. Fox, G. Cutter (Birmingham, Phoenix, East Hanover, US; Winnipeg, CA; Cleveland, US)
15:30 - 17:00 Neuro-ophthalmology
NMO, CRION or MS: what we say when we have recurrent optic neuritis P 604
A.B. Falcăo, D.B. Bichuetti, E.M.L. Oliveira, A.A. Gabbai (Săo Paulo, BR)
15:30 - 17:00 Adaptative and Innate immunology
Epstein-Barr virus (EBV)-specific antibodies in multiple sclerosis patients, including targeted investigation of a candidate EBV nuclear antigen-1 (EBNA-1) B cell epitope P 349
K. Strautins, M. Tschochner, C. Berry, D. Nolan (Perth, AU)
15:30 - 17:00 Diagnosis and differential diagnosis
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis P 178
I. Katz Sand, S. Krieger, C. Farrell, A. Miller (New York, US)
15:30 - 17:00 Clinical assessment tools
Walking distances comparison between one and six minutes in multiple sclerosis patients P 283
C.T. Guerreiro, D.G. Brum, A.A. Barreira (Săo Paulo, BR)
15:30 - 17:00 Long-term treatment monitoring
How do multiple sclerosis patients in the NARCOMS registry navigate their treatment options beyond first-line therapies? P 525
A. Salter, T. Tyry, S. Cofield, N. Agashivala, S. Ryu, R.A. Marrie, R. Fox, G. Cutter (Birmingham, Phoenix, East Hanover, US; Winnipeg, CA; Cleveland, US)
15:30 - 17:00 Pregnancy and MS
The impact of menopause on multiple sclerosis P 276
S Rubin, J. Bernard (Chicago, US)
15:30 - 17:00 Epidemiology
Developing a tool-kit for measurement of risk factors and prospective harmonisation of paediatric MS case-control studies P 242
S. Magalhaes, I. Fortier, B. Banwell, A. Bar-Or, H. Hanwell, M. Pugliatti, C. Wolfson (Montreal, Toronto, CA; Sassari, IT)
15:30 - 17:00 Paediatric MS
Increased body mass index in paediatric onset multiple sclerosis P 226
A. Musallam, N. Baruch, S. Messina, R. Bove, B. Healy, T. Chitnis (Boston, US)
15:30 - 17:00 Quality of life
Unmet needs of adults with multiple sclerosis living in the northwest United States P 587
K. Johnson, D. Amtmann, A. Verrall, V. Weir (Seattle, US)
15:30 - 17:00 Long-term treatment monitoring
Clinical and MRI outcomes following cessation of daclizumab therapy P 524
J. Rose, M. Rojas, A. Fjeldstad, N. Carlson (Salt Lake City, US)
15:30 - 17:00 Paediatric MS
Antibody response against EBV antigens and myelin oligodendrocyte glycoprotein in paediatric patients with demyelinating CNS diseases P 228
F. Di Pauli, S. Mader, K. Rostasy, K. Schanda, B. Bajer-Kornek, B. Kuenz, R. Ehling, M. Reindl, T. Berger (Innsbruck, AT)
15:30 - 17:00 Grey matter damage in MS
Meningeal inflammation and cortical pathology play a prominent role in primary progressive multiple sclerosis P 315
R. Reynolds, O. Howell, S. Choi, D. Carassiti, R. Magliozzi, D. Gveric, P. Muraro, R. Nicholas, F. Roncaroli (London, GB; Rome, IT)
15:30 - 17:00 Genetics / transcriptomics
Role of HERV-K18 haplotypes in multiple sclerosis development (meta-analysis) P 344
B. de la Hera, M. García-Montojo, J. Varadé, A. de la Encarnación, M. Domínguez-Mozo, A. Arias-Leal, M. A. García-Martínez, V. de las Heras, R. Arroyo, E. Gómez de la Concha, R. Álvarez-Lafuente, E. Urcelay (Madrid, ES)
15:30 - 17:00 Biomarkers
Cystatin C as a marker of the neurodegeneration in MS P 609
V. Sladkova, J. Mares, J. Langova, P. Kanovsky (Olomouc, CZ)
15:30 - 17:00 Tools for detecting therapeutic response
Natalizumab treatment effects sustained decrease in serum levels of fibronectin and soluble adhesion molecules sVCAM-1 and sICAM-3 P 553
K. Oppermann, A. Harrer, G. Pilz, P. Wipfler, S. Afazel, E. Haschke-Becher, E. Trinka, J. Kraus (Salzburg, AT)
15:30 - 17:00 Epidemiology
Mutiple sclerosis in Hamburg, Germany – prevalence estimates for subgroups P 247
N. Erikli, S. Hadjilou, J. Poettgen, D. Kilian, J.P. Stellmann, C. Heesen (Hamburg, DE)
15:30 - 17:00 MS and infections
Unusual course and manifestation of natalizumab associated PML in a patient with multiple sclerosis P 365
T. Kümpfel, J. Havla, K. Lippmann, R. Hohlfeld (Munich, Neuburg, DE)
15:30 - 17:00 Biomarkers
Insulin resistance and serum lipid profile are associated with disability in multiple sclerosis patients P 619
S.R. Oliveira, A.P. Kallaur, A.N.C. Simăo, D.R. Kaimen-Maciel, J. Lopes, R. Andrade, W. Pereira, H.K. Morimoto, E.M.V. Reiche (Londrina, BR)
15:30 - 17:00 Risk management for disease modifying treatments
Characterisation of intra-cycle and long-term lymphocyte VLA-4 saturation dynamics in a natalizumab infusing population P 531
J. Foley, T. Hoyt, A. Christensen (Salt Lake City, US)
15:30 - 17:00 Neuropsychology and fatigue
Assessment of different tests for tracking cognitive changes during MS relapses P 437
L. Vahter, L. Bachmann, T. Saarup, K. Rohulaid, K. Kannel, A. Reitsnik, U. Sorro, H. Maamägi, K. Gross-Paju (Tallinn, EE)
15:30 - 17:00 Biomarkers
Expression of cytokines reflecting the Th17/Treg balance and MS disease activity. Effects of ivMP, IFN-beta and glatiramer Acetate P 608
V. van Pesch, H.A. Dang, N. Muls, C.J.M. Sindic (Brussels, BE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
British Columbia CCSVI Registry: preliminary survey results P 626
I. Yee, A. Traboulsee, A. Sadovnick, L. Machan (Vancouver, CA)
15:30 - 17:00 Imaging
Two-year progression of iron accumulation in subcortical nuclei in multiple sclerosis using high-field MRI P 420
A. Walsh, G. Blevins, A. Wilman (Edmonton, CA)
15:30 - 17:00 MS and infections
Relation of Helicobacter pylori infection and multiple sclerosis in Iranian patients P 360
N. Mohebi, M. Moghaddasi, M. Mamarabadi (Tehran, IR)
15:30 - 17:00 Devic’s NMO spectrum
Neuromyelitis optica spectrum disorder as a paraneoplastic disorder in a patient with breast cancer P 203
W. Vargas, S. Gauthier, N. Nealon, T. Vartanian, J. Perumal (New York, US)
15:30 - 17:00 Databases and Pharmacoepidemiology
Treatment patterns after lack of response to first-line disease-modifying therapy for relapsing-remitting multiple sclerosis P 258
B. Teter, N. Agashivala, R. Hashmonay, B. Weinstock-Guttman (Buffalo, East Hanover, US)
15:30 - 17:00 Neuroprotection
Lipoic acid prevents axonal spheroid formation and severing in adult neurons during oxidative stress P 506
A. Barsukova, M. Forte, D. Bourdette (Portland, US)
15:30 - 17:00 Tools for detecting therapeutic response
Longitudinal follow-up of MRI volumetry in routine clinical practice P 552
D. Horakova, T. Kalincik, M. Tyblova, J. Krasensky, M. Vaneckova, Z. Seidl, E. Havrdova (Prague, CZ)
15:30 - 17:00 Imaging
Multi-component relaxation reveals distinct patterns of white matter involvement in primary progressive multiple sclerosis and primary lateral sclerosis P 421
S. Kolind, A. Seddigh, N. Sibtain, S. Deoni, G.J. Barker, A. Traboulsee, S.C.R. Williams, M.R. Turner, P.A. Brex (Vancouver, CA; London, GB; Providence, US; Oxford, GB)
15:30 - 17:00 Neuropsychology and fatigue
Construction and pre-validation study of a cognitive-ergonomic questionnaire of work in multiple sclerosis P 449
G. Delrue, A. Monisse, A. Balvier, A.-S. Nyssen, P. Calay, S. Belachew (Ličge, BE)
15:30 - 17:00 Immunomodulation
Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing–remitting multiple sclerosis P 491
P.A. Calabresi, D. Goodin, D. Jeffery, L. Kappos, F.D. Lublin, K. Rammohan, A.T. Reder, T. Vollmer, M.A. Agius, L. Cappiello, T. Stites, B.B. Li, M. Malhotra, P. von Rosenstiel, E.-W. Radue (Baltimore, San Francisco, North Carolina, US; Basel, CH; New York, Miami, Chicago, Aurora, Davis, East Hanover, US)
15:30 - 17:00 Immunomodulation
Natalizumab (Tysabri) treatment outcome in terms of safety and efficacy in older patients and/or with longer disease duration – a Swedish nationwide long-term follow-up P 486
H. Matell, O. Sveinsson, C. Holmén, J. Hillert, T. Olsson, F. Piehl (Stockholm, SE)
15:30 - 17:00 Biomarkers
CSF histamine levels in multiple sclerosis patients P 606
U. Kallweit, K. Aritake, C.L. Bassetti, S. Blumenthal, O. Hayaishi, M. Linnebank, Y. Urade, C.R. Baumann (Zurich, CH; Osaka, JP)
15:30 - 17:00 Clinical assessment tools
Symbol digit modalities test and faces symbol test better reflect white matter damage than paced auditory serial addition test in relapsing-remitting multiple sclerosis P 292
A. Freing, M. Scheel, N. Weinges-Evers, L. Wieder, J. Dörr, F. Paul, A. U. Brandt, J. Würfel (Berlin, DE)
15:30 - 17:00 Paediatric MS
The use of modafinil and amantadine in the treatment of fatigue in paediatric MS P 221
J. O'Mahony, B. Banwell, S. Khan, E.A. Yeh (Toronto, CA)
15:30 - 17:00 Imaging
Longitudinal assessment of metabolic alterations in the brains of patients with secondary progressive multiple sclerosis P 386
P. Lee, S. Lynch, A. Hughes, D. Denney, I.-Y. Choi (Kansas City, Lawrence, US)
15:30 - 17:00 Immunomodulation
Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients P 472
R. Pul, F. Morbiducci, J. Skuljec, T. Skripuletz, N. Garde, E.V. Voss, C. Trebst, M. Stangel (Hannover, DE)
15:30 - 17:00 Diagnosis and differential diagnosis
Time gain using the 2010 McDonald criteria for the diagnosis of multiple sclerosis after a clinically isolated syndrome P 184
E. Thouvenot, M.-L. Inghilleri, B. Clarivet, M. Charif, B. Carlander, W. Camu, G. Mercier (Nîmes, Montpellier, FR)
15:30 - 17:00 Grey matter damage in MS
Gene expression profiling of cortical lesions in secondary progressive multiple sclerosis P 318
R. Magliozzi, E. Aricň, P. Durrenberger, O. Howell, F. Roncaroli, R. Nicholas, F. Aloisi, R. Reynolds (Rome, IT; London, GB)
15:30 - 17:00 Pathology
Increased cerebrospinal fluid bradykinin correlate with lesion load P 309
M. Degn, L.T. Jensen, J. Frederiksen (Glostrup, DK)
15:30 - 17:00 Risk management for disease modifying treatments
Remain vigilant after natalizumab discontinuation: three remarkable cases P 538
S. Roggerone, F. Durand-Dubief, F. Chenevier, S. Berroir, E. Creisson, A. Benoit, S. Boulogne, C. Laurencin, S. Vukusic, C. Confavreux (Bron, Annemasse, Thonon, FR)
15:30 - 17:00 Comprehensive care and rehabilitation
Predictors of efficacy of a short-term intensive inpatient motor rehabilitation in patients affected with multiple sclerosis P 579
G. Liberatore, P. Rossi, D. Ungaro, A. Nuara, L. Saraceno, R. Gatti, M. Comola, G. Comi, F. Martinelli Boneschi (Milan, IT)
15:30 - 17:00 Risk management for disease modifying treatments
Natalizumab discontinuation and the role of corticosteroid treatment. An observational study P 542
Ŕ. Vidal-Jordana, M. Tintoré, C. Tur, F. Pérez-Miralles, A. Horga, J. Sastre-Garriga, C. Auger, J. Río, C. Nos, Í. Galán, J. Castilló, G. Arrambide, M.J. Vicente, A. Rovira, X. Montalban (Barcelona, ES)
15:30 - 17:00 Experimental models
Unravelling an unexpected role for the proteoglycan NG2 in EAE P 324
A. Uccelli, S. Morando, F. Girolamo, S. Casazza, D. Virgintino, R. Furlan, R. Perris, C. Bendotti, G. Ferrara (Genoa, Bari, Milan, Parma, IT)
15:30 - 17:00 Treatment of specific symptoms
The effects of telephone-based physical activity counselling on fatigue, pain, symptoms and quality of life in people with multiple sclerosis and major depression P 566
A.M. Verrall, H. Bombardier, M. Ehde, E. Gibbons, G.H. Kraft (Seattle, US)
15:30 - 17:00 Risk management for disease modifying treatments
Safety and tolerability of the first dose of fingolimod: first experience in a tertiary outpatient clinic P 537
P. Ng, S. Hum, N. Spinelli, Y. Lapierre (Montreal, CA)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Cerebrospinal venous outflow in MS patients and fatigue/depression P 635
E.L.J. Hoogervorst, S.C. Tromp, S.T.F.M. Frequin (Nieuwegein, NL)
15:30 - 17:00 Biomarkers
SIGLEC1 and SIGLEC7 expression in peripheral blood monocytes of patients with multiple sclerosis P 620
S. Malhotra, J. Castilló, M. Bustamante, Ŕ. Vidal-Jordana, X. Montalban, M. Comabella (Barcelona, ES)
15:30 - 17:00 Economic burden
Cost-effectiveness of multiple sclerosis treatment in Latin America assessed by the Markov model based on long-term clinical data P 307
Y. Fragoso, A. Finkelsztejn, A. Gabbai, A. Carra, M. Macias-Islas, A. Tarulla, R. Arcega-Revilla, J. Duran-Quiroz, C. Carcamo-Rodriguez, J. Garcia-Bonitto, D. Vizcarra-Escobar, G. Orosco-Escobar, C. Oehninger-Gatti, V. Bedoya, P. Abad-Herrera (Santos, Porto Alegre, Săo Paulo, BR; Buenos Aires, AR; Guadalajara, MX; Puebla, MX; La Paz, BO; Santiago, CL; Bogota, CO; Lima, PE; Caracas, VE; Montevideo, UY; Assuncion, PY; Quito, EC)
15:30 - 17:00 Epidemiology
Age-specific sex ratio of multiple sclerosis in Sweden P 255
I. Boström, A.M. Landtblom (Kristinehamn, Linköping, SE)
15:30 - 17:00 Grey matter damage in MS
Cognitive deficit is associated with subcortical grey matter volume in relapsing-remitting multiple sclerosis patients P 321
A. Kalinowska-Lyszczarz, M. Pawlak, W. Paprzycki, W. Kozubski (Poznan, PL)
15:30 - 17:00 Paediatric MS
Retinal nerve fibre layer thickness thresholds for visual function in paediatric demyelinating disease: further evidence of the RNFL tipping point P 223
Y.A. Reginald, F. Costello, J. O'Mahoney, J.R. Buncic, B. Banwell on behalf of the Canadian Pediatric Demyelinating Disease Study
15:30 - 17:00 Grey matter damage in MS
Cerebellar cortical lesion load is related to clinical disability in multiple sclerosis patients P 322
A. Damasceno, B. Damasceno, F. Cendes (Campinas, BR)
15:30 - 17:00 Treatment of specific symptoms
The effects of resistance training and physical activities in groups in comparison for the treatment of chronic fatigue in patients with multiple sclerosis P 570
L. Bernhardt, C. Jolk, R. Alcantara, P. Platen, M. Marziniak, K. Weßling (Münster, Bochum, DE)
15:30 - 17:00 Biomarkers
Contactin 2 and contactin-associated protein 2 antibodies in patients with multiple sclerosis and clinically isolated syndrome P 618
P. Nytrova, P. Waters, D. Horakova, Y. Hacohen, T. Kalincik, P. Zbornikova, J. Dusankova Blahova, J. Krasensky, M. Vaneckova, E. Havrdova, K.P. Wandinger, A. Vincent (Oxford, GB; Prague, CZ; Lübeck, DE)
15:30 - 17:00 Diagnosis and differential diagnosis
Multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy with hypertrophic cranial and spinal neuroradiculopathy mimicking neurofibromatosis: report of a case series P 180
D. De Feo, M. Maria Josč, M. Rodegher, B. Colombo, D. Dalla Libera, S. Gerevini, A. Quattrini, U. Del Carro, G. Comi, V. Martinelli (Milan, IT)
15:30 - 17:00 Biomarkers
20-kDa Nogo A: highly specific and sensitive biomarker for multiple sclerosis P 621
M. Matysiak, A. Jurewicz, I. Selmaj, L. Bartyzel, P. Kadrowicz, K. Selmaj (Lodz, PL)
15:30 - 17:00 Natural history
Modelling longitudinal change in multiple sclerosis P 233
S. Hum, Y. Lapierre, S.C. Scott, L.E. Finch, N.E. Mayo (Montreal, CA)
15:30 - 17:00 Experimental models
High resolution genetic mapping of the cytokine response in the rat heterogeneous stock P 325
S. Flytzani, P. Stridh, D. Ekman, M. Diez, J. Öckinger, A. Beyeen, A. Gillett, A. Ortlieb, N. Abdelmagid, M. Jagodic, T. Olsson (Stockholm, SE)
15:30 - 17:00 Diagnosis and differential diagnosis
Nf-H CSF levels in patients with clinically isolated syndromes P 190
M. Tintoré, J. Kuhle, G. Arrambide, M. Limberg, C. Espejo, E. Simón, M. Comabella, C. Auger, A. Rovira, X. Montalban (Barcelona, ES; Basel, CH)
15:30 - 17:00 Quality of life
The psychosocial impact of MS patients and their caregivers in the Turkish population P 592
D. Yandim Kuscu, G. Yilmaz Canturk, S. Tumen Oner, U. Dural Senoguz, B. Topcular, M.K. Kuscu (Istanbul, TR)
15:30 - 17:00 Comprehensive care and rehabilitation
Risk factors of reduced bone mass in patients with multiple sclerosis P 574
C. Boz, S. Zengin Karahan (Trabzon, TR)
15:30 - 17:00 Imaging
Warmer outdoor temperature is associated with decreased cognitive efficiency in multiple sclerosis P 389
V. Leavitt, J. Sumowski, G. Wylie, N. Chiaravalloti, J. DeLuca (West Orange, US)
15:30 - 17:00 Imaging
No evidence for dynamic neuroplastic changes in cognitively stable multiple sclerosis patients over two years of follow-up P 415
C. Enzinger, M. Loitfelder, A. Pichler, K. Koschutnig, K. Petrovic, S. Fuchs, S. Ropele, M. Jehna, C. Langkammer, A. Mader, C. Neuper, F. Fazekas (Graz, AT)
15:30 - 17:00 Economic burden
Multiple sclerosis: employment and employability – patient reported perspectives P 301
M. Gudesblatt, R. Goldstein, J. Kalina, M. Zarif, B. Bumstead, L. Fafard, I. Topalli, M. Buhse (Patchogue, New York, Cambridge, Stony Brook, US)
15:30 - 17:00 Neuro-ophthalmology
Manual and automated segmentation of retinal layers in single transfoveal OCT scans of MS patients P 600
P. Albrecht, M. Ringelstein, A.K. Müller, N. Keser, J. Harmel, H.-P. Hartung, A. Methner, O. Aktas (Düsseldorf, DE)
15:30 - 17:00 Devic’s NMO spectrum
Efficacy of rituximab or mitoxantrone in patients with Devic's disease P 214
L. Molina, D. Sanchez, H. Juarez (Mexico City, MX)
15:30 - 17:00 Experimental models
Protection of oligodendroglia in experimental NMO lesions P 334
C. Wrzos, J. Bennett, W. Brück, S. Nessler, C. Stadelmann (Göttingen, DE; Denver, US)
15:30 - 17:00 MS symptoms
Impaired social cognition in multiple sclerosis occurs independently of neuropsychological deficits and depression P 262
J. Pöttgen, S. Moritz, S. Reh, I. Dziobek, C. Heesen, S. Gold (Hamburg, Berlin, DE)
15:30 - 17:00 Long-term treatment monitoring
Natalizumab results in sustained freedom from disease activity in highly active relapsing-remitting MS patients: a four-year follow-up P 526
S.B. Kelly, M. Duggan, L. Buckley, K. Kinsella, M. Hutchinson, N. Tubridy, C. McGuigan (Dublin, IE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Multiple stenosis or multiple sclerosis? P 624
G. Panczel, C. Rozsa, K. Kovacs, I. Szikora, Z. Berentei, I. Gubucz, M. Marosfoi, A. Rozsa (Budapest, HU)
15:30 - 17:00 Imaging
Characterisation of enhancing and non-enhancing MS lesions with susceptibility-weighted imaging P 407
P. Eisele, M. Griebe, K. Szabo, M. Wolf, M.G. Hennerici, A. Gass (Mannheim, DE)
15:30 - 17:00 Economic burden
Costs of multiple sclerosis in Latin America and the Caribbean: systematic review of the literature P 305
M. Romano, G. Machnicki, J.I. Rojas, N. Frider, J. Correale (Buenos Aires, AR)
15:30 - 17:00 Others
The oldest multiple sclerosis patient living actively until age 97 P 561
M. Elian (London, GB)
15:30 - 17:00 Genetics / transcriptomics
Association of CD40 gene polymorphisms with the multiple sclerosis in population of Russian Federation P 341
E.A. Kudryavtseva, A.S. Rozhdestvenskii, A.V. Kakulya, E.V. Khanokh, N.A. Malkova, D.S. Korobko, F.A. Platonov, E.G. Aref'eva, N.N. Zagorskaya, V.M. Alifirova, M. Titova, V.P. Puzyrev, I.V. Smagina, S.A. El'chaninova, A.G. Zolovkina, E.Y. Tsareva, O.O. Favorova, A.N. Boiko, M.L. Filipenko (Novosibirsk, Omsk, Yakutsk, Kemerovo, Tomsk, Barnaul, Moscow, RU)
15:30 - 17:00 Epidemiology
Reversed causality might explain the association between reproductive history and MS: results from the Epidemiological Investigation of Multiple Sclerosis (EIMS) P 256
L. Alfredsson, A.K. Hedström, J. Hillert, T. Olsson (Stockholm, SE)
15:30 - 17:00 Immunomodulation
Further insights on immunomodulatory mechanisms of natalizumab in multiple sclerosis P 478
M. Ruggieri, P. Iaffaldano, M. Mastrapasqua, D. Paolicelli, M. Trojano (Bari, IT)
15:30 - 17:00 MS symptoms
Central pain in patients with multiple sclerosis P 268
S. Feketová, I. Waczulíková, J. Mareš, P. Kukumberg (Bratislava, SK; Olomouc, CZ)
15:30 - 17:00 Immunomodulation
Analysis of genetic models predicting the response to GA on two-year follow-up of relapsing-remitting multiple sclerosis patient data P 480
F. Martinelli Boneschi, A. Tchelet, F. Esposito, P. Manunta, J. Levy, S. Weiss, L. Citterio, G. Pavan, G. Liberatore, P. Brambilla, V. Martinelli, G. Comi (Milan, IT; Netanya, IL; London, GB)
15:30 - 17:00 Clinical assessment tools
Development of an objective testbattery for motor and cognitive fatigue in patients with relapsing-remitting and secondary progressive multiple sclerosis P 291
U. Hofstadt-van Oy, U. Menge, R. Weimer, J. Burschka, P. Oschmann (Bayreuth, DE)
15:30 - 17:00 Tools for detecting therapeutic response
Rio Score and Modified Rio Score validation in an Italian cohort of relapsing-remitting multiple sclerosis patients P 549
M. Romeo, V. Martinelli, M. Rodegher, S. Maida, E. Perego, G. Comi (Milan, IT)
15:30 - 17:00 Neurophysiology
iSP study in multiple sclerosis relapsing-remitting during and after a motor relapse P 426
L. Straffi, R. Chieffo, E. Coppi, F. Spagnolo, A. Inuggi, A. Nuara, G. Di Maggio, G. Comi, L. Leocani (Milan, IT)
15:30 - 17:00 Neurophysiology
Optical coherence tomography and visual-evoked potentials: which is more sensitive in multiple sclerosis? P 425
G. Di Maggio, M. Bianco, L. Ferrari, S. Medaglini, M. Rodegher, B. Colombo, L. Moiola, V. Martinelli, G. Comi, L. Leocani (Milan, IT)
15:30 - 17:00 Neurophysiology
Correlations between auditory consonant trigram test, paced auditory serial addition test health-related quality of life during and after treatment of relapses in patients with clinically isolated syndrome P 430
S. Ozakbas, B. Piri Cinar, O. Ozturk, A. Gurkan, E. Idiman (Izmir, TR)
15:30 - 17:00 MS Variants
High expression of HLA-DRB1*1501 variant and DRB5 gene associate with multiple sclerosis in a Caucasian population P 198
A. Alcina, M. Abad-Grau, M. Fedetz, G. Izquierdo, M. Lucas, O. Fernández, N. Dorothy, A. Catalá-Rabasa, C. Delgado, C. Arnál, F. Matesanz (Granada, Malaga, ES)
15:30 - 17:00 Risk management for disease modifying treatments
Initiating a low-dose class Ia anti-arrhythmic (dextromethorphan/quinidine) in fingolimod-treated patients may be safe and effective: the first case series P 529
D. Kantor (Ponte Vedra, US)
15:30 - 17:00 Adaptative and Innate immunology
Effect of rituximab on white blood cell subtypes after single and multiple treatments in MS and NMO P 356
U. Vinayagasundaram, E.M. Mowry, I.R. Matthews, J. Marino, J. Cheng, E. Waubant (Cleveland, San Francisco, US)
15:30 - 17:00 Devic’s NMO spectrum
The spectrum of demyelinating diseases in a cohort of patients from Rio de Janeiro (Brazil) P 217
M. Papais-Alvarenga, R. Papais-Alvarenga, C. Vasconcelos, M. Alvarenga, S. Camargo, E. Batista, G. Santos (Rio de Janeiro, BR)
15:30 - 17:00 Immunomodulation
Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS-II): subgroup analyses by previous DMT use P 483
M.S. Freedman, D.L. Arnold, J. Cohen, C. Confavreux, E.J. Fox, H.-P. Hartung, E. Havrdova, K. Selmaj, H. Weiner, T. Miller, C.L. Twyman, M. Vallee, D.H. Margolin, M. Panzara, D.A.S. Compston for the CARE-MS II investigators
15:30 - 17:00 Neuro-ophthalmology
Pattern of retinal neuronal loss in multiple sclerosis and neuromyelitis optica without optic neuritis measured by optical coherence tomography P 594
N. Kim, H.J. Kim, J.Y. Cho, K.S. Jeong, C.Y. Park (Goyang-si, KR)
15:30 - 17:00 Risk management for disease modifying treatments
Immunostimulatory effect of G-CSF is potentially beneficial in natalizumab-associated PML/IRIS P 528
D. Stefoski, M. Ko, R. Brillante, A. Javed, R. Balabanov (Chicago, US)
15:30 - 17:00 Clinical assessment tools
Backward masking paradigm captures delays in speed of processing in multiple sclerosis on a millisecond scale P 286
J.H. Bacon, T.E. Bacon, I. Kister, Y. Strauchler, G. Tsikhanovski Bochner, M. Omari, A. Bochkanova, J. Herbert (New York, US)
15:30 - 17:00 Immunomodulation
Diffusion tensor imaging predicts development of natalizumab-associated progressive multifocal leukoencephalopathy P 458
D. Ontaneda, K. Sakaie, J. Lin, X. Wang, M. Lowe, M. Phillips, R. Fox (Cleveland, US)
15:30 - 17:00 Risk management for disease modifying treatments
Safety of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II) P 545
E. Havrdova, D. L. Arnold, J. Cohen, A. J. Coles, C. Confavreux, E. J. Fox, H.-P. Hartung, K. Selmaj, H. Weiner, T. Miller, C.L. Twyman, S. L. Lake, D. H. Margolin, M. Panzara, D.A.S. Compston for the CARE-MS II investigators
15:30 - 17:00 Diagnosis and differential diagnosis
Neuromyelitis optica previously diagnosed as multiple sclerosis P 191
P. Zago Melo, F. Jorge, R. Faria Simm, S. Apóstolos Pereira, C. Galvăo, C. Hobi, L. Moraes, M. Fazzito, D. Sato, M. Lana-Peixoto, D. Callegaro (Săo Paulo, BR)
15:30 - 17:00 Treatment of specific symptoms
Evaluation of the abuse potential of dalfampridine extended-release tablets P 565
M. Jara, D. Gauvin, A. Caggiano, B. Walter, T. Parry, H. Henney (Hawthorne, Mattawan, US)
15:30 - 17:00 Quality of life
Evaluation of the effect of dalfampridine-ER on the EQ-5D based on an MSWS-12 to EQ-5D mapping equation derived in North American patients P 588
M. Sidovar, B. Limone, J. Gaebler, S. Lee, C. Coleman (Hawthorne, Hartford, Weston, US)
15:30 - 17:00 Comprehensive care and rehabilitation
Which pain indicators are most associated with walking capacity in individuals with multiple sclerosis? P 575
S. Shahrbanian, P. Duquette, A. Kuspinar, S. Teng, N. Mayo (Montreal, CA)
15:30 - 17:00 Imaging
Can anti-TNFa therapy cause clinically silent MS-like white matter lesions? An MRI study and case analysis P 393
S.Y. Lim, C.R. Tench, D.P. Auer, I. Pande, M. Abaei, C.S. Constantinescu (Nottingham, GB)
15:30 - 17:00 Long-term treatment monitoring
Five-year safety and efficacy data of natalizumab from the STRATA study P 520
L. Kappos, A. Goodman, F. Lublin, P. O'Connor, C. Polman, L.M. Cristiano, F. Forrestal, P. Duda (Basel, CH; Rochester, New York, US; Toronto, CA; Amsterdam, NL; Cambridge, US)
15:30 - 17:00 MS and infections
Human herpesvirus in multiple sclerosis patients P 363
R.B. Thomaz, G.S. Olival, C.P. Tilbery, J.V. Bermudez, L.H.S. Nali, C.M. Romano, L. Moraes, D. Callegaro, V. Cavenaghi, J.S. Casseb, A.C. Penalva de Oliveira, C. Fink, L.S. Sumita (Săo Paulo, BR)
15:30 - 17:00 Natural history
Similarities in disability profiles in North American Research Committee on Multiple Sclerosis (NARCOMS) registry and Genetic Analysis of Multiple Sclerosis in Europeans (GAMES) dataset P 235
I. Kister, E. Chamot, G. Cutter, A. Salter, T.E. Bacon, J. Herbert (New York, Birmingham, US)
15:30 - 17:00 Biomarkers
Biomarkers of blood-brain barrier in the progression of multiple sclerosis P 605
A. Valado, T. Proença, J. Sargento-Freitas, S. Batista, L. Sousa, C.R. Oliveira, I. Baldeiras (Coimbra, PT)
15:30 - 17:00 Paediatric MS
Adolescent-parent relationships in paediatric MS patients P 225
E.A. Boyko, O.V. Bykova, I.A. Nankina, T.T. Batysheva, A.N. Boyko (Moscow, RU)
15:30 - 17:00 Neurophysiology
Measuring axonal loss in multiple sclerosis P 429
V. Fernandez, M.J. Postigo, P. Urbaneja, A. León, A. Alonso, M Guerrero, O. Fernández (Málaga, ES)
15:30 - 17:00 Diagnosis and differential diagnosis
Hamburg isolated clinical syndrome (HIS) cohort – sensitivity of diagnostic criteria P 185
B. Kaulen, A. Neuhaus, L. Reitz, S. Siemonsen, K. Radelfahr, J.P. Stellmann, M. Daumer, C. Heesen (Hamburg, Munich, DE)
15:30 - 17:00 Neuroprotection
Brain reserve and cognitive reserve in MS patients. Lifetime maximal brain size and early life cognitive leisure independently protect against disease-related cognitive decline P 505
J.F. Sumowski, M.A. Rocca, V.M. Leavitt, G. Riccitelli, G. Comi, J. DeLuca, M. Filippi (West Orange, US; Milan, IT)
15:30 - 17:00 Quality of life
Information provision for persons with multiple sclerosis (Cochrane Review) P 583
S. Köpke, A. Solari, F. Khan, C. Heesen, A. Giordano (Lübeck, DE; Milan, IT; Melbourne, AU; Hamburg, DE)
15:30 - 17:00 Environmental risk factors
Smoking and disease progression in patients with multiple sclerosis: UK cohort study P 375
A. Manouchehrinia, C. Tench, J. Maxted, R. Bibani, J. Britton, C. Constantinescu (Nottingham, GB)
15:30 - 17:00 Epidemiology
Demographic, clinical manifestations and course of multiple sclerosis: a retrospective study P 244
E.H. Ait Ben Haddou, K. El Alaoui Taoussi, N. Chtaou, Y. Hsaini, A. Satte, M. Alhyan, I. Derouich, J. Oumerzouk, J. Mounach, W. Regragui, Z. Souirti, R. Abouqal, O. Messouak, H. Ouhabi, A. Bourazza, F. Belahcen, A. Benomar, M. Yahyaoui (Rabat, Fes, MA)
15:30 - 17:00 Imaging
Longitudinal pre-processing decreases the required sample size for measurement of cortical atrophy in multicentre MS clinical trials P 419
K. Nakamura, S. Narayanan, D. Arnold (Montreal, CA)
15:30 - 17:00 Tools for detecting therapeutic response
Antibody dissociation rates are predictive of neutralising antibody course: a comparison of interferon-beta-1b-treated patients with transient versus sustained NAbs P 551
E. Gibbs, J. Oger (Vancouver, CA)
15:30 - 17:00 Tools for detecting therapeutic response
The use of in vivo 1H - magnetic resonance spectroscopy for evaluating the efficacy of treatment of patients with relapsing-remitting multiple sclerosis with copaxone (glatiramer acetate) P 548
Z. Rozhkova, T. Kobys, O. Myalovitska, I. Lobanova (Kiev, UA)
15:30 - 17:00 Natural history
Age-related white matter microstructural changes in multiple sclerosis P 234
M. Ivkovic, K. Fujimoto, G. Passiatore, J. Perumal, N. Nealon, T. Vartanian, S. Gauthier (New York, US)
15:30 - 17:00 Neuropsychology and fatigue
Brief International Cognitive Assessment for MS (BICAMS): reliability and identifying statistically reliable change P 433
R.H.B. Benedict, M.P. Amato, J. Boringa, B. Brochet, F. Foley, S. Fredrikson, P. Hämäläinen, H.-P. Hartung, L. Krupp, I.K. Penner, A. Reder, D. Langdon (Buffalo, US; Florence, IT; Amersfoort, NL; Bordeaux, FR; New York, US; Stockholm, SE; Masku, FI; Düsseldorf, DE; Basel, CH; Chicago, US; London, GB)
15:30 - 17:00 Risk management for disease modifying treatments
Cellular response to JC virus: a longitudinal study in a population of natalizumab-treated multiple sclerosis patients P 540
S. Masera, C. Costa, F. Dematteis, G. Superti, A. Romagnolo, A. Mattioda, L. Pinessi, L. Lopiano, R. Cavallo, P. Cavalla (Turin, IT)
15:30 - 17:00 Imaging
Spinal cord metabolic changes at onset of a relapse in relapsing-remitting multiple sclerosis P 395
K. Abdel-Aziz, B. Solanky, M.C. Yiannakas, C.A.M. Wheeler-Kingshott, A.J. Thompson, O. Ciccarelli (London, GB)
15:30 - 17:00 Genetics / transcriptomics
MicroRNA expression dynamics during interferon-beta treatment in peripheral blood of multiple sclerosis patients P 346
M. Hecker, M. Thamilarasan, C. Angerstein, B.K. Paap, D. Koczan, H.-J. Thiesen, U.K. Zettl (Rostock, DE)
15:30 - 17:00 Immunomodulation
Maraviroc for treatment of immune reconstitution inflammatory syndrome following natalizumab-associated progressive multifocal leukoencephalopathy P 465
P.S. Giacomini, A. Rosenberg, D. Araujo, M.-N. Boivin, L. Poliquin-Lasnier, C. Xia, D. Tampieri, S. Narayanan, D. L. Arnold, N. Arbour, D. B. Clifford, A. Bar-Or (Montreal, CA; St. Louis, US)
15:30 - 17:00 Immunomodulation
Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study P 464
D.H. Miller, M. Hutchinson, R.J. Fox, J.T. Phillips, M. Kita, E. Havrdova, J. O’Gorman, M. Yang, V. Viglietta, K.T. Dawson (London, GB; Dublin, IE; Cleveland, Dallas, Seattle, US; Prague, CZ; Weston, US)
15:30 - 17:00 Experimental models
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease P 329
A.T. Argaw, L. Asp, J. Zhang, K. Navrazhina, T. Pham, J. Mariani, S. Mahase, D. Dutta, J. Seto, E. Kramer, N. Ferrara, M. Sofroniew, G. John (New York, South San Francisco, Los Angeles, US)
15:30 - 17:00 Pathology
Lesion formation in multiple sclerosis and spontaneous experimental autoimmune encephalomyelitis is associated with early disturbances in the blood-brain barrier P 312
J. Alvarez, S. Terouz, A. Godschalk, O. Saint-Laurent, A. Prat (Montreal, CA)
15:30 - 17:00 Immunomodulation
Non-inferiority of azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomised trial P 460
L. Massacesi, I. Tramacere, M.D. Benedetti, G. Filippini, L. La Mantia, A. Solari, C. Milanese on behalf of the MAIN trial Study group
15:30 - 17:00 Treatment of specific symptoms
Cannabis as a symptomatic treatment for MS: clinically meaningful MUSEC to the stiffness and walking problems of people with MS P 571
J.C. Hobart, J.P. Zajicek (Plymouth, GB)
15:30 - 17:00 Environmental risk factors
Prognostic factors in clinically isolated syndromes: the role of vitamin D P 373
V. Martinelli, G. Dalla Costa, B. Colombo, D. Dalla Libera, L. Leocani, R. Furlan, A. Rubinacci, M. Filippi, G. Comi (Milan, IT)
15:30 - 17:00 Devic’s NMO spectrum
Differences in optic neuritis related retinal damage between patients with neuromyelitis optica and multiple sclerosis P 207
E. Schneider, H. Zimmermann, T. Oberwahrenbrock, A.U. Brandt, B. Wildemann, F. Paul (Berlin, Heidelberg, DE)
15:30 - 17:00 Neuropsychology and fatigue
Italian version of Minimal Assessment of Cognitive Function in Multiple Sclerosis: a pilot study P 446
S. Migliore, A. Ghazaryan, D. Landi, P. Pasqualetti, F. Moffa, M.M. Filippi, F. Vernieri (Rome, IT)
15:30 - 17:00 Immunomodulation
Clinical effects of BG-12 in subgroups of patients with relapsing–remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies P 466
A. Bar-Or, R.J. Fox, R. Gold, G. Giovannoni, M. Kita, J. O’Gorman, M. Yang, S.I. Sheikh, V. Viglietta, K.T. Dawson, M. Hutchinson (Montreal, CA; Cleveland, US; Bochum, DE; London, GB; Seattle, Weston, US; Dublin, IE)
15:30 - 17:00 Quality of life
Is it different what multiple sclerosis patients and their caregivers perceive as unmet needs? P 593
L. Lorefice, E. Cocco, G. Mura, G. Fenu, J. Frau, G. Coghe, G. Coni, C. Sardu, M.G. Marrosu (Cagliari, IT)
15:30 - 17:00 Long-term treatment monitoring
Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients P 518
D. Baroncini, A. Ghezzi, M. A. Rocca, P.O. Annovazzi, A. Bianchi, G. Minonzio, M. Zaffaroni, M. Filippi, G. Comi (Gallarate, Milan, Milan-Gallarate, IT)
15:30 - 17:00 Devic’s NMO spectrum
Neurology Mosaic 17: a reliable test for NMO and NMO-related disorders diagnosis. P 209
L. Granieri, F. Marnetto, P. Valentino, M. Capobianco, A. Bertolotto (Orbassano, IT)
15:30 - 17:00 Immunomodulation
The response to Toll-like receptor stimulation is impaired in plasmacytoid dendritic cells of multiple sclerosis patients undergoing interferon-b therapy P 479
M. Severa, F. Rizzo, E. Giacomini, R. Mechelli, V. Gafa, D. Vittori, G. Coarelli, M. Salvetti, E.M. Coccia (Rome, IT; Reims, FR)
15:30 - 17:00 Risk management for disease modifying treatments
JCV antibodies seroconversion on natalizumab treatment and predictive factors: preliminary data P 539
R. Lanzillo, R. Liuzzi, A. Guacci, L. Amato, L. Vallefuoco, G. Vacca, G. Orefice, G. Portella, V. Brescia Morra (Naples, IT)
15:30 - 17:00 Imaging
Influence of T2 lesion load on cognitive impairment at the early phase of MS P 411
N. Moll, F. Reuter, W. Zaaraoui, A. Rico, I. Malikova, L. Crespy, A. Faivre, A. Loundou, P. Auquier, P. Cozzone, J.P. Ranjeva, B. Audoin, J. Pelletier (Marseille, FR)
15:30 - 17:00 Immunomodulation
Reasons for switching first-line disease-modifying therapies in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC) P 455
D. Wynn, M. Cascione, N. Agashivala, K. McCague, L. Pestreich, L. Schofield, L. Barbato, E. Kim (Northbrook, Tampa, East Hanover, US)
15:30 - 17:00 Treatment of specific symptoms
FTY720 attenuates experimental neuropathic pain through mechanisms independent of its immunosuppressive properties P 563
J. Zhang, J.P. Zhou, X.Q. Shi, Y.C. Wu, H. Huang, S.H. Lee, J. Antel (Montreal, CA)
15:30 - 17:00 Neuropsychology and fatigue
Benign multiple sclerosis in a cohort of Brazilian patients: cognitive outcomes P 438
G. Santos, C.C. Ferreira Vasconcelos, S. Gomes Camargo, F. Hampshire Araujo, J. Calvet Kallembach, R. Alves Paes, D.-N. Rodrigues Cerqueira, T.C. Monteiro, L.C. Santos Thuler, R. Papais Alvarenga (Rio de Janeiro, BR)
15:30 - 17:00 Neuro-ophthalmology
Quantification of retinal vessels in multiple sclerosis P 602
E.M. Kadas, F. Bilger, L. Ludin, T. Oberwahrenbrock, A.U. Brandt, F. Paul (Berlin, DE)
15:30 - 17:00 Neuropsychology and fatigue
Language dysfunctions in multiple sclerosis P 441
F. Blanc, M.O. Kieffer, D. Baron, A. Michel, N. Cremel, B. Jung, J.B. Chanson, N. Collongues, J. de Seze (Strasbourg, FR)
15:30 - 17:00 Experimental models
ONO-4641, a potent and selective sphingosine 1-phosphate receptor-1 and -5 agonist, reverses chronic and progressive neurological deficits in preclinical models of multiple sclerosis P 340
A. Savinainen, F. Bernard, T. Crandall, S. Nock, R. Chang, N. Martinier, T. Seabrook, P. Smith, H. Kurata, H. Habashita, S. Nakade, U. Boschert, T. Dellovade (Billerica, US; Geneva, CH; Osaka, JP)
15:30 - 17:00 Immunomodulation
Safety and tolerability of BG-12 in patients with relapsing–remitting multiple sclerosis: an integrated analysis of the placebo-controlled studies P 484
K. Selmaj, R.J. Fox, R. Gold, E. Havrdova, L. Kappos, K. Raghupathi, H. Yuan, M. Novas, M.T. Sweetser, V. Viglietta, S.I. Sheikh, K.T. Dawson, J.T. Phillips (Lodz, PL; Cleveland, US; Bochum, DE; Prague, CZ; Basel, CH; Weston, Dallas, US)
15:30 - 17:00 Devic’s NMO spectrum
Neuromyelitis optica in Austria in 2011: to gap the bridge between neuroepidemiological research and practice in a study population of 8.4 Million people P 218
F. Aboul-Enein, M. Reindl, M. Storch, T. Berger, W. Kristoferitsch on behalf of the ARGE NMO Austria
15:30 - 17:00 Devic’s NMO spectrum
Diagnostic biopsy of spinal tumours: need for prior aquaporin-4 antibody testing P 208
M. Ringelstein, I. Metz, K. Ruprecht, A. Koch, J. Rappold, J. Harmel, C. Mathys, S. Jarius, W. Brück, H.-P. Hartung, F. Paul, O. Aktas (Düsseldorf, Göttingen, Berlin, Hochegg, Heidelberg, DE)
15:30 - 17:00 Imaging
R2* based iron mapping in multiple sclerosis: a multicentre study P 416
S. Ropele, M. Wattjes, I.D. Kilsdonk, W. de Graaf, C. Langkammer, J.L. Frederiksen, D. Fuglř, O. Ciccarelli, M. Khalil, M.A. Rocca, T. Sprenger, L. Kappos, M. Filippi, A. Rovira, D. Miller, F. Barkhof, F. Fazekas (Graz, AT; Amsterdam, NL; Copenhagen, DK; London, GB; Milan, IT; Basel, CH; Barcelona, ES)
15:30 - 17:00 Grey matter damage in MS
Does white matter damage predict later grey matter changes in early primary-progressive MS? P 313
B. Bodini, D. Chard, D. Altmann, D. Tozer, D.H. Miller, A.J. Thompson, C. Wheeler-Kingshott, O. Ciccarelli (London, GB)
15:30 - 17:00 Long-term treatment monitoring
Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA) P 522
T. Ziemssen, M. Meergans, P. Vollmar, R. Kempcke, F. Tracik, T. van Lokven (Dresden, Nuremberg, DE)
15:30 - 17:00 Immunomodulation
Interferon-beta induces hepatocyte growth factor in monocytes of multiple sclerosis patients P 469
N. Molnarfi, M. Benkhoucha, K. Bjarnadóttir, C. Juillard, P.H. Lalive (Geneva, CH)
15:30 - 17:00 Adaptative and Innate immunology
The CD11b+ B1-cell subpopulation is diminished in relapsing-remitting multiple sclerosis patients P 357
C. Třrring, T. Petersen, P. Höllsberg (Arhus, DK)
15:30 - 17:00 Clinical assessment tools
The CogState Brief Battery (CBB): clinical advantages in detecting early cognitive impairment in patients with multiple sclerosis (preliminary data) P 289
L. de Meijer, E. Grobbee, D. Darby, J. Gale, P. Maruff, L. Kurczycki, J. Haartsen, H. Butzkueven, O. Skibina (Melbourne, AU)
15:30 - 17:00 Paediatric MS
Age of menarche and MS risk in paediatric patients with acute demyelination P 222
J. O'Mahony, C. Phan, H. Hanwell, A.D. Sadovnick, R.A. Marrie, B. Banwell on behalf of the Canadian Paediatric Demyelinating Disease Network
15:30 - 17:00 Risk management for disease modifying treatments
Attitude of Italian neurologists about neutralising antibodies to interferon-beta P 541
F. Marnetto, M. Caldano, A. Sala, S. Malucchi, F. Sperli, P. Valentino, C. Carcione, F. Gilli, M. Zaffaroni, R. Bergamaschi, P. Borrelli, A. Bertolotto (Orbassano, Gallarate, Pavia, IT)
15:30 - 17:00 Adaptative and Innate immunology
Auto-antibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort P 355
Y. Hacohen, M. Absoud, L. Jacobson, M. Woodhall, P. Waters, W.K. Chong, C. Cummins, C. De Goede, K. Foster, R. Gunny, C. Hemingway, P.E. Jardine, R. Kneen, M. Likeman, K. Nischal, M.G. Pike, N. Sibtain, W. Whitehouse, E. Wassmer, A. Vincent, M. Lim on behalf of the UK & Ireland Childhood CNS Inflammatory Demyelination Working Group
15:30 - 17:00 Devic’s NMO spectrum
Diagnostic dilemma of Japanese patients with AQP4 antibody P 213
I. Kawachi, K. Yanagawa, E. Saji, M. Arakawa, A. Yokoseki, M. Hokari, M. Nishizawa (Niigata, JP)
15:30 - 17:00 Immunomodulation
Early therapy with IFNB-1b started at the first event suggestive of MS reduces the evolution of persistent T1 hypointensities on brain MRI P 488
F. Barkhof, G. Nagtegaal, M.P:. Wattjes, C.H. Polman, H.E. Hulst, M.S. Freedman, H.-P. Hartung, D.H. Miller, X. Montalbán, L. Kappos, G. Edan, D. Pleimes, K. Beckmann, C. Pohl, B. Stemper, R. Sandbrink (Amsterdam, NL; Ottawa, CA; Düsseldorf, DE; London, GB; Barcelona, ES; Basel, CH; Rennes, FR; Montville, US; Berlin, DE)
15:30 - 17:00 Paediatric MS
Report of 25 paediatric multiple sclerosis cases P 224
M. Alhyan, K. El Alaoui Taoussi, E.H. Ait Ben Haddou, W. Regragui, W. Ahid, R. Abouqal, A. Benomar, M. Yahyaoui (Rabat, MA)
15:30 - 17:00 Others
An association study on the R92Q mutation in the TNFRSF1A gene and symptoms compatible with a TNFRSF1A-associated periodic syndrome (TRAPS) in multiple sclerosis patients P 560
L.A. Gerdes, W. Igl, S. Schwenke, R. Sandbrink, B. Stemper, R. Hohlfeld, T. Kümpfel, C. Pohl (Munich, Berlin, DE)
15:30 - 17:00 Long-term treatment monitoring
Adherence to disease-modifying treatments in Turkish cohort P 514
S. Yildiz, U. Uygunoglu, A. Bingol, E. Goksel, I. Aydin Canturk, N. Isik, N. Sutlas, D. Yandim Kuscu, B. Kocer, A. Kurne, B. Topcular, G. Demir Akman, O. Anlar, H. Efendi, A. Altintas, S. Saip, R. Karabudak, A. Siva (Istanbul, Ankara, Kocaeli, TR)
15:30 - 17:00 Diagnosis and differential diagnosis
Prediction of early conversion to multiple sclerosis in clinically isolated syndrome P 186
B. Piri Cinar, S. Ozakbas, E. Idiman (Izmir, TR)
15:30 - 17:00 Neuro-ophthalmology
Optical nerve diameter and echogenicity are impaired in demyelinating diseases P 601
J. Fernández-Domínguez, R. García-Rodríguez, V. Mateos (Latores Oviedo, ES)
15:30 - 17:00 Imaging
MR molecular Imaging of VCAM-1 in EAE mice treated by statin: a new perspective for diagnosis and therapeutic management P 422
R. Macrez, M. Gauberti, A. Montagne, D. Vivien, F. Docagne, G. Defer (Caen, FR)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Hydration status may confound CCSVI ultrasound assessment P 627
C. Diaconu, R. Fox, M. Lu, A. Grattan, A. Rae-Grant, H. Gornik, S. Kim (Cleveland, US)
15:30 - 17:00 Environmental risk factors
Low prevalence of cerebrospinal fluid oligoclonal IgG bands in Greek patients with multiple sclerosis P 376
E. Andreadou, S. Chatzipanagiotou, V.C. Constantinides, C. Kyriazi, A. Tsatsi, M.E. Evangelopoulos, M. Michalopoulou, F. Boufidou, C. Kilidireas, A. Rombos, C. Nicolaou, E. Stamboulis (Athens, GR)
15:30 - 17:00 MS and infections
Acute disseminated encephalomyelitis in two renal transplant patients: is there a role for EBV reactivation? P 368
N. Caucheteux, A. Maarouf, L. Daelman, O. Toupance, S. Lavaud, A. Tourbah (Reims, FR)
15:30 - 17:00 Epidemiology
Polyautoimmunity in multiple sclerosis P 248
E. Koutlas, G. Deretzi, J. Rudolf, T. Tsironis, C. Zakestidis, P. Petrou, I. Tsiptsios (Thessaloniki, GR)
15:30 - 17:00 Experimental models
Tertiary lymphoid organ development facilitates determinant spreading of the MP4-specific T-cell response P 335
S. Kuerten, C. Kerkloh, A. Schickel, K. Addicks, G. Fink, M. Schroeter, C. Kaiser (Cologne, DE)
15:30 - 17:00 Immunomodulation
Does immunotherapy influence the vaccination response among patients with multiple sclerosis? P 461
H.K. Olberg, R.J. Cox, J.K. Nřstbakken, J.H. Aarseth, C.H. Vedeler, K.M. Myhr (Bergen, NO)
15:30 - 17:00 Adaptative and Innate immunology
Multiple sclerosis: high-throughput T-cell receptor sequencing reveals clonal expansions of Epstein-Barr virus specific T-cells in the cerebrospinal fluid P 347
A. Lossius, J. Johansen, F. Vartdal, H. Robins, T. Holmřy, J. Olweus (Oslo, NO; Seattle, US; Lřrenskog, NO)
15:30 - 17:00 Diagnosis and differential diagnosis
Predictive factors for MS in patients with clinically isolated syndromes P 196
A. Ruet, G. Arrambide, B. Brochet, C. Auger, E. Simon, A. Rovira, X. Montalban, M. Tintore (Bordeaux, FR; Barcelona, ES)
15:30 - 17:00 Clinical assessment tools
Postural sway analysis as tool to assess balance impairments in individuals with multiple sclerosis P 299
E. Cocco, G. Coghe, J. Frau, C. Scalas, G. Fenu, L. Lorefice, M. Melis, M.G. Marrosu, M. Pau (Cagliari, IT)
15:30 - 17:00 Pregnancy and MS
Longitudinal optical coherence tomography study in MS patients during pregnancy and postpartum breastfeeding P 278
I. Ayzenberg, K. Hellwig, R. Gold, S. Schippling (Bochum, DE; Zurich, CH)
15:30 - 17:00 Devic’s NMO spectrum
Visual and motor disability in a cohort of patients with neuromyelitis optica in South Wales and the South West of England P 205
S. Luppe, K. Harding, T. Pickersgill, N. Robertson (Cardiff, GB)
15:30 - 17:00 Treatment of specific symptoms
Evaluation of fampridine response by multivariate analysis of mobility in multiple sclerosis P 569
T. Schultheiß, R. Kempcke, K. Thomas, S. Sobek, T. Ziemssen (Dresden, DE)
15:30 - 17:00 MS and infections
Neuropathological study of Epstein Barr-virus infection in the MS brain P 361
J.S. Tzartos, G. Khan, J. Middeldorp, G. Giovannoni, U.C. Meier (Athens, GR; Al Ain, AE; Amsterdam, NL; London, GB)
15:30 - 17:00 Immunomodulation
Interferon-beta-1b treatment in clinical practice: final results of a large international observational study P 481
J. Kuhle, K. Beckmann, J.-P. Bugge, L. Kappos for the BEST Study Group
15:30 - 17:00 Imaging
Relationship between cognitive impairment and functional connectivity changes in multiple sclerosis patients during resting state P 397
A.J. Cruz-Gómez, N. Ventura Campos, A. Belenguer, C. Ávila, C. Forn (Castelló de la Plana, ES)
15:30 - 17:00 Databases and Pharmacoepidemiology
Leveraging electronic health records for research in multiple sclerosis P 257
Z. Xia, R. Bove, T. Cai, S. Cheng, R. Perez, V. Gainer, S. Murphy, P. Chen, G. Savova, K. Liao, E. Karlson, S. Shaw, A. Ananthakrishnan, P. Szolovits, S. Churchill, I. Kohane, R. Plenge, P. De Jager (Boston, Charlestown, Cambridge, US)
15:30 - 17:00 Immunomodulation
Peripheral blood mononuclear cell phenotypes under treatment with fingolimod: a prospective study of a German cohort of patients with relapsing-remitting multiple sclerosis P 475
T. Dehmel, B. Opgenoorth, H.-P. Hartung, M. Diaz-Lorente, B.C. Kieseier (Düsseldorf, DE)
15:30 - 17:00 Immunosuppression
Mitoxantrone therapy for multiple sclerosis: the Nova Scotia experience P 500
N. Parks, J. Wadhawan, T. Campbell, V. Bhan (Halifax, CA)
15:30 - 17:00 Long-term treatment monitoring
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: clinical effects at 36 months in the open-label extension phase of the ALLEGRO study P 516
G. Comi, D. Jeffery, L. Kappos, X. Montalban, A.N. Boyko, M.A. Rocca, M. Filippi on behalf of the ALLEGRO Study Group
15:30 - 17:00 Clinical assessment tools
Correlation of brain atrophy with cognitive evaluation and OCT results in multiple sclerosis P 296
S. Yurtogullari, O. Taskapilioglu, B. Hakyemez, B. Bilgic, B. Ozturk, A. Bayram, N. Turkes, D. Sigirli, O.F. Turan, M. Bakar (Bursa, Istanbul, TR)
15:30 - 17:00 Biomarkers
Multiparameter assay evaluation and quantification of inflammatory cytokines in cerebrospinal fluid and serum of multiple sclerosis patients P 622
A. Malekzadeh, N. Wijnstok, H. Twaalfhoven, B. van Oosten, V. de Groot, M. Blankenstein, C. Teunissen (Amsterdam, NL)
15:30 - 17:00 Clinical assessment tools
Employing fuzzy concept to MSFC as an alternative score for quantising the progression of MS disease P 298
J. Razjouyan, S. Gharibzadeh, A. Fallah, M. Raza, A.R. Azimi, M.A. Sahraian (Tehran, IR)
15:30 - 17:00 Risk management for disease modifying treatments
Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies P 530
J.P. DiMarco, P. O'Connor, J.A. Cohen, A.T. Reder, L. Zhang-Auberson, D. Tang, W. Collins, L. Kappos (Charlottesville, US; Toronto, CA; Cleveland, Chicago, US; Basel, CH; East Hanover, US)
15:30 - 17:00 Immunomodulation
Long-term immunological changes during fingolimod therapy in MS P 476
T. Sehr, U. Hainke, M. Zendzian-Piotrowska, R. Bucki, K. Thomas, M. Marggraf, T. Ziemssen (Dresden, DE; Bialystok, PL; Philadelphia, US)
15:30 - 17:00 Immunomodulation
Autologous mesenchymal stem cell transplantation in multiple sclerosis: a randomised, double-blind, crossover with placebo phase II study P 462
M. Sepulveda, Y. Blanco, S. Llufriu, I. Gabilondo, P. Villoslada, P. Marín, J. Berenguer, M. Squarcia, B. Sánchez-Dalmau, S. Ortiz, N. Solŕ, F. Graus, A. Saiz (Barcelona, ES)
15:30 - 17:00 Adaptative and Innate immunology
Liver X receptor activation alters the Teffector / Treg balance and enhances the suppressive capacity of Tregs derived from multiple sclerosis patients P 351
M. Herold, B. Grützke, S. Hucke, H. Wiendl, L. Klotz (Münster, DE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Comparison of intravascular ultrasound to gold standard catheter venography for detection of extra-cranial venous abnormalities indicative of CCSVI: results of the PREMiSe (Prospective Randomized Endovascular therapy in Multiple Sclerosis) study P 632
Y. Karmon, R. Zivadinov, B. Weinstock-Guttman, K. Dolic, C. Kennedy, K. Marr, V. Valnarov, A. Siddiqui (Buffalo, US)
15:30 - 17:00 Grey matter damage in MS
Molecular basis of memory dysfunction in MS patients P 316
R. Dutta, A. Chang, A. Chomyk, S. Deckhard, M. Ribaudo, K. Doud, R. Fox, B. Trapp (Cleveland, US)
15:30 - 17:00 Devic’s NMO spectrum
Autologous haematopoietic stem cell transplantation following high-dose immunosuppressive therapy in neuromyelitis optica P 201
J.D. Bowen, H. Hagglund, G.H. Kraft, A. Wundes, F. Piehl, R. Storb, G.E. Georges, K. Maravilla, R.A. Nash (Seattle, US; Stockholm, SE; Denver, US)
15:30 - 17:00 Clinical assessment tools
Manovolumetric pattern in multiple sclerosis patients with anorectal dysfunctions P 294
M. Capobianco, S. Marola, A. Surace, E. Boero, A. Ferrarese, I. De Stefano, M. Scaglia, A. Di Sapio, M. Nano, A. Bertolotto (Orbassano, IT)
15:30 - 17:00 Environmental risk factors
Epstein-Barr virus shedding in children with multiple sclerosis P 374
C. Yea, C. Darrell, S. McGovern, S. Khan, M. McGowan, J. Pinto, S. McCorrister, G. Westmacott, D. Arnold, D. Sadovnick, R. Tellier, A. Bar-Or, B. Banwell on behalf of The Canadian Demyelinating Disease Network
15:30 - 17:00 Paediatric MS
MRI pattern classification using cluster analysis for early prediction of multiple sclerosis in paediatric acquired demyelinating syndromes P 227
M. Absoud, M.J. Lim, K. Chong, C.G. De Goede, K. Foster, R. Gunny, C. Hemingway, P. Jardine, R. Kneen, M. Likeman, K.K. Nischal, M.G. Pike, N.A. Sibtain, W.P. Whitehouse, E. Wassmer, C. Cummins on behalf of the UK & Ireland Childhood CNS Inflammatory Demyelination Working Group
15:30 - 17:00 MS and infections
Preliminary search for a Japanese macaque rhadinovirus-like virus in multiple sclerosis subjects P 369
D. Bourdette, S. Wong (Portland, US)
15:30 - 17:00 Pregnancy and MS
Post-marketing pregnancy outcomes in patients exposed to intramuscular interferon-beta-1a P 274
S. Tomczyk, B. Sperling (Weston, US)
15:30 - 17:00 Neuropsychology and fatigue
Influence of emotional valence in episodic memory in multiple sclerosis: neuropsychological and MRI study P 443
N. Derache, A. Mondou, F. Doidy, R. Makouri, P. Piolino, F. Eustache, G.L. Defer, B. Desgranges (Caen, Paris, FR)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Heart disease, overweight and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities P 633
K. Dolic, B. Weinstock-Guttman, K. Marr, V. Valnarov, E. Carl, J. Hagemeier, C. Kennedy, C. Kilanowski, D. Hojnacki, M. Ramanathan, R. Zivadinov (Buffalo, US)
15:30 - 17:00 Adaptative and Innate immunology
Interleukin-15 amplifies the pathogenic activity of CD4+CD28- T cells in multiple sclerosis patients P 348
B. Broux, B. Van Wijmeersch, P. Stinissen, N. Hellings (Diepenbeek, BE)
15:30 - 17:00 Neuroprotection
Effects of BG-12 on magnetic resonance imaging and magnetisation transfer ratio outcomes in relapsing–remitting multiple sclerosis: findings from the phase 3 DEFINE study P 509
D.L. Arnold, R. Gold, L. Kappos, A. Bar-Or, G. Giovannoni, K. Selmaj, M. Yang, R. Zhang, M. Stephan, K.T. Dawson (Montreal, CA; Bochum, DE; Basel, CH; London, GB; Lodz, PL; Weston, US)
15:30 - 17:00 Imaging
Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis P 385
C. Beggs, S. Shepherd, M. Dwyer, P. Polak, C. Magnano, E. Carl, G. Poloni, B. Weinstock-Guttman, R. Zivadinov (Bradford, GB; Buffalo, US)
15:30 - 17:00 Imaging
Imbalance in multiple sclerosis: a result of cerebellum and spinal cord atrophy P 401
L. Prosperini, N. Petsas, D. Fortuna, E. Sbardella, E. Raz, F. Tona, C. Pozzilli, P. Pantano (Rome, IT)
15:30 - 17:00 Quality of life
Effects of BG-12 on quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study P 586
M. Kita, R.J. Fox, J.T. Phillips, M. Hutchinson, E. Havrdova, S.P. Sarda, J. Kong, V. Viglietta, S.I. Sheikh, K.T. Dawson (Seattle, Cleveland, Dallas, US; Dublin, IE; Prague, CZ; Weston, US)
15:30 - 17:00 Tools for detecting therapeutic response
Anti-phospholipid antibodies are associated with response to interferon-beta-1a treatment in MS: results from a 3-year longitudinal study P 556
R. Zivadinov, M. Ramanathan, J. Ambrus, S. Hussein, D. Ramasamy, M. Dwyer, N. Bergsland, A. Minagar, B. Weinstock-Guttman (Buffalo, US)
15:30 - 17:00 Immunomodulation
Effect of teriflunomide on the pharmacodynamic and pharmacokinetic profiles of warfarin in healthy male subjects P 453
S. Turpault, S. Mair, Z. Meng, A. Hochet, F. Menguy-Vacheron (Bridgewater, US; Nottingham, GB; Chilly Mazarin, FR)
15:30 - 17:00 Genetics / transcriptomics
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis P 343
R. Ratzer, H.B. Sřndergaard, P.S. Sřrensen, J.C. Christensen, F. Sellebjerg (Copenhagen, DK)
15:30 - 17:00 Economic burden
A cost-effectiveness analysis of subcutaneous interferon-beta-1a 44mcg three times a week versus no treatment for patients with a single demyelinating event in Sweden P 304
S. Fredrikson, E. McLeod, N. Henry, A. Pitcher, M. Cuche, L. Fajutrao, R. Perard, D. Bates, A. Chan (Stockholm, SE; London, GB; Geneva, CH; Solna, SE; Middlesex, Newcastle, GB; Bochum, DE)
15:30 - 17:00 Imaging
Exploring the relationship between regional grey matter atrophy and cognitive impairment in paediatric multiple sclerosis P 400
M.A. Rocca, M. Absinta, M.P. Amato, A. Ghezzi, L. Moiola, A. Fiorino, P. Veggiotti, G. Comi, M. Filippi and the MS and Neuroimaging Study Groups of the Italian Neurological Society
15:30 - 17:00 Experimental models
Selective oligodendrocyte loss associated with wide-spread mitochondrial dysfunction in the cuprizone-induced experimental demyelination P 337
S. Komoly, P. Acs, M. Selak, B. Kalman (Pecs, HU; Philadelphia, US; Munich, DE)
15:30 - 17:00 Immunomodulation
Regulatory T-cell numbers in patients with RRMS were not associated with clinical or MRI outcomes in the SELECT study P 473
R. Gold, K. Selmaj, X. You, J. Sheridan, L. Amaravadi, J. Fontenot, J. Elkins (Bochum, DE; Lodz, PL; Cambridge, Redwood City, US)
15:30 - 17:00 Imaging
A supervised approach to segment multiple sclerosis lesions using context-rich features and a boosting classifier P 398
M. Cabezas, A. Oliver, X. Lladó, Y. Díez, J. Freixenet, J.C. Vilanova, A. Quiles, G. Laguillo, L. Ramió-Torrentŕ, D. Pareto, A. Rovira (Girona, Barcelona, ES)
15:30 - 17:00 Quality of life
The impact of increasing disability on quality of life in multiple sclerosis P 584
E. Fogarty, C. Walsh, C. McGuigan, M. Barry, N. Tubridy (Dublin, IE)
15:30 - 17:00 Grey matter damage in MS
Patterns of regional grey and white matter atrophy associated to PASAT and SDMT performances in relapsing-remitting multiple sclerosis patients P 320
G. Riccitelli, M.A. Rocca, E. Pagani, V. Martinelli, M. Radaelli, G. Comi, M. Filippi (Milan, IT)
15:30 - 17:00 Imaging
Cerebellar peduncles intrinsic damage in multiple sclerosis: association with clinical disabilty P 405
P. Preziosa, M.A. Rocca, S. Mesaros, E. Pagani, T. Stosic-Opincal, J. Drulovic, G. Comi, M. Filippi (Milan, IT; Belgrade, RS)
15:30 - 17:00 Risk management for disease modifying treatments
Fingolimod reduces the risk of recurrence of disease activity during the first 12 months after natalizumab discontinuation in multiple sclerosis P 536
J. Havla, B. Tackenberg, K. Hellwig, I. Meinl, M. Krumbholz, F. Seitz, C. Eienbröcker, R. Gold, R. Hohlfeld, I. Kleiter, T. Kümpfel (Munich, Marburg, Bochum, DE)
15:30 - 17:00 Neuropsychology and fatigue
Measuring cognitive fatigue in multiple sclerosis P 432
S.A. Morrow (London, CA)
15:30 - 17:00 Databases and Pharmacoepidemiology
MS therapy adherence and relapse risk P 260
T. Leist, H. Zwibel, M. Schwartz, B. Cohen, M. Tullman, P. K. Coyle on behalf of the TOP MS Steering Committee
15:30 - 17:00 Grey matter damage in MS
Bi-monthly evolution of cortical atrophy in early relapsing-remitting multiple sclerosis over 2 years. A longitudinal study P 317
R. Zivadinov, C. Tekwe, N. Bergsland, O. Dolezal, E. Havrdova, J. Krasensky, M. Dwyer, Z. Seidl, D. Ramasamy, M. Vaneckova, D. Horakova (Buffalo, US; Prague, CZ)
15:30 - 17:00 Neuro-ophthalmology
The relationship between OCT and H-MRS parameters in MS patients P 596
M. Davydovskaya, M. Cysar, V. Akopyan, A. Podoprigora, I. Pronin, V. Kornienko (Moscow, RU)
15:30 - 17:00 Long-term treatment monitoring
IRF5 genotypes, relapses and progression in multiple sclerosis patients treated with interferon-beta P 527
F. Sellebjerg, H.B. Sřndergaard, N. Koch-Henriksen, P.S. Sřrensen, A.B. Oturai (Copenhagen, DK)
15:30 - 17:00 Imaging
Local functional connectivity is decreased across multiple cortical areas in multiple sclerosis P 384
E. Klawiter, S. Tobyne, S. Govindarajan, J. Sepulcre, E. Tinelli, R. Buckner, R.P. Kinkel, B. Rosen, C. Mainero (Boston, US; Rome, IT)
15:30 - 17:00 Environmental risk factors
Fatty fish intake decrease multiple sclerosis risk among people exposed to low levels of ultraviolet radiation P 371
M. Bäärnhielm, T. Olsson, L. Alfredsson (Stockholm, SE)
15:30 - 17:00 Imaging
Evaluation of an albumin binding gadolinium contrast agent in multiple sclerosis P 409
A. Magnus, J. Lamy, J. de Sčze, J. Dietemann, J. Armspach, S. Kremer (Strasbourg, FR)
15:30 - 17:00 Experimental models
Gene expression profile of brain cells in response to treatment with interferon-beta and C-phycocyanin in the experimental autoimmune encephalomyelitis model P 327
G. Penton-Rol, M. Nazabal-Galvez, N. Lagumersindez-Denis, L. Muzio, A. Bergami, J. Fernandez-Masso, A. Cintado-Benitez, N. Polentarutti, T. Veliz, G. Guillen-Nieto, R. Furlan, A. Mantovani, E. Penton-Arias (Havana, CU; Milan, IT)
15:30 - 17:00 Immunomodulation
Endoglycosidase S converts neuromyelitis optica anti-aquaporin-4 immunoglobulin G from a pathogenic to a therapeutic antibody P 454
L. Tradtrantip, J. Ratelade, H. Zhang, A.S. Verkman (San Francisco, US)
15:30 - 17:00 Epidemiology
Relationship between body mass index and disease severity in an online multiple sclerosis population P 241
R. Bove, E. Secor, T. Vaughan, T. Chitnis, P. Wicks, P. De Jager (Boston, Cambridge, US)
15:30 - 17:00 Treatment of specific symptoms
Office-based, single-shot bolus trial of intrathecal ziconotide in patients with painful myelopathy and neuropathy P 564
J. Nicholas, M. Bartoszek, C. O’Connell, B. Morgan-Followell, V. Lawson, D. Pitt, A. Boster (Columbus, US)
15:30 - 17:00 Imaging
Multiple sclerosis impairs regional functional connectivity in the cerebellum P 414
A.-M. Dogonowski, K. Winther Jřrgensen, K.H. Madsen, P. Soelberg Sřrensen, O.B. Paulson, M. Blinkenberg, H.R. Siebner (Hvidovre, Copenhagen, DK)
15:30 - 17:00 Clinical assessment tools
MS Curves: a new online tool for assessing MS severity using the MSBase Registry P 287
S.E. Hughes, T. Spelman, E. Bianchi, S. Méchati, H. Butzkueven on behalf of the MSBase investigators
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Prospective, case-control study of CCSVI with imaging-blinded assessments P 628
J. Wolinsky, L. Kramer, A. Barreto, A. Cohen, S. Brod, T.-T. Bui, P. Narayana, J. Jemelka, F. Nelson, J. Lindsey (Houston, US)
15:30 - 17:00 Experimental models
Induction of CD39+ Tregs in both murine EAE and human PBMC by a gut commensal derived polysaccharide antigen P 339
K. Telesford, Y. Wang, S. Begum-Haque, J. Ochoa-Repáraz, D.L. Kasper, L.H. Kasper (Lebanon, Boston, US)
15:30 - 17:00 Clinical assessment tools
Improving the psychometric properties of the multiple sclerosis functional composite index: replacing the PASAT-3” with a brief measure of vigilant attention P 288
C. Edgar, J.E. Swartz, T. Feaster, K.A. Wesnes (Goring-on-Thames, GB; Wayne, US)
15:30 - 17:00 Neuropsychology and fatigue
Computerised cognitive training in MS: preliminary outcomes for working memory, information processing speed, and executive functioning P 435
L. Hancock, J. Bruce, J. Thelen, L. Fletcher, J. McGee, A. Ness, B. Baker, S. Lynch (Kansas City, US)
15:30 - 17:00 Adaptative and Innate immunology
Prolactin modulates B cell responses in multiple sclerosis P 350
J. Correale, M. Farez, M. Ysrraelit (Buenos Aires, AR)
15:30 - 17:00 Experimental models
Marginal zone/B220+CD21hiCD23low B-cells is associated with autoimmune pathology in an animal model of multiple-sclerosis: immunomodulatory effect of glatiramer acetate P 330
S. Begum-Haque, M. Christy, Y. Wang, K. Telesford, A. Haque, L.H. Kasper (Lebanon, US)
15:30 - 17:00 Others
Clinically isolated syndromes and conversion to relapsing-remitting multiple sclerosis: a study on possible predictors, including cerebrospinal fluid oligoclonal IgM bands P 559
D. Ferraro, A.M. Simone, R. Bedin, V. Galli, F. Vitetta, L. Federzoni, R. D'Amico, P.F. Nichelli, P. Sola (Modena, IT)
15:30 - 17:00 Immunomodulation
Daclizumab HYP monotherapy reduces black holes and T2 burden of disease in relapsing-remitting multiple sclerosis: results of the SELECT trial P 471
E.W. Radue, R. Gold, G. Giovannoni, D. Stefoski, N. Mueller-Lenke, S. Glyman, K. Riester, J. Elkins (Basel, CH; Bochum, DE; London, GB; Chicago, US; Cambridge, US)
15:30 - 17:00 MS symptoms
Onabotulinumtoxin A decreases urinary incontinence and improves quality of life in multiple sclerosis patients with neurogenic detrusor overactivity P 266
V. Keppenne, D. Ginsberg, W. Lam, C. Thompson, J. Heesakkers (Ličge, BE; Los Angeles, Irvine, US; Nijmegen, NL)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Cine cerebrospinal fluid imaging changes in patients with multiple sclerosis after venous angioplasty. A 1-year follow-up study P 634
R. Zivadinov, C. Magnano, R. Galeotti, C. Schirda, B. Weinstock-Guttman, E. Menegatti, J. Hagemeier, A.M. Malagoni, D. Hojnacki, C. Kennedy, I. Bartolomei, C. Beggs, F. Salvi, P. Zamboni (Buffalo, US; Ferrara, IT; Bologna, IT; Bradford, GB)
15:30 - 17:00 Imaging
Biological origin of MR phase contrast in white matter lesions at 7T P 383
P. Maggi, P. Sati, S. Macri, E. Leibovitch, M. Absinta, L. Massacesi, S. Westmoreland, S. Jacobson, A. Silva, D.S. Reich (Bethesda, Boston, US)
15:30 - 17:00 Immunomodulation
Effect of daclizumab HYP treatment in highly active relapsing-remitting multiple sclerosis: results from the SELECT study P 463
G. Giovannoni, E.W. Radue, E. Havrdova, K. Riester, S. Greenberg, S. Glyman, J. Elkins (London, GB; Basel, CH; Prague, CZ; Cambridge, Redwood City, US)
15:30 - 17:00 Experimental models
Glatiramer acetate does not interfere with CNS immune surveillance in an animal model of Toxoplasmosis gondii infection P 338
R. Hussain, L. Hayardeny, M. Raetz, F. Yarovinsky, O. Stuve (Dallas, US; Petah Tikva, IL)
15:30 - 17:00 Neuroprotection
Olesoxime improves clinical score and promotes remyelination in MOG-induced experimental autoimmune encephalomyelitis P 512
T. Bordet, M. Cayre, C. Zimmer, K. Magalon, A. Viola, P. Durbec, R.M. Pruss (Marseille, FR)
15:30 - 17:00 Imaging
Functional connectivity abnormalities and cognitive impairment in relapse-onset MS patients: a whole-brain functional network connectivity analysis P 404
M. Filippi, P. Valsasina, P. Preziosa, G. Riccitelli, V. Martinelli, G. Comi, M.A. Rocca (Milan, IT)
15:30 - 17:00 Epidemiology
Early identification of aggressive multiple sclerosis using EDSS P 239
T. Scott, C. Hackett, C. Schramke (Pittsburgh, US)
15:30 - 17:00 Imaging
Assessing correlation of regional white and grey matter damage with motor and cognitive impairment in multiple sclerosis P 402
E. Sbardella, F. Tona, N. Petsas, L. Prosperini, E. Raz, C. Pozzilli, P. Pantano (Rome, IT)
15:30 - 17:00 Experimental models
The role of TIM-3 in the development of Theiler's Murine encephalomyelitis virus-induced dymyelinating disease P 331
T. Kaneyama, H. Tomiki, S. Tsugane, M. Ichikawa, H. Yagita, B. Kim, C.S. Koh (Matsumoto, Tokyo, JP; Chicago, US)
15:30 - 17:00 Neuroprotection
The inhibition of oxidative stress by a xanthine oxidase inhibitor ameliorates EAE P 503
J.A. Honorat, M. Kinoshita, T. Okuno, K. Takata, T. Kohda, S. Tada, H. Mochizuki, S. Sakoda, Y. Nakatsuji (Suita, Toyonaka, JP)
15:30 - 17:00 Long-term treatment monitoring
Long-term safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the TYSABRI(R) observational programme P 519
F. Pellegrini, S. Belachew, H. Butzkueven, L. Kappos, M. Trojano, H. Wiendl, A. Zhang, R. Arnold (Chieti, IT; Ličge, BE; Melbourne, AU; Basel, CH; Bari, IT; Münster, DE; Weston, US)
15:30 - 17:00 Paediatric MS
Detecting cognitive and psychoaffective deficits in children and juveniles with multiple sclerosis: The MUSICADO study P 229
P. Calabrese, K. Storm van`s Gravesande, A. Blaschek, F. Heinen, P. Hupke, V. Mall (Basel, CH; Vienna, AT; Munich, Göttingen, Freiburg, DE)
15:30 - 17:00 Pregnancy and MS
Preliminary evaluation of pregnancy outcomes from the TYSABRI® (natalizumab) Pregnancy Exposure Registry P 275
L.M. Cristiano, C. Bozic, G. Bloomgren, S. Friend, Y.-J. Liu (Weston, US)
15:30 - 17:00 Imaging
Longitudinal absolute metabolite quantification and reproducibility in healthy controls and MS patients using CSI P 390
O.T. Wiebenga, A.M. Klauser, G.J.A. Nagtegaal, C.H. Polman, F. Barkhof, J.J.G. Geurts, P.J.W. Pouwels (Amsterdam, NL)
15:30 - 17:00 Others
Osteoporosis and fracture risk in multiple sclerosis P 562
R. Dobson, S. Ramagopalan, G. Giovannoni (London, GB)
15:30 - 17:00 Biomarkers
Extracellular Actin Scavenger system as a diagnostic/prognosis tool in multiple sclerosis P 613
S. Perga, A. Giuliano Albo, K. Lis, N. Minari, R. Reviglione, F. Marnetto, F. Gilli, M. Malentacchi, M. Capobianco, D. Corpillo, A. Bertolotto (Orbassano, Colleretto Giacosa, IT)
15:30 - 17:00 Neuroprotection
ACTH 1-39 protects oligodendroglial progenitor cells from excitotoxic and inflammation-related damage and promotes their proliferation and differentiation P 507
J. Benjamins, L. Nedelkoska, B. Bealmear, R. Lisak (Detroit, US)
15:30 - 17:00 Quality of life
The quality of life assessment in patients with multiple sclerosis using MusiQoL questionnaire: results of the nationwide multicentre study in Russia P 582
A. Boyko, O. Boyko, A. Khitry, O. Rozenson on behalf of the investigators in the EMR200077-510 project
15:30 - 17:00 Clinical assessment tools
Displaying the motor components of the MSFC as an interval score on a IPhone / IPad app with sagas20/10 P 297
S. Vaney, S. Bayard, C. Kuonen, M. Zeiter, S. Rapillard, T. Rapillard (Crans Montana, Vétroz, CH)
15:30 - 17:00 Risk management for disease modifying treatments
Thyroid function and autoimmunity during long-term disease-modifying therapy in patient with multiple sclerosis, data from every-day practice P 534
A. Boyko, L. Petrova, E. Gusev (Moscow, RU)
15:30 - 17:00 Adaptative and Innate immunology
High secreted levels of EGF from immune cells of patients with RR-MS may be related to the impaired neuronal repair P 359
A. Karni, K. Mausner-Fainberg, Y. Amir-Levy (Tel Aviv, IL)
15:30 - 17:00 MS and infections
An open-label observational pilot study to evaluate the safety and immunogenicity of the herpes zoster vaccine in patients with multiple sclerosis P 367
C. McGraw, M. Inglese, C. Hannigan, M. Petracca, A. Miller (New York, US)
15:30 - 17:00 Paediatric MS
Vitamin D deficiency as the enviromental risk factor for child multiple sclerosis P 219
M. Bilska, K. Kotulska-Józwiak (Warsaw, PL)
15:30 - 17:00 Economic burden
Treatment experience, burden, and unmet needs (encoms) in multiple sclerosis study: the costs of MS patients in Argentina P 306
C. Ysrraelit, F. Caceres, A.M. Villa, M. Parada Marcilla, M. Melcon, M.M. Resk, J.I. Rojas, G. Kuperman, G. Seifer, G. Machnicki, J. Cúneo on behalf of the ENCOMS STUDY GROUP
15:30 - 17:00 Imaging
Spinal cord 18flourodeoxyglucose positron emission tomography discriminates neoplastic from inflammatory myelopathic aetiologies P 387
E.P. Flanagan, C. Hunt, V. Lowe, J. Mandrekar, S. Pittock, B. O'Neill, M. Keegan (Rochester, US)
15:30 - 17:00 Imaging
The development of cognitive impairment correlates with the metabolic alterations in different brain structures in patients with relapsing-remitting and progressive multiple sclerosis P 412
G. Shkilnyuk, A. Ilves, G. Katayeva, L. Prakhova, T. Reznikova, I. Stolyarov (St-Petersburg, RU)
15:30 - 17:00 Grey matter damage in MS
Heterogeneity of cortical lesions in multiple sclerosis: clinical and pathological implications P 323
E. Kooi, E.M.M Strijbis, P. van der Valk, J.J.G. Geurts (Amsterdam, NL)
15:30 - 17:00 Devic’s NMO spectrum
The differential diagnoses of patients presenting with longitudinally extensive transverse myelitis: analysis of 76 cases P 204
J. Kitley, M.I. Leite, J. Palace (Oxford, GB)
15:30 - 17:00 Neuropsychology and fatigue
The relationship between emotion processing deficits and moral judgment in patients with multiple sclerosis P 450
V. Sinay, F. Manes, E. Gleichgerrcht (Buenos Aires, AR)
15:30 - 17:00 Diagnosis and differential diagnosis
Anti-TNF alpha agents and CNS demyelination: further evidence of an association? P 194
K. O'Connell, C. McGuigan (Dublin, IE)
15:30 - 17:00 Clinical assessment tools
Technical feasibility of implementing multifocal VEP for multicentre clinical trials P 281
D. Cadavid, N. Levin, F. Costello, A. Rahilly, A. Klistorner (Cambridge, US; Jerusalem, IL; Calgary, CA; Sydney, AU)
15:30 - 17:00 Epidemiology
Relationship between hours of daylight, date of birth and risk of multiple sclerosis P 249
A. Antiguedad, C. Llarena, M. Mendibe (Bilbao, ES)
15:30 - 17:00 Epidemiology
Association of changes in EDSS with confirmed MS relapses P 236
P. K. Coyle, H. Zwibel, T. Leist, M. Tullman, B. Cohen, M. Lage on behalf of the TOP MS Study Steering Committeee
15:30 - 17:00 Imaging
Alteration in cerebral haemodynamics in multiple sclerosis P 396
D. Paling, E. Petersen, D. Tozer, C. Wheeler-Kingshott, R. Kapoor, D. Miller, X. Golay (London, GB; Utrecht, NL)
15:30 - 17:00 Pathology
IL-7, IL-9 and IL-12 are associated with current aspects of disease, but do not predict disease course in multiple sclerosis P 311
K.E. Harding, M.D. Cossburn, P. Moore, T.P. Pickersgill, M. Wardle, N.P. Robertson (Cardiff, Poole, Liverpool, GB)
15:30 - 17:00 Devic’s NMO spectrum
Factors associated with the aquaporin-4 antibodies positivity in patients with longitidunally extensive transverse myelitis: possible role of asymptomatic visual-evoked potential abnormality P 211
H.R. Yang, S.M. Kim, P. Waters, M. Woodhall, J.E. Kim, J.S. Kim, J.J. Sung, K.S. Park, S.W. Ahn, K.K. Kim, S.Y. Pyun, K.W. Lee (Gyeonggi-do, Seoul, KR; Oxford, GB)
15:30 - 17:00 Imaging
An ImageJ-based automated method to quantify oligodendrocyte and microglia parameters in multiple sclerosis animal models P 406
T. Reiß, K. Berger, T. Clarner, C. Beyer, M. Kipp (Aachen, DE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Intra and extra cranial arterial, venous and CSF analysis comparing MS patients and healthy controls P 630
S. El Sankari, O. Balédent, V. van Pesch, T. Duprez, C. Sindic (Bruxelles, BE; Amiens, FR)
15:30 - 17:00 Imaging
Brain medullary veins visibility with susceptibility-weighted MR imaging in clinically isolated syndromes and relapsing-remitting multiple sclerosis P 399
A. Rovira, F. Aymerich, C. Auger, E. Huerga, R. Mitjana, M. Tintoré, J. Alonso, X. Montalban (Barcelona, ES)
15:30 - 17:00 Biomarkers
Relapses influence prognosis in clinically isolated syndrome P 623
T. Kalincik, M. Vaneckova, M. Tyblova, J. Krasensky, Z. Seidl, E. Havrdova, D. Horakova (Melbourne, AU; Prague, CZ)
15:30 - 17:00 Environmental risk factors
Vitamin A and absence of systemic inflammation as risk factors for multiple sclerosis P 372
J. Salzer, G. Hallmans, M. Nyström, H. Stenlund, G. Wadell, P. Sundström (Umeĺ, SE)
15:30 - 17:00 Imaging
Revised McDonald criteria for early multiple sclerosis diagnistics: applicability in Russian population P 413
I. Shalenkov, A. Belova, B. Shahov, D. Shakurova (N. Novgorod, RU)
15:30 - 17:00 Clinical assessment tools
A practical definition of aggressive onset multiple sclerosis P 285
J. Perumal, S. Gauthier, N. Nealon, T. Vartanian (New York, US)
15:30 - 17:00 Devic’s NMO spectrum
Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content or supramolecular assembly P 200
A. Rossi, J. Ratelade, M. Papadopoulos, J. Bennett, A. Verkman (San Francisco, US; London, GB; Denver, US)
15:30 - 17:00 Immunomodulation
A comparison of the efficacy of interferon-beta and glatiramer acetate in relapse-rate reduction: a prospective randomisation study P 497
C. Crentsil, N. Scolding, A. Wilkins, J. Burrow, L. Bennetto, K. Ingles, D. Cottrell (Bristol, GB)
15:30 - 17:00 Diagnosis and differential diagnosis
Metabolic profiling of patient's sera by HRMAS-NMR spectroscopy: a new analytical tool for distinguishing neuromyelitis optica from multiple sclerosis? P 182
F.M. Moussallieh, K. Elbayed, J.B. Chanson, G. Rudolf, M. Piotto, J. de Sčze, I.J. Namer (Strasbourg, Wissembourg, FR)
15:30 - 17:00 Immunomodulation
Novel humanised antibody therapy in multiple sclerosis targeting immunopathogenic protein from endogenous retroviral element while preserving host’s immune system P 470
H. Perron, J.B. Bertrand, R. Faucard, C. Bernard, J. VanHorssen, R. Firouzi, J. Portoukalian, R. Germi, M. Garcia-Montojo, P. Morand, P. Marche, K. Sanhadji, J.-L. Touraine, A. Lang, F. Curtin (Plan les Ouates, CH; Lyon, FR; Amsterdam, NL; Grenoble, FR)
15:30 - 17:00 Adaptative and Innate immunology
Role of circulating CD4+CD8+ double positive T-cells in multiple sclerosis P 352
L. Sammet, S.D. Schröder, D.-H. Lee, R. Linker, A. Waschbisch (Erlangen, DE)
15:30 - 17:00 Immunomodulation
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis P 489
R. Aharoni, R. Saada, R. Eilam, L. Hayardeny, M. Sela, R. Arnon (Rehovot, Natanya, IL)
15:30 - 17:00 Experimental models
Astrocyte-targeted production of interleukin-17A is not sufficient to induce severe inflammatory CNS disease but promotes accumulation of activated microglia/macrophages in different models of brain inflammation P 332
J. Zimmermann, M. Emrich, M. Krauthausen, M. Hofer, I.L. Campbell, M. Müller (Bonn, Marburg, DE; Sydney, AU)
15:30 - 17:00 Neuropsychology and fatigue
Extensive neuropsychological assessment of cognitive impairment in multiple sclerosis patients P 451
S. Gebel, R. Luerding, S. Schwab-Malek, R. Weissert (Regensburg, DE)
15:30 - 17:00 Immunomodulation
Therapeutic decision after JC virus testing in a cohort of patients treated with natalizumab P 496
J.C. Ongagna, S. Courtois, C. Gaultier, A. Kopf, M.C. Fleury, G. Ahle, N. Collongues, J.P. Chanson, C. Marcel, F. Blanc, J. De Seze (Strasbourg, Mulhouse, Colmar, Haguenau, FR)
15:30 - 17:00 Neurophysiology
Comparison of multifocal and conventional visual-evoked potentials in assessing patients with multiple sclerosis P 428
K. Morris, A. Klistorner, C. Yiannikas (Sydney, AU)
15:30 - 17:00 Devic’s NMO spectrum
Altered topological organisation of white matter structural networks in patients with neuromyelitis optica P 212
Y. Liu, Y. Duan, N. Shu, H. Butzkueven, K. Li (Beijing, CN; Melbourne, AU)
15:30 - 17:00 Neurobiology
17-beta estradiol differentially affects Cx43 and AQP4 expression in a model of astrocyte-microglia culture P 379
Z. Moinfar, H. Dambach, S. Sahin, D. Hinkerohe, R. Gold, P.M. Faustmann (Bochum, DE)
15:30 - 17:00 Devic’s NMO spectrum
Absence of reactivity against myelin oligodendrocyte glycoprotein in neuromyelitis optica P 206
J.B. Chanson, G. Pacini, N. Collongues, G. Rudolf, E. Trifilieff, P. Rovero, J. De Seze, A.M. Papini (Strasbourg, FR; Florence, IT)
15:30 - 17:00 Imaging
Investigation of the corticospinal tract integrity and cortical thickness in patients with multiple sclerosis P 408
M. Pawlitzki, J. Heidel, E. Stadler, J. Kaufmann, M. Sailer (Magdeburg, DE)
15:30 - 17:00 Neuropsychology and fatigue
Alexithymia and interhemispheric transfer in patients with clinically isolated syndrome P 442
C. Jougleux, R. Lopes, H. Zephir, C. Delmaire, C. Moroni, P. Vermersch (Lille, FR)
15:30 - 17:00 Neuroprotection
Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study P 502
M. Mohyeddin Bonab, M.A. Sahraian, A. Aghsaie, S. Ahmadi Karvigh, S.M. Hosseinian, B. Nikbin, J. Lotfi, S. Khorramnia, M.R. Motamed, M. Togha, M.H. Harirchian, N. Beladi Moghadam, K. Alikhani, S. Yadegari, S. Jafarian, M.R. Gheini (Tehran, IR; Calgary, CA)
15:30 - 17:00 Others
Safety and pharmacokinetics of GNbAC1, a humanised monoclonal antibody against the multiple sclerosis retrovirus envelope protein P 558
F. Curtin, A.B Lang, H. Perron, T. Derfuss, P. Lalive, L. Kappos, H.-P. Hartung (Geneva, Basel, CH; Düsseldorf, DE)
15:30 - 17:00 Biology of recovery
Laquinimod treatment reverses cortical and hippocampal pathology due to inflammatory demyelination in a chronic mouse model of multiple sclerosis P 380
R. Patel, G. Hannsun, T. McLaughlin, D. Ichwan, A. Khalaj, S. Moore, S. Tiwari-Woodruff (Los Angeles, US)
15:30 - 17:00 Neuroprotection
Copaxone treatment inhibits axon degeneration and myelination in the corpus callosum of mice with experimental autoimmune encephalomyelitis P 508
G. Hannsun, S. Moore, R. Patel, J. Yoon, S. Tiwari-Woodruff (Los Angeles, US)
15:30 - 17:00 Immunosuppression
Autologous Stem Cell Transplantation International Multiple Sclerosis (ASTIMS) trial: a randomised, phase II, controlled, multicentre trial P 498
G.L. Mancardi, M.P. Sormani, F. Gualandi, A. Saiz, E. Carreras, E. Merelli, A. Donelli, A. Lugaresi, P. Di Bartolomeo, A. Rambaldi, M. Rottoli, M.P. Amato, L. Massacesi, M. Di Gioia, L. Vuolo, D. Currň, L. Roccatagliata, E. Capello, A. Uccelli, P. Iacopino, U. Aguglia, M. Filippi, R. Saccardi (Genoa, Barcelona, Modena, Chieti, Bergamo, Florence, Reggio Calabria, Milan, IT)
15:30 - 17:00 Immunomodulation
A phase 1b, randomised, placebo-controlled, multiple-dose study of human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis P 456
F. Lublin, J. Bowen, J. Huddlestone, M. Kremenchutzky, A. Carpenter, J. Corboy, M. Freedman, L. Krupp, C. Paulo, R. Hariri, S. Fischkoff (New York, Seattle, Tacoma, US; London, CA; Minneapolis, Aurora, US; Ottawa, CA; Stony Brook, Warrren, US)
15:30 - 17:00 Diagnosis and differential diagnosis
The optic nerve head component of the multifocal electroretinogram: a novel signature for dissecting pathophysiologic mechanisms in MS P 177
D. Graves, T. Frohman, Z. Schnurman, D. Conger, A. Conger, B. Greenberg, S. Beh, S. Saidha, J. Ratchford, S. Galetta, P. Calabresi, L. Balcer, A. Green, E. Frohman (Dallas, Baltimore, Philadelphia, San Francisco, US)
15:30 - 17:00 Epidemiology
The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review P 252
E. Cristiano, J. Rojas, M. Romano, N. Frider, G. Machnicki, D. Callegaro, T. Corona, J. Flores, F. Gracia, M. Macias, D. Giunta, J. Correale (Buenos Aires, AR; Sao Paulo, BR; Mexico, MX; Panama, PA; Guadalajara, MX)
15:30 - 17:00 Risk management for disease modifying treatments
Experience with nataluzimab use, JCV antibody testing and treatment decisions P 533
E. Williamson, L. Buchbinder, K. Plascencia, M. Bravo, J. Aparicio, M. Burnett (Los Angeles, US)
15:30 - 17:00 Imaging
A comparison of motor reorganisation between African-American and Caucasian-American patients with MS P 388
R. Teodorescu, W. Zaaraoui, J. Howard, H. Jaggi, J. Herbert, J. Ranjeva, M. Inglese (New York, US; Marseille, FR)
15:30 - 17:00 Tools for detecting therapeutic response
Relation of disease activity-free status to visual function in the AFFIRM trial P 557
L.J. Balcer, S.L. Galetta, A. Zhang, R. Arnold (Philadelphia, Weston, US)
15:30 - 17:00 Devic’s NMO spectrum
Initial presentation of central nervous system demyelinating disease in Thai patients: retrospective study P 216
A. Nawa-Apisak, M. Apiwattanakul (Bangkok, TH)
15:30 - 17:00 Risk management for disease modifying treatments
Patient preferences for attributes of disease-modifying multiple sclerosis therapies: preliminary results of a conjoint analysis P 532
L. Wilson, A. Loucks, G. Gipson, E. Miller, L. Zhong, C. McCulloch, M. Azarraga, C. Gonzalez, M. Owen, E. Waubant (San Francisco, US)
15:30 - 17:00 MS symptoms
Physical exercise: a double-edged sword with benefits and risks on multiple sclerosis related fatigue. Identifying good and bad responders P 272
N. Téllez, M.J Neri, M. Archanco, A. Vázquez, M. Benito, V. García, M.F Muńoz, R. Fernández (Valladolid, ES)
15:30 - 17:00 Devic’s NMO spectrum
Autologous haematopoietic stem cell transplant in patients with neuromyelitis optica P 199
J.M. Burton, J. Storek, P. Duggan, F. Costello, D. Genest, R. Bell, L. Metz (Calgary, CA)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Anatomical cadaver study of the internal jugular veins' configuration in non-MS persons P 631
M. Denislic, M. Zorc, Z. Milosevic, O. Mendiz, R. Zorc Pleskovic, D. Ravnik (Ljubljana, SI; Buenos Aires, AR)
15:30 - 17:00 Clinical assessment tools
Multiple Sclerosis Severity Scale: depression, fatigue and quality of life and perceived cognitive deficit correlates P 300
M. Gudesblatt, M. Zarif, O. Gorbatsevych, B. Bumstead, M. Buhse, L. Fafard, I. Topalli, G. Doniger (Patchogue, Stony Brook, Cambridge, Bellaire, US)
15:30 - 17:00 Quality of life
Impact of electroacupuncture on quality of life for patients with relapsing-remitting multiple sclerosis under treatment with immunomodulators: a randomised study P 585
J.G. Quispe-Cabanillas, A. Damasceno, F. Von Glehn, C.O. Brandăo, B.P. Damasceno, W. Silveira, L.M.B. Santos (Campinas - SP, BR)
15:30 - 17:00 Comprehensive care and rehabilitation
Multiple sclerosis: intrathecal baclofen therapy provides measurable gains beyond spasticity reduction P 577
B. Bumstead, J. Megna, M. Zarif, J. Sylvia, C. Burke, S. Thotam, C. Rosenberg, L. Fafard, M. Buhse, L. Muratori, S. Bennett, M. Gudesblatt (Patchogue, Bay Shore, Stony Brook, Buffalo, US)
15:30 - 17:00 Economic burden
First interim results on treatment satisfaction and pharmaco-economic data comparing fingolimod and first-line therapies in multiple sclerosis patients in Germany (PANGAEA and PEARL) P 302
S. Ortler, T. Ziemssen, M. Meergans, F. Tracik, A. van Lokven (Nuremberg, Dresden, DE)
15:30 - 17:00 Treatment of specific symptoms
Musculo-skeletal pain in multiple sclerosis: results of a prospective study in 52 patients treated with an interdisciplinary concept P 567
J. Bräuer, W. Pöllmann, M. Starck (Berg, DE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
The prevalence of incidental findings in multiple sclerosis patients and control subjects evaluated for possible chronic cerebrospinal venous insufficiency: Do multiple sclerosis researchers report incidental findings? P 625
J. Trufyn, J. Scott, J. Modi, M. Goyal, D. Lautner, D. Bhayana, J. Davenport, J. Mah, J.M. Burton, M.D. Hill, F. Costello (Calgary, CA)
15:30 - 17:00 Tools for detecting therapeutic response
Multiple sclerosis and gait impairment: moving from the subjective to the objective – Measurement as markers for disease progression P 555
M. Gudesblatt, E. Lamberg, R. McKenna, M. Zarif, C. Burke, B. Bumstead, M. Buhse, L. Fafard, L. Muratori (Patchogue, Stony Brook, US)
15:30 - 17:00 Epidemiology
Seasonal variation of relapse rate and ultraviolet radiation levels are sinusoidal and their phase-shifted relationship is latitude-dependent P 237
T. Spelman, O. Gray, M. Trojano, A. Lugaresi, G. Izquierdo, C. Zwanikken, P. Duquette, F. Grand'Maison, V. Shaygannejad, P. Grammond, C. Oreja-Guevara, R. Hupperts, C. Boz, G. Giuliani, T. Petersen, R. Bergamaschi, G. Iuliano, E. van Munster, J. Lechner-Scott, R. Alroughani, M. Barnett, H. Butzkueven on behalf of the MSBase Investigators
15:30 - 17:00 Biomarkers
Increase of interleukin-6 levels is related with depressive phenomena in the acute (relapsing) phase of multiple sclerosis P 610
E. Koutsouraki, E. Hatzifilippou, D. Michmizos, C. Cotsavasiloglou, V. Costa, S. Baloyannis (Thessaloniki, GR)
15:30 - 17:00 Natural history
Follow-up study of patients with clinically isolated syndrome who did not develop multiple sclerosis when reaching the age of expected survival in the population P 231
L. Novakova, B. Skoog, O. Andersen (Gothenburg, SE)
15:30 - 17:00 Biomarkers
MicroRNA and dicer expression as a marker of MS dysimmunity and response to interferon therapy P 616
B. Weinstock-Guttman, W.J. Magner, M. Ramanathan, A. Khan, M. Dillon, K. McGowan, T. Tomasi (Buffalo, US)
15:30 - 17:00 Epidemiology
Incidence of life-threatening immune thrombocytopenia in a multiple sclerosis clinic cohort P 238
D. Barone, K. Barone (Westampton, US)
15:30 - 17:00 Clinical assessment tools
Longitudinal assessment of hand function in individuals with multiple sclerosis P 280
G. von Geldern, R. Marasigan, S. Newsome, P. Calabresi, K. Zackowski (Baltimore, US)
15:30 - 17:00 Diagnosis and differential diagnosis
Aplication of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinian cohort of patients with clinically isolated syndromes P 193
L. Patrucco, J.I. Rojas, S. Tizio, E. Cristiano (Buenos Aires, AR)
15:30 - 17:00 Neurobiology
Region specific protection of cuprizone-induced demyelination in CCL2/3 double deficient animals P 378
M. Rickert, K. Berger, T. Reiß, T. Clarner, C. Beyer, M. Kipp (Aachen, DE)
15:30 - 17:00 Diagnosis and differential diagnosis
Diagnostic efficacy of the flow cytometric aquaporin-4 autoantibody assay: comparison with conventional cell-based assay P 195
H.R. Yang, S.M. Kim, Y.J. Kim, K.W. Lee, K.C. Jung, S.W. Ahn, K.K. Kim, S.Y. Pyun, J.E. Kim, K.S. Park (Gyeonggi-do, Seoul, KR)
15:30 - 17:00 Neuropsychology and fatigue
Correlation of hormonal status and cytokine profiles with fatigue in patients with multiple sclerosis: a case-control study P 439
D. Athanasopoulos, D. Kitsos, N. Protopapas, A. Liverezas, C.E. Karageorgiou (Athens, GR)
15:30 - 17:00 Adaptative and Innate immunology
Maintenance of chronic/sterile inflammation in MS: induction of cytokine production in human monocytes by T-cell surface lipids P 353
D. Burger, L. Gruaz, I. Riezman, H. Riezman (Geneva, CH)
15:30 - 17:00 Imaging
Model-based meta-analysis of lesion count time dynamics in multiple sclerosis P 410
F. Mercier (Wintzenheim, FR)
15:30 - 17:00 MS Variants
Distinct HLA polymorphisms among atopic myelitis, multiple sclerosis and neuromyelitis optica patients in Japan P 197
S. Sato, N. Isobe, S. Yoshimura, Y. Kanamori, K. Masaki, T. Matsushita, J.-I. Kira (Fukuoka, JP)
15:30 - 17:00 Immunomodulation
Robust induction of fibrotic responses in normal human lung fibroblasts by non-selective S1P receptor modulators, but not by the S1P1 receptor modulator ponesimod P 467
K. Sobel, K. Menyhart, B. Renault, N. Killer, R. Studer, Y. Bauer, O. Nayler, J. Gatfield (Allschwil, CH)
15:30 - 17:00 Diagnosis and differential diagnosis
White matter lesions in Behcet's disease: neuro-Behcet's disease or multiple sclerosis? P 188
G. Akman-Demir, M. Mutlu, A. Kiyat-Atamer, E. Shugaiv, M. Kurtuncu, I. Tugal-Tutkun, E. Tuzun, M. Eraksoy, S. Bahar (Istanbul, TR)
15:30 - 17:00 Neuroprotection
Fingolimod is neuroprotective after toxin-induced central nervous system demyelination P 511
A. Slowik, T. Schmidt, S. Amor, C. Beyer, M. Kipp (Aachen, DE; Amsterdam, NL)
15:30 - 17:00 Devic’s NMO spectrum
Recurrent optic neuritis: the importance of the differential diagnosis P 215
I. Palmi-Cortes, V. Meca-Lallana, B. Canneti, F.J. Valenzuela-Rojas, J. Vivancos (Madrid, ES)
15:30 - 17:00 Epidemiology
The relationship between body size and the risk of multiple sclerosis. The EnvIMS study P 253
K. Wesnes, T. Riise, K. Bjřrnevik, K.M. Myhr, S. Magalhaes, C. Wolfson, T. Holmřy, I. Casetta, J. Drulovic, E. Granieri, M. Kampman, A.M. Landtblom, K. Lauer, T. Pekmezovic, M. Pugliatti (Bergen, NO; Montreal, CA; Oslo, NO; Ferrara, IT; Belgrade, RS; Tromsř, NO; Linköping, SE; Darmstadt, DE; Sassari, IT)
15:30 - 17:00 Comprehensive care and rehabilitation
Preventive health care access in women with severe neurologic disability P 576
K. Dobos, B. Healy, M. Houtchens (Boston, US)
15:30 - 17:00 Immunomodulation
In-vivo response to interferon-alpha is preserved in multiple sclerosis patients with neutralising antibodies against interferon-beta P 487
M. Magyari, H Bach Sřndergaard, F. Sellebjerg, P. Soelberg Sřrensen (Copenhagen, DK)
15:30 - 17:00 Immunomodulation
MicroRNA-301a represents a promising therapeutic target for controlling of autoimmune demyelination P 485
M. Mycko, M. Cichalewska, A. Machlanska, H. Cwiklinska, K. Selmaj (Lodz, PL)
15:30 - 17:00 Epidemiology
Temporal trends in hospital admissions in multiple sclerosis: findings from British Columbia, Canada P 243
C. Evans, E. Kingwell, F. Zhu, J. Oger, Y. Zhao, BC MS Clinic Neurologists, H. Tremlett (Vancouver, CA)
15:30 - 17:00 Biomarkers
Ceruloplasmin system activation is representative of brain damage in relapsing-remitting multiple sclerosis P 611
D. Landi, S. Vollaro, R. Squitti, D. Lupoi, A. Coniglio, E. Falato, A. Ghazaryan, M. Corbetto, F. Vernieri, M.M. Filippi (Rome, IT)
15:30 - 17:00 Experimental models
Recovery from motor deficit with ERbeta ligand Indazole-Cl in a mouse model of multiple sclerosis P 328
S. Moore, G. Hannsun, J. Yoon, T. Yoo, N. Yasui, J. Katzenellenbogen, S. Tiwari-Woodruff (Los Angeles, Urbana, US)
15:30 - 17:00 Neuro-ophthalmology
Comparison of two retinal nerve fibre layer segmentation algorithms for the Heidelberg Spectralis P 603
L. Balk, M. Mayer, B. Uitdehaag, A. Petzold (Amsterdam, NL; Erlangen, DE)
15:30 - 17:00 MS and infections
The envelope protein of the human endogenous retrovirus type W family member multiple sclerosis-associated retrovirus is present in human chronic active MS lesions and inhibits oligodendroglial precursor cell differentiation via nitrosative stress P 366
D. Kremer, T. Schichel, M. Förster, C. Bernard, J. van Horssen, H.-P. Hartung, H. Perron, P. Küry (Düsseldorf, DE; Geneva, CH; Amsterdam, NL)
17:00 - 17:15 Temporal changes in MS epidemiology (Auditorium Lumičre)
Overview 100
N. Koch-Henriksen (Aalborg, DK)
17:00 - 17:15 PML and IRIS (Forum 2 & 3)
The PML spectrum 97
D. Clifford (St. Louis, US)
17:15 - 17:30 Temporal changes in MS epidemiology (Auditorium Lumičre)
The French OFSEP experience 101
T. Moreau (Dijon, FR)
17:15 - 17:30 PML and IRIS (Forum 2 & 3)
Epidemiology of natalizumab-associated PML and IRIS in MS 98
P. Vermersch (Lille, FR)
17:15 - 17:30 Devic's neuromyelitis optica spectrum (Amphitheatre)
CRION/RION 95
D. Bichuetti (Sao Paulo, BR)
17:30 - 17:45 PML and IRIS (Forum 2 & 3)
Imaging findings for PML in natalizumab-treated MS patients 99
N. Richert, G. Bloomgren, D. Cadavid, T. Dong-Si, S. Richman, B. Ticho (Weston, US)
17:30 - 17:45 Temporal changes in MS epidemiology (Auditorium Lumičre)
Increasing multiple sclerosis incidence in Tehran, Iran: a Joinpoint Trend Analysis 102
P. Heydarpour, K. Mohammad, M.S. Yekaninejad, J. Lotfi, M.A. Sahraian (Tehran, IR)
17:30 - 17:45 Devic's neuromyelitis optica spectrum (Amphitheatre)
Clinical and MR features of paediatric aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorders 96
S. Tenembaum, S. Pittock, J. Princich, V. Lennon, M. Segura (Buenos Aires, AR; Rochester, US)
18:00 - 19:00 Almirall:
MS spasticity symptoms management.
Endocannabinoid system modulator data beyond clinical trials (Auditorium Lumičre)
MS spasticity daily management, retrospective data from EU 103
T. Berger (Innsbruck, AT)
18:00 - 19:00 Almirall:
MS spasticity symptoms management.
Endocannabinoid system modulator data beyond clinical trials (Auditorium Lumičre)
Endocannabinoid system modulator use in the everyday clinical practice in UK and Spain 104
J.A. Garcia Merino (Madrid, ES)
18:00 - 19:00 Almirall:
MS spasticity symptoms management.
Endocannabinoid system modulator data beyond clinical trials (Auditorium Lumičre)
A new MS spasticity treatment option effect in everyday clinical practice and cost-effectiveness in Germany 105
P. Flachenecker (Bad Wilbad, DE)
19:15 - 20:15 Teva Pharmaceutical Industries: New concepts in MS pathology shed light on MS treatment approaches (Amphitheatre)
Laquinimod: a new MS therapy with evidence for CNS direct effect 108
G. Comi (Milan, IT)
19:15 - 20:15 Teva Pharmaceutical Industries: New concepts in MS pathology shed light on MS treatment approaches (Amphitheatre)
MS pathology: from focal to diffuse damage 107
W. Brück (Göttingen, DE)
19:15 - 20:15 Teva Pharmaceutical Industries: New concepts in MS pathology shed light on MS treatment approaches (Amphitheatre)
Peripheral and central immunomodulation - new insights of glatiramer acetate 106
O. Khan (Detroit, US)

Friday, October 12, 2012

09:15 - 09:30 Platform presentation of selected abstracts on therapy and clinical trials (Amphitheatre)
EDSS changes and progression in the CombiRx randomised clinical trial: 3-year results 109
G. Cutter, S. Cofield, T. Gustafson, R. Conwit, J. Wolinsky, F. Lublin for the The CombiRx Investigators
09:15 - 09:30 Platform presentation of selected abstracts on MS disease evolution (Forum 2 & 3)
Predicting clinical conversion to multiple sclerosis in patients with clinically isolated syndrome using machine learning techniques 113
O. Ciccarelli, P.P. Kwok, V. Wottschel, D. Chard, M.L. Stromillo, N. De Stefano, A.J. Thompson, D.H. Miller, D.H. Alexander (London, GB; Lübeck, DE; Siena, IT)
09:15 - 09:30 Platform presentation of selected abstracts on fatigue and cognition (Auditorium Lumičre)
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomised double-blind trial 117
M.P. Amato, B. Goretti, E. Portaccio, R.G. Viterbo, P. Iaffaldano, M. Trojano (Florence, Bari, IT)
09:30 - 09:45 Platform presentation of selected abstracts on therapy and clinical trials (Amphitheatre)
Eosinophil pathogenicity in neuromyelitis optica by ADCC and CDCC mechanisms: Potential therapeutic efficacy of over-the-counter eosinophil stabilizing drugs 110
H. Zhang, J. Ratelade, A.S. Verkman (San Francisco, US)
09:30 - 09:45 Platform presentation of selected abstracts on MS disease evolution (Forum 2 & 3)
Magnetic resonance phase predicts acute multiple sclerosis lesions 114
A. Rauscher, V. Wiggermann, E. Hernández Torres, I. Vavasour, C. Laule, W. Moore, D. Li, A. Traboulsee, A. MacKay (Vancouver, CA)
09:30 - 09:45 Platform presentation of selected abstracts on fatigue and cognition (Auditorium Lumičre)
Fatigue in multiple sclerosis: relation to quantitative neurologic and visual outcomes 118
S. Chahin, D. Miller, R. Sakai, J. Wilson, A. Green, P. Calabresi, E. Frohman, S. Galetta, L. Balcer (Philadelphia, Cleveland, San Francisco, Baltimore, Dallas, US)
09:45 - 10:00 Platform presentation of selected abstracts on MS disease evolution (Forum 2 & 3)
Topographic analysis of visual-evoked potentials improves sensitivity for previous optic neuritis 115
M. Hardmeier, F. Hatz, Y. Naegelin, C. Schindler, L. Kappos, M. Seeck, P. Fuhr, C. Michel (Basel, Geneva, CH)
09:45 - 10:00 Platform presentation of selected abstracts on fatigue and cognition (Auditorium Lumičre)
Relationship between cognition and working hours in people with clinically isolated syndrome and early relapsing-remitting multiple sclerosis 119
P. Jongen, K. Wesnes, B. Van Geel, P. Pop, E. Sanders, H. Schrijver, L. Visser, J. Gilhuis, O. Sinnige, A. Brands (Nijmegen, NL; Goring, GB; Alkmaar, Venray, Breda, Hoorn, Tilburg, Delft, Leeuwarden, Utrecht, NL)
09:45 - 10:00 Platform presentation of selected abstracts on therapy and clinical trials (Amphitheatre)
Statistical properties of time to first relapse as an endpoint in multiple sclerosis clinical trials 111
A. Signori, P. Siri, M.P. Sormani (Genoa, Turin, IT)
10:00 - 10:15 Platform presentation of selected abstracts on therapy and clinical trials (Amphitheatre)
Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of an Italian cohort of 462 cases 112
A. Ghezzi, P.O. Annovazzi, M.P. Amato, R. Balgera, P. Banfi, M. L. Bartolozzi, R. Bergamaschi, A. Bertolotto, A. Bianchi, A Bosco, E. Capello, M. Capobianco, R. Capra, P. Cavalla, R. Clerici, G. Coarelli, E. Cocco, N. De Rossi, C. Di Tillio, M.T. Ferrň, A. Gallo, P. Gallo, L. Lamantia, A. Lugaresi, G. Lus, S. Malucchi, L. Moiola, L. Provinciali, F. Patti, P. Perini, P. Perrone, A. Protti, M.E. Rodegher, P. Rossi, M. Rottoli, M. Rovaris, G. Salemi, M. Salvetti, I. Simone, M.R. Tola, M. Trojano, F. Vitetta, M.G. Marrosu, G. Comi and MS Study Group, Italian Society of Neurology
10:00 - 10:15 Platform presentation of selected abstracts on fatigue and cognition (Auditorium Lumičre)
Grey matter damage predicts the accumulation of disability and cognitive impairment 13 years later in patients with multiple sclerosis 120
M. Filippi, P. Preziosa, M. Copetti, G. Riccitelli, M.A. Horsfield, V. Martinelli, G. Comi, M.A. Rocca (Milan, San Giovanni Rotondo (FG), IT; Leicester, GB)
10:00 - 10:15 Platform presentation of selected abstracts on MS disease evolution (Forum 2 & 3)
It’s time to change the way we measure change: demonstration, explanation, recommendations 116
J.C. Hobart, S.J. Cano, A.J. Thompson, D. Andrich (Plymouth, GB; Perth, AU)
10:45 - 11:05 From databases and cohorts to pharmaco-epidemiology (Auditorium Lumičre)
Pharmaco-epidemiology: methodological aspects 131
G. Tognoni (Santa Maria Imbaro (Chieti), IT)
10:45 - 11:05 From natural to treated history (Forum 2 & 3)
Standpoint of the neurologist 126
C. Confavreux (Lyon, FR)
10:45 - 11:05 Beyond clinical monitoring of progression in MS (Amphitheatre)
Biological markers 121
A. Petzold (Amsterdam, NL)
11:05 - 11:25 From natural to treated history (Forum 2 & 3)
From natural to treated history - standpoint of the methodologist 127
M.P. Sormani (Genoa, IT)
11:05 - 11:25 Beyond clinical monitoring of progression in MS (Amphitheatre)
MR and OCT markers 122
D. Miller (London, GB)
11:25 - 11:40 Beyond clinical monitoring of progression in MS (Amphitheatre)
Retinal atrophy and brain damage in MS: a model for trans-synaptic neuronal degeneration? 123
I. Gabilondo, A. Saiz, E. Martinez, E. Fraga, S. Llufriu, S. Ortiz, C. Falcon, J. Berenguer, N. Sola, M. Sepulveda, Y. Blanco, F. Graus, B. Sanchez-Dalmau, P. Villoslada (Barcelona, ES)
11:25 - 11:40 From databases and cohorts to pharmaco-epidemiology (Auditorium Lumičre)
Comparison of natalizumab and interferon-beta/glatiramer efficacy using propensity-matched registry data 133
T. Spelman, F. Pellegrini, A. Zhang, R. Hyde, A. Pace, R. Arnold, M. Trojano, H. Wiendl, L. Kappos, S. Belachew, F. Verheul, F. Grand'Maison, G. Izquierdo, H. Butzkueven on behalf of the MSCOMET Investigators (an MSBase Substudy) and the TOP investigators
11:25 - 11:40 From natural to treated history (Forum 2 & 3)
Do all patients with multiple sclerosis ultimately develop progressive MS? 128
M. Tutuncu, J. Tang, N. Abou Zeid, N. Kale, D. Crusan, E. Atkinson, A. Siva, S. Pittock, I. Pirko, M. Keegan, C. Lucchinetti, J. Noseworthy, M. Rodriguez, B. Weinshenker, O. Kantarci (Istanbul, TR; Minneapolis, US; Beirut, LB; Rochester, US)
11:40 - 11:55 From databases and cohorts to pharmaco-epidemiology (Auditorium Lumičre)
The SURVIMUS study, a large multicentre study on long-term mortality of multiple sclerosis patients in France 134
E. Leray, S. Vukusic, C. Confavreux, M. Debouverie, M. Clanet, B. Brochet, J. de Sčze, H. Zéphir, P. Vermersch, C. Lebrun-Frenay, G. Defer, T. Moreau, P. Clavelou, J. Pelletier, L. Rumbach, P. Cabre, J.P. Camdessanché, J. Yaouanq, E. Le Page, G. Edan (Rennes, Lyon, Nancy, Toulouse, Bordeaux, Strasbourg, Lille, Nice, Caen, Dijon, Clermont-Ferrand, Marseille, Besançon, Fort de France, Saint-Etienne, FR)
11:40 - 11:55 From natural to treated history (Forum 2 & 3)
Relation of long-term exposure to subcutaneous interferon-beta-1a with clinical outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS-15 study 129
L. Kappos, P. Cornelisse, L. Lehr, J. Kuhle, B. Uitdehaag (Basel, Geneva, CH; Amsterdam, NL)
11:40 - 11:55 Beyond clinical monitoring of progression in MS (Amphitheatre)
Mechanisms of disability in relapse onset multiple sclerosis of long disease duration 124
H. Kearney, M.A. Rocca, L. Balk, J. Sastre-Garriga, J. Reinhardt, S. Ruggieri, A. Rovira, L. Kappos, M. Rovaris, C. Gasperini, X. Montalban, J.J.G. Geurts, F. Barkhof, M. Filippi, D.R. Altmann, O. Ciccarelli, D.H. Miller, D.T. Chard on behalf of the MAGNIMS collaborative group
11:55 - 12:10 From natural to treated history (Forum 2 & 3)
Cognitive issues in childhood and juvenile multiple sclerosis patients: five-year results 130
M.P. Amato, B. Goretti, A. Ghezzi, S. Lori, B. Hakiki, M. Giannini, L. Pastň, L. Razzolini, L. Moiola, M. Falautano, R.G. Viterbo, F. Patti, S. Cilia, C. Pozzilli, V. Bianchi, M. Roscio, V. Martinelli, G. Comi, E. Portaccio, M. Trojano on behalf of the MS Study Group of the Italian Neurological Society
11:55 - 12:10 From databases and cohorts to pharmaco-epidemiology (Auditorium Lumičre)
The natural history of aggressive multiple sclerosis: findings from British Columbia, Canada 135
S. Menon, F. Zhu, A. Shirani, J. Oger, A. Traboulsee, M. Freedman, BC. MS Clinic Neurologists, H. Tremlett (Vancouver, Ottawa, CA)
11:55 - 12:10 Beyond clinical monitoring of progression in MS (Amphitheatre)
Probing the clinico-radiological paradox of the spinal cord in multiple sclerosis with quantitative MRI 125
J. Oh, S. Saidha, M. Chen, S. Smith, J. Prince, C. Jones, P. van Zijl, D. Reich, P. Calabresi (Baltimore, US)
12:45 - 13:45 Bayer HealthCare: Novel performance measures for early and long-term gains (Forum 2 & 3)
The ultimate long-term measure - survival 138
A. Reder (Chicago, US)
12:45 - 13:45 Bayer HealthCare: Novel performance measures for early and long-term gains (Forum 2 & 3)
Novel measures broadening our understanding of treatment benefits and risks 137
X. Montalban (Barcelona, ES)
12:45 - 13:45 Bayer HealthCare: Novel performance measures for early and long-term gains (Forum 2 & 3)
Historical measures of response and outcomes 136
T. Ziemssen (Dresden, DE)
14:00 - 14:20 Pregnancy (Auditorium Lumičre)
Prognosis- pregnancy 139
M.P. Amato (Florence, IT)
14:00 - 14:20 Imaging (Forum 2 & 3)
Demyelination and remyelination 144
F. Barkhof (Amsterdam, NL)
14:00 - 14:20 Disease-modifying treatments (Amphitheatre)
Oral treatments: past, present, future 149
C.H. Polman (Amsterdam, NL)
14:20 - 14:40 Pregnancy (Auditorium Lumičre)
MS treatments during pregnancy 140
E. Waubant (San Francisco, US)
14:20 - 14:40 Imaging (Forum 2 & 3)
Positron emission tomography (PET) and molecular imaging for multiple sclerosis 145
B. Stankoff, L. Freeman, B. Bodini, L. Bottin, A. Chardain, C. Lubetzki, M. Bottlaender (Paris, Orsay, FR)
14:40 - 14:55 Pregnancy (Auditorium Lumičre)
Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya™ (fingolimod) Pregnancy Exposure Registry in multiple sclerosis 141
Y. Geissbühler, H. Butzkueven, S. Hernández-Diaz, K. Hellwig, G. Koren, T. MacDonald, H. Tilson, K. Starzyk, E. Plana, M. Cremer, P. von Rosenstiel, D. Anand, V. Dong, R. Schlosshauer, G. Karlsson, X. Zhang (Basel, CH; Parkville, AU; Boston, US; Bochum, DE; Toronto, CA; Dundee, GB; Chapel Hill, Cambridge, US; Barcelona, ES; East Hanover, US)
14:40 - 14:55 Imaging (Forum 2 & 3)
Improved detection of cortical lesions using 7T magnetisation transfer imaging in patients with multiple sclerosis 146
R. Abdel-Fahim, N. Mistry, O. Mougin, A. Blazejewska, P. Gowland, N. Evangelou (Nottingham, GB)
14:40 - 14:55 Disease-modifying treatments (Amphitheatre)
Clinical efficacy of BG-12 in relapsing–remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies 151
R. Gold, D. H. Miller, J. T. Phillips, D. L. Arnold, K. Selmaj, M. Yang, R. Zhang, K. T. Dawson, V. Viglietta, S. I. Sheikh, R. J. Fox (Bochum, DE; London, GB; Dallas, US; Montreal, CA; Lodz, PL; Weston, Cleveland, US)
14:55 - 15:10 Imaging (Forum 2 & 3)
Resting state functional connectivity abnormalities are associated with cognitive impairment in patients with paediatric multiple sclerosis 147
M. Filippi, M.A. Rocca, P. Valsasina, M.P. Amato, M. Absinta, A. Ghezzi, L. Moiola, A. Fiorino, P. Veggiotti, G. Comi and the MS and Neuroimaging Study Groups of the Italian Neurological Society
14:55 - 15:10 Pregnancy (Auditorium Lumičre)
The impact of pregnancy on progression of relapsing-remitting multiple sclerosis 142
I. Karp, A. Manganas, M.-P. Sylvestre, E. Roger, A. Ho, P. Duquette (Montreal, CA)
14:55 - 15:10 Disease-modifying treatments (Amphitheatre)
Efficacy and safety of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis: results from a phase IIb, randomised, double-blind, placebo-controlled trial 152
T. Olsson, A. Boster, O. Fernandez, M.S. Freedman, C. Pozzilli, D. Bach, O. Berkani, M. Mueller, T. Sidorenko, M. Melanson (Stockholm, SE; Columbus, US; Malaga, ES; Ottawa, CA; Rome, IT; Allschwil, CH; Cincinnati, US)
15:10 - 15:25 Pregnancy (Auditorium Lumičre)
The POPARTMUS French-Italian multicentric trial of Post Partum Progestin and Estriol in Multiple Sclerosis: final results 143
S. Vukusic, M. El-Etr, I. Ionescu, F. Cotton, H. Merle, C. Cornu, B. Frangoulis, L. Remontet, N. Bossard, L. Durelli, E.E. Baulieu, C. Confavreux on behalf of the POPARTMUS Investigators group
15:10 - 15:25 Imaging (Forum 2 & 3)
Dynamic changes in grey matter volume over 5 years in primary progressive multiple sclerosis: a tensor-based morphometry study 148
A. Eshaghi, B. Bodini, G. Ridgway, D. García-Lorenzo, D. Tozer, M.A. Sahraian, A.J. Thompson, O. Ciccarelli (London, GB; Paris, FR; Tehran, IR)
15:10 - 15:25 Disease-modifying treatments (Amphitheatre)
The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study 153
L. Kappos, G. Comi, C. Confavreux, M.S. Freedman, A.E. Miller, T. Olsson, J.S. Wolinsky, T. Bagulho, J.-L. Delhay, Y. Zheng, P. Truffinet, P.W. O'Connor (Basel, CH; Milan, IT; Lyon, FR; Ottawa, CA; New York, US; Stockholm, SE; Houston, Bridgewater, US; Chilly Mazarin, FR; Toronto, CA)
15:30 - 17:00 Risk management for disease modifying treatments
Autoimmunity in patients treated with alemtuzumab for relapsing-remitting multiple sclerosis P 1005
E.J. Fox, D.L. Arnold, J. Cohen, A.J. Coles, C. Confavreux, H.-P. Hartung, E. Havrdova, K. Selmaj, H. Weiner, S.L. Lake, D.H. Margolin, P. Oyuela, M. Panzara, D.A.S. Compston for the CARE-MS investigators
15:30 - 17:00 Late Breaking News
A phase II, open-label, dose escalation of intravenous (IV) MIS416 in progressive multiple sclerosis P 1095
A. Luckey, T.J. Anderson, M.H. Silverman (Christchurch, NZ; Marblehead, US)
15:30 - 17:00 Long-term treatment monitoring
Long-term observation on management of natalizumab discontinuation P 977
F. Sangalli, L. Moiola, L. Ferrč, M. Radaelli, V. Barcella, V. Martinelli, G. Comi (Milan, IT)
15:30 - 17:00 Neuroprotection
Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial P 968
Y. Zhao, D.K.B. Li, A. Riddehough, A. Traboulsee, D. Masterman, F. Gilberg, L. Kappos, D. Leppert (Vancouver, CA; Basel, CH)
15:30 - 17:00 Neuroprotection
Laquinimod decreases the activation of microglia: potential for neuroprotection? P 967
M. Mishra, C. Silva, J. Wang, V.W. Yong (Calgary, CA)
15:30 - 17:00 Clinical assessment tools
Patient-determined MS Severity Scale: ranking disease severity based on patient-rated disability P 747
I. Kister, E. Chamot, G. Cutter, A. Salter, T.E. Bacon, J. Herbert (New York, Birmingham, US)
15:30 - 17:00 Paediatric MS
Retinal nerve fibre layer thickness in paediatric demyelinating disease: the Canadian Paediatric Disease Study Group P 679
Y.A. Reginald, F. Costello, J. O'Mahoney, J.R. Buncic, B. Banwell on behalf of The Canadian Pediatric Demyelinating Disease Study
15:30 - 17:00 Diagnosis and differential diagnosis
Demographic and clinical features of familiar MS in Brazilian patients P 655
R. Papais-Alvarenga, M. Bernardes, F. Costa-Pereira, M. Papais-Alvarenga, E. Batista, C. Vasconcelos (Rio de Janeiro, BR)
15:30 - 17:00 Treatment of specific symptoms
Dalfampridine extended release tablets: safety profile after 2 years of post-marketing experience in the United States P 1026
M. Jara, M. Adera, A. Adedeji, H. Henney, E. Carrazana (Hawthorne, US)
15:30 - 17:00 Pregnancy and MS
The Italian version of the Motherhood Choice: a decision aid for women with MS considering motherhood P 734
E. Bianchi, A. Giordano, E. Pietrolongo, A. Lugaresi, G. Fulcher, C. Borreani, M. Messmer Uccelli, A. Solari (Milan, Chieti, IT; Lidcombe, AU; Genoa, IT)
15:30 - 17:00 Epidemiology
The new electronic, self-administered version of the Control Preference Scale P 695
A. Giordano, J. Kasper, E. Pietrolongo, C. Antozzi, G. Moretti, M. Pugliatti, A. van Nunen, J. Drulovic, L. Vahter, S. Koepke, C. Heesen, A. Solari on behalf of the AutoMS project
15:30 - 17:00 Diagnosis and differential diagnosis
Intrathecal antibody synthesis in demyelinating disease cohort: can oligoclonal band status act as a surrogate for seperation in time? P 636
P. Hardeman, L. Horton, S. Hughes, P. Chaudhry, E. Frohman, D. Graves, B. Greenberg (Dallas, US)
15:30 - 17:00 Quality of life
Contributions of socioeconomic status and disability level to depression ratings in multiple sclerosis P 1055
P. Moore, K. Harding, H. Clarkson, T. Pickersgill, N. Robertson (Liverpool, Cardiff, Plymouth, GB)
15:30 - 17:00 Long-term treatment monitoring
Looking for the best therapeutical strategy after the 24th natalizumab administration. The TY-STOP study P 976
M. Clerico, S. De Mercanti, F. Piazza, D. Gned, V. Brescia Morra, R. Lanzillo, L. Amato, M. Quarantelli, A. Ghezzi, A. Bianchi, D. Baroncini, M. Gibbin, J. Vargas, G. Salemi, S. Realmuto, M.T. Ferrň, F. Vitetta, L. Mascolo, D. Paolicelli, M. Trojano, L. Durelli (Orbassano (Turin), Naples, Gallarate, Palermo, Crema, Modena, Bari, IT)
15:30 - 17:00 Late Breaking News
Oligodendroglial cells are present in a subset of inactive MS lesions with pronounced axonal damage P 1100
E. Bahn, C. Wegner, W. Brück (Göttingen, DE)
15:30 - 17:00 Paediatric MS
Cognitive relapse in the absence of new neurological symptoms: clinical utility of neuropsychological assessment in a case with juvenile multiple sclerosis P 687
I.K. Penner, M. Hubacher, M. Rasenack, T. Sprenger, P. Weber, Y. Naegelin (Basel, CH)
15:30 - 17:00 Quality of life
The utility of the Functional Index for Living with multiple sclerosis in clinical practice: preliminary results P 1051
J. Cooper, A. Courtney, E. Fox, L. Jehle, M. Kirk-Junior, V. Nolan, J. Wesson (Berkeley, Dallas, Round Rock, US)
15:30 - 17:00 Late Breaking News
Application of the International Cooperative Ataxia Rating Scale to quantitative balance assessment in multiple sclerosis patients P 1105
D.J. Kimbrough, R. Marasigan, J. Wang, P.A. Calabresi, K.M. Zackowski (Baltimore, US)
15:30 - 17:00 Imaging
Brain sodium accumulation and spreading correlate with disability in multiple sclerosis P 863
W. Zaaraoui, B. Audoin, S. Konstandin, A.M. Nagel, E. Soulier, I. Malikova, A. Rico, F. Reuter, P. Viout, S. Confort-Gouny, P.J. Cozzone, J. Pelletier, L.R. Schad, J.-P. Ranjeva (Marseille, FR; Mannheim, Heidelberg, DE)
15:30 - 17:00 Tools for detecting therapeutic response
Neutralising antibodies against interferon-beta and their correlation with clinical and magnetic resonance imaging activity in Japanese multiple sclerosis patients P 1015
D. Sato, I. Nakashima, T. Fukazawa, Y. Shimizu, Y. Tomizawa, K. Yokoyama, T. Misu, Y. Itoyama, M. Aoki, K. Fujihara (Sendai, Sapporo, Tokyo, JP)
15:30 - 17:00 Diagnosis and differential diagnosis
Long-term outcome of CLIPPERS in a consecutive series of 12 patients P 644
P. Labauge, G. Taieb, C. Duflos, D. Renard, B. Audoin, E. Kaphan, J. Pelletier, N. Limousin, C. Tranchant, S. Kremer, J. De Seze, R. Lefaucheur, D. Maltete, D. Brassat, M. Clanet, P. Desbordes, E. Thouvenot, L. Magy, T. Vincent, J. Faillie, N. de Champfleur, G. Castelnovo, S. Eimer, D. Figarella Branger, E. Uro Coste (Montpellier, Nimes, Marseille, Tours, Strasbourg, Rouen, Toulouse, Dax, Limoges, Bordeaux, FR)
15:30 - 17:00 Epidemiology
Consanguineous marriage and multiple sclerosis P 703
H. Maghzi, V. Moradi, M. Etemadifar, A.H. Maghzi (Isfahan, Babolsar, IR)
15:30 - 17:00 Immunomodulation
Effects of inhibitors of the renin-angiotensin-system on clinical and MRI outcomes in patients with multiple sclerosis receiving interferon-beta-1b or glatiramer acetate. A post-hoc-analysis of the BEYOND study P 942
M. Doerner, K. Beckmann, V. Knappertz, V. Limmroth and the BEYOND Steering Committee
15:30 - 17:00 Immunomodulation
Effect of two dosing frequencies of subcutaneous interferon-beta-1a on conversion to MS and MRI measures of disease in patients with a first clinical demyelinating event: 3-year results of phase III, double-blind, multicentre trials (REFLEX/REFLEXION) P 940
G. Comi, M.S. Freedman, N. De Stefano, F. Barkhof, C.H. Polman, B.M.J. Uitdehaag, L. Lehr, D. Issard, S. Haller, B. Hennessy, L. Kappos (Milan, IT; Ottawa, CA; Siena, IT; Amsterdam, NL; Geneva, Basel, CH)
15:30 - 17:00 Immunomodulation
Effect of two dosing frequencies of subcutaneous interferon-beta-1a on brain volume changes in patients with a first clinical demyelinating event: 36-month results of a phase III, double-blind, multicentre trial (REFLEX) and its extension (REFLEXION) P 947
F. Barkhof, M.S. Freedman, G. Comi, L. Kappos, C.H. Polman, B.M.J. Uitdehaag, L. Lehr, D. Issard, S. Haller, B. Hennessy, N. De Stefano (Amsterdam, NL; Ottawa, CA; Milan, IT; Basel, CH; Geneva, CH; Siena, IT)
15:30 - 17:00 Others
Patient education programme on diagnosis, prognosis and early therapy for persons with early multiple sclerosis – multicentre, randomised, controlled trial (ISRCTN12440282) P 1023
S. Köpke, S. Kern, K. Fischer, J. Kasper, I. Kleiter, M. Berghoff, F. Paul, M. Marziniak, T. Ziemssen, C. Heesen (Lübeck, Dresden, Hamburg, Bochum, Giessen, Berlin, Münster, DE)
15:30 - 17:00 Imaging
Olfactory bulb volume and neuropsychological performance, fatigue severity and depression in multiple sclerosis patients P 837
T. Yonekawa, I.K. Penner, Y. Naegelin, J. Kuhle, C. Stippich, E.-W. Radue, L. Kappos, T. Sprenger, O. Yaldizli (Fukuoka, JP; Basel, CH)
15:30 - 17:00 Treatment of specific symptoms
Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study P 1024
S.A. Morrow, A Smerbeck, K. Patrick, D. Cookfair, B. Weinstock-Guttman, R.H.B. Benedict (London, CA; Buffalo, US)
15:30 - 17:00 Risk management for disease modifying treatments
Detection of polyomavirus JC DNA and anti-JCV antibody in MS patients under natalizumab therapy P 1008
V. Clausi, F. Martelli, A.M. Repice, C. Mechi, E. Magnani, L. Massacesi, A. Azzi, S. Giannecchini (Florence, IT)
15:30 - 17:00 Diagnosis and differential diagnosis
Non-organ-specific auto-immunity disease in NMO-spectrum disorders – Brazilian experience P 651
S. Apostolos-Pereira, F. Jorge, P. Zago, R. Simm, M. Fazzito, C. Galvao, C. Hobi, M. Lana-Peixoto, P. Marchiori, A. Dellavance, D. Callegaro on behalf of BCTRIMS
15:30 - 17:00 Paediatric MS
Paediatric multiple sclerosis and vitamin D status P 681
N. Ben Achour, I. Kraoua, H. Touaiti, H. Benrhouma, A. Rouissi, I. Turki, N. Gouider- Khouja (Tunis, TN)
15:30 - 17:00 Paediatric MS
Early onset multiple sclerosis, a population-based cross-sectional study P 682
J.L. Frederiksen, E.B. Hoegh (Glostrup, DK)
15:30 - 17:00 Quality of life
Impact of yoga on the quality of life of patients with multiple sclerosis P 1049
I. Truschel, J.C. Ongagna, M.-R. Metzger, C. Zaenker, J. De Seze (Colmar, FR)
15:30 - 17:00 Risk management for disease modifying treatments
Natalizumab de-escalation to interferon-beta-1b in multiple sclerosis: a randomised, controlled, pilot trial P 1001
C. Zecca, S. Meier, S. Tschuor, N. Nadarajah, F. Cotton, M. Sinzel, D. Leppert, C.R.G. Guttmann, C. Gobbi (Lugano, CH; Boston, US; Lyon, FR; Küsnacht, Basel, CH)
15:30 - 17:00 Economic burden
Difficulties felt in the work in persons with multiple sclerosis P 764
J.C. Ongagna, J. Pinelli, C. Zaenker, J. De Sčze (Colmar, FR)
15:30 - 17:00 Adaptative and Innate immunology
Axonal and oligodendrocyte-localised antibody deposits in MS lesions P 804
M.C. Sadaba, M.M. Esiri, J. Tzartos, C. Paino, M. Garcia-Villanueva, J.C. Alvarez-Cermeno, L.M. Villar (Madrid, ES; Oxford, GB)
15:30 - 17:00 Environmental risk factors
Serum 25-hydroxyvitamin D concentrations among patients in BENEFIT predicts conversion to multiple sclerosis, MRI lesions, and brain volume loss P 831
A. Ascherio, K. Munger, C. Simon, L. Kappos, C.H. Polman, M.S. Freedman, H.-P. Hartung, D.H. Miller, X. Montalbán, G. Edan, F. Barkhof, R. White, R. Sandbrink, C. Pohl (Cambridge, US; Basel, CH; Amsterdam, NL; Ottawa, CA; Düsseldorf, DE; London, GB; Barcelona, ES; Rennes, FR; Vancouver, CA; Berlin, DE)
15:30 - 17:00 MS and infections
The risk of developing MS following vacination for hepatitis B, Human papilloma virus and influenza including H1N1 P 820
A. Holstebroe, J.L. Frederiksen (Glostrup, DK)
15:30 - 17:00 Imaging
Specific in vivo imaging of inflammation, de-and remyelination using fluorescence molecular tomography P 862
S. Albrecht, M. Eisenblätter, L. Wachsmuth, T. Vogl, C. Faber, T. Kuhlmann (Münster, DE)
15:30 - 17:00 Diagnosis and differential diagnosis
Overcoming chondroitin sulfate proteoglycan inhibition of oligodendrocyte-lineage cells and remyelination P 650
L. Lau, M. Keough, F. Yong, V.W. Yong (Calgary, CA)
15:30 - 17:00 Clinical assessment tools
Construct validity of a novel tool to measure balance ability in MS patients P 753
C. Soaz, P. Stellmann, M. Jlussi, C. Heesen, A. Neuhaus, M. Daumer (Munich, Hamburg, DE)
15:30 - 17:00 Neurophysiology
Simultaneous rTMS and piano playing improve hand dexterity and induce changes in cortical excitability in a professional pianist affected by multiple sclerosis: a case report P 880
A. Nuara, L. Straffi, F. Spagnolo, P. Rossi, G. Comi, M. Comola, L. Leocani (Milan, IT)
15:30 - 17:00 Neuroprotection
Targeting tPA/NMDA interactions with an active immunisation: Proof of concept of a novel strategy for MS treatment P 970
R. Macrez, A. Montagne, M. Gauberti, D. Vivien, G. Defer, F. Docagne (Caen, FR)
15:30 - 17:00 Quality of life
Impact of depression on quality of life in multiple sclerosis patients P 1054
A. Bingol, E. Goksel, S. Yildiz, U. Uygunoglu, N.O. Demirci, A. Altintas, S. Saip, A. Siva (Istanbul, TR)
15:30 - 17:00 Immunomodulation
Laquinimod and the human innate immune system P 936
T. Sehr, K. Thomas, M. Marggraf, L. Hayardeny, T. Ziemssen (Dresden, DE; Netanya, IL)
15:30 - 17:00 Neurobiology
The effects of reactive oxygen species on axonal transport: implications for multiple sclerosis P 834
C. Fang, G. Banker, D. Bourdette (Portland, US)
15:30 - 17:00 Immunomodulation
Lymphocyte subset dynamics following alemtuzumab treatment in the CARE-MS I study P 935
H.-P. Hartung, D.L. Arnold, J. Cohen, C. Confavreux, E.J. Fox, E. Havrdova, K. Selmaj, H. Weiner, V. Brinar, G. Giovannoni, M. Stojanovic, S.L. Lake, D.H. Margolin, M. Panzara, D.A.S. Compston for the CARE-MS I investigators
15:30 - 17:00 Adaptative and Innate immunology
Alemtuzumab treatment in MS: how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) levels change? 24-month immunological report during 323 and 324 genzyme trials P 816
S. De Mercanti, S. Rolla, A. Cucci, E. Viglietta, A. Giai Via, D. Taverna, V. Bardina, F. Novelli, F. Piazza, J. Vargas, M. Gibbin, A. Vladic, I. Adamec, V. Brinar, M. Habek, E. Cocco, P. Annovazzi, D. Horŕkovŕ, I. Kovŕrovŕ, M. Clerico, L. Durelli (Orbassano, Turin, IT; Zagreb, HR; Cagliari, Gallarate, IT; Prague, CZ)
15:30 - 17:00 Devic’s NMO spectrum
The effect of NMO-IgG and complement against primary human astrocytes in culture P 672
S. Nishiyama, T. Misu, N. Sugeno, T. Takahashi, I. Nakashima, M. Aoki, K. Fujihara (Sendai, Yonezawa, JP)
15:30 - 17:00 Biomarkers
Role of serum amyloid A in multiple sclerosis and neuromyelitis optica P 1080
H. Yokote, Y. Yagi, T. Amino, T. Kamata (Musashino, JP)
15:30 - 17:00 Adaptative and Innate immunology
Impaired suppressor function of CD56bright NK cells in early multiple sclerosis P 815
A. Laroni, E. Armentani, I. Gandoglia, F. Ivaldi, A. Uccelli (Genoa, IT)
15:30 - 17:00 Biomarkers
Plasma cerebrosterol measures predict cognitive processing speed deterioration 7 years later in MS patients P 1069
L. Stawiarz, G. Bergendal, O. Almkvist, S. Fredrikson, J. Link, V. Leoni, I. Björkhem, A. Glaser, J. Hillert, V.D. Karrenbauer (Stockholm, SE; Milan, IT)
15:30 - 17:00 Long-term treatment monitoring
Long-term safety of fingolimod in relapsing multiple sclerosis: update to integrated analyses of phase 2 and 3 studies and extension phases P 983
J.A. Cohen, P. O'Connor, T. Caliolio, P. von Rosenstiel, L. Zhang-Auberson, A. Keil, W. Collins, N. Sfikas, L. Kappos (Cleveland, US; Toronto, CA; East Hanover, US; Basel, CH)
15:30 - 17:00 Late Breaking News
Impact of infratentorial lesions on affected fibers in multiple sclerosis P 1102
A. Droby, V. Fleischer, H. Zimmermann, M. Carnini, E. Zindler, J. Wilting, V. Siffrin, M. Erb, J. Gawehn, A. Hildebrandt, B. Baier*, F. Zipp* (Mainz, Tübingen, DE)
15:30 - 17:00 Experimental models
BIIB033 Anti-LINGO-1 antibody reduces optic nerve axonal degeneration in MOG- EAE rodent models P 785
D. Cadavid, H. Butzkueven, Y. Liu, S. Mi (Cambridge, US; Melbourne, AU; Beijing, CN)
15:30 - 17:00 Grey matter damage in MS
Co-localisation of grey matter volume reduction and grey matter lesions in multiple sclerosis P 769
S.H.P. van de Pavert, N. Muhlert, V. Sethi, C.A. Wheeler-Kingshott, A.J. Thompson, J.J.G. Geurts, T.A. Yousry, D.H. Miller, D.T. Chard, O. Ciccarelli (London, GB; Amsterdam, NL)
15:30 - 17:00 Paediatric MS
Evaluation of vitamin D-related parameters in a multinational paediatric multiple sclerosis case-control study P 676
H.E. Hanwell, B. Bhan, M.R. Bardini, A. Belman, A. Boiko, O. Bykova, M.-E. Dilenge, K. Farrell, M. Freedman, J. Hahn, M. Iivanainen, J. Kennedy, M. Kremenchutzky, L. Krupp, J.K. Mah, J. Ness, M. Rensel, M. Ruggieri, M. Sevon, C. Stoian, E. Waubant, B. Weinstock-Guttman, S. Tenembaum, E.A. Yeh, R. Vieth, R.A. Marrie, A. Bar-Or, B. Banwell on behalf of the Wadsworth Pediatric Multiple Sclerosis Study Group
15:30 - 17:00 Late Breaking News
Long-term safety and tolerability of oral BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis: interim results from ENDORSE P 1103
J.T. Phillips, R.J. Fox, K. Selmaj, K. Raghupathi, J. O’Gorman, M. Novas, M.T. Sweetser, V. Viglietta, K.T. Dawson, R. Gold (Dallas, Cleveland, US; Lodz, PL; Weston, US; Bochum, DE)
15:30 - 17:00 Devic’s NMO spectrum
Alemtuzumab for treatment of neuromyelitis optica P 660
J.M. Gelfand, B.A. Cree (San Francisco, US)
15:30 - 17:00 Late Breaking News
A comprehensive assessment of the relationship between depression and MS-related disability in a large cross sectional clinical cohort P 1109
R.A. Bermel, D. Gunzler, S. Lewis, A. Perzynski, D.M. Miller (Cleveland, US)
15:30 - 17:00 Late Breaking News
Does the STRATIFY JCV TM antibody test encourage natalizumab cessation? P 1106
R. Lonergan, K. Kinsella, S.B. Kelly, M. Duggan, L. Buckley, N. Tubridy, M. Hutchinson, C. McGuigan (Dublin, IE)
15:30 - 17:00 Neuroprotection
Development of anti-SEMA4D monoclonal antibody for the treatment of multiple sclerosis P 963
T. Fisher, C. Reilly, L. Winter, J. Veeraraghavan, A. Jonason, J. Seils, H. Huang, H. Bussler, E. Klimatcheva, J. Decker, S. Torno, R. Kirk, C. Cornelius, T. Richards, J Caplan, A. Howell, P. Kenney, M. Scrivens, L. Croy, T. Pandina, M. Doherty, G. Seigel, W. Wang, E. Evans, W. Bowers, M. Paris, J. Leonard, R. Watkins, P. Foster, M. Zauderer, E. Smith (Rochester, US)
15:30 - 17:00 Pregnancy and MS
Birth hospitalisation in mothers with multiple sclerosis and their newborns P 738
E. Lu, Y. Zhao, F. Zhu, M. van der Kop, A. Synnes, L. Dahlgren, A.D. Sadovnick, A.-L. Sayao, H. Tremlett (Vancouver, CA)
15:30 - 17:00 Neurophysiology
EEG index related to altered orienting network in multiple sclerosis patients P 884
A. Galvao-Carmona, A.R. Hidalgo-Muńoz, M. Borges, M. García-Valdecasas, J.M. García-Moreno, D. Páramo, J.L. Ruíz-Peńa, G. Izquierdo, M. Vázquez-Marrufo (Seville, ES)
15:30 - 17:00 MS and infections
Mycobacterium avium subsp. Paratuberculosis and multiple sclerosis in Sardinian patients P 819
E. Cocco, J. Frau, D. Cossu, G. Coghe, L. Lorefice, G. Fenu, M. Melis, M.R. Murru, C. Sardu, L. Sechi, M.G. Marrosu (Cagliari, Sassari, IT)
15:30 - 17:00 Neuropsychology and fatigue
Is information processing speed or verbal fluency the primary deficit in multiple sclerosis? P 897
H. Brissart, E. Morele, C. Baumann, M. LePerf, M. Leininger, L. Taillemite, M. Pagura, C. Dillier, S. Pittion, E. Spitz, M. Debouverie (Nancy, Vandoeuvre les Nancy, Metz, FR)
15:30 - 17:00 Neuropsychology and fatigue
Decisions under ambiguity and decisions under risk in multiple sclerosis P 905
M.F. Farez, L. Crivelli, R. Leiguarda, J. Correale (Buenos Aires, AR)
15:30 - 17:00 Treatment of specific symptoms
Measurement of daily mobility under fampridine-therapy with Movisens-system in patients with multiple sclerosis P 1030
R. Kempcke, T. Schultheiß, S. Sobek, K. Thomas, L. Shammas, S. Hey, T. Zentek, A. Rashid, T. Ziemssen (Dresden, Karlsruhe, DE)
15:30 - 17:00 Genetics / transcriptomics
A weighted genetic risk score to predict neutralising antibodies to interferon-beta in multiple sclerosis patients P 803
B. Hemmer, W. Igl, D. Buck, M. Mühlau, S. Schwenke, B. Müller-Myhsok, R. Sandbrink, C. Pohl (Munich, Berlin, DE)
15:30 - 17:00 Imaging
Effect of alemtuzumab vs. Rebif® on brain MRI measurements P 877
D.L. Arnold, J. Cohen, A.J. Coles, C. Confavreux, E. Fisher, E.J. Fox, H.-P. Hartung, E. Havrdova, K. Selmaj, H. Weiner, T. Miller, C.L. Twyman, S.L. Lake, D.H. Margolin, M. Panzara, M. Rizzo, D.A.S. Compston for the CARE-MS II investigators
15:30 - 17:00 Paediatric MS
Natalizumab in paediatric multiple sclerosis: long-term results of 55 cases P 684
A. Ghezzi, C. Pozzilli, L. Moiola, V. Brescia Morra, L.M.E. Grimaldi, G. Lus, F. Rinaldi, M. A. Rocca, M. Trojano, A. Bianchi, M. Filippi, G. Comi (also participated F. Bortolon, R. Capra, G. Coniglio, C. Gasperini, N. Milani, A. Lugaresi, L. Provinciali, E. Pucci, M.R. Rottoli, P. Sarchielli)
15:30 - 17:00 Biomarkers
Urinary and CSF biomarkers in multiple sclerosis P 1081
R. Dobson, J. Topping, A. Davis, G. Giovannoni (London, GB)
15:30 - 17:00 Immunosuppression
Prolonged remission with cyclophosphamide in a patient with CLIPPERS complicating MS P 957
M.R. Ortega, S. Delgado, J. Maldonado, L. Tornes, W. Sheremata, K.W. Rammohan (Miami, US)
15:30 - 17:00 Diagnosis and differential diagnosis
Aquaporin-4 expression and supramolecular aggregation may determine tissue susceptibility to neuromyelitis optica P 637
M. Matiello, D. Sun, J. Schaefer-Klein, B. Weinshenker (Rochester, US)
15:30 - 17:00 Imaging
Improved longitudinal gray matter atrophy assessment via a combination of SIENA and a 4-dimensional hidden Markov random field model P 840
M.G. Dwyer, N.P. Bergsland, R. Zivadinov (Buffalo, US)
15:30 - 17:00 Natural history
Disability progression in multiple sclerosis is faster than observed P 689
M.G. Brown, S. Kirby, M. Asbridge, R. McKelvey, T.J. Murray, L. Lethbridge, P. Andreou for the Dalhousie MS Research Group
15:30 - 17:00 Grey matter damage in MS
The regional cortical atrophy is correlated with T1 lesion load in early stages of relapsing-remitting multiple sclerosis P 779
C.M. Rimkus, T.F. Junqueira, D. Callegaro, M.C.G. Otaduy, C.C. Leite (Săo Paulo, BR)
15:30 - 17:00 Immunomodulation
Influence of different natalizumab treatment intervals and treatment holiday on CNS/peripheral immunstatus and free and cell bound natalizumab P 931
U. Hainke, T. Sehr, M. Marggraf, K. Thomas, T. Ziemssen (Dresden, DE)
15:30 - 17:00 Pathology
Oxidative stress is associated with disability in relapsing-remitting multiple sclerosis patients P 767
S.R. Oliveira, A.P. Kallaur, A.N.C. Simăo, D.R. Kaimen-Maciel, J. Lopes, C. Panis, W.L.C.J. Pereira, R.M. de Andrade, E.M.V. Reiche (Londrina, BR)
15:30 - 17:00 Neuropsychology and fatigue
Function is in the eye of self-efficacy P 887
L. Strober, J. DeLuca, N. Chiaravalloti (West Orange, US)
15:30 - 17:00 Late Breaking News
Functional disability after natalizumab-associated PML in a large cohort of survivors P 1098
T. Dong-Si, S. Richman, A. Gangadharan, N. Richert, S. Datta, J. McIninch, J. Philip, C. Bozic, G. Bloomgren (Weston, US)
15:30 - 17:00 Treatment of specific symptoms
Open-label extension patient retention rates with dalfampridine extended-release tablets in multiple sclerosis P 1027
R. Schapiro, F. Bethoux, T. Brown, L. Williamson, A. Rabinowicz, L. Marinucci, E. Carrazana (Minneapolis, Cleveland, Kirkland, Hawthorne, US)
15:30 - 17:00 Adaptative and Innate immunology
Peripheral B-lymphocyte subpopulations in relapsing remitting MS - who plays what? P 811
C. Sievers, M. Meira, J. Kuhle, T. Derfuss, P. Fontoura, L. Kappos, R.L.P. Lindberg (Basel, CH)
15:30 - 17:00 Pregnancy and MS
Predictive factors for postpartum relapses in multiple sclerosis P 736
P. Duquette, M. Asano, E. Roger, C. Larochelle, S. Scott, N. Mayo (Montreal, CA)
15:30 - 17:00 Neuro-ophthalmology
The retinal nerve fibre layer of patients with neuromyelitis optica and chronic relapsing optic neuritis are more severely affected than patients with multiple sclerosis: an exploratory study P 1067
D.B. Bichuetti, A.S. Camargo, A.B. Falcăo, I.M. Tavares, A.A. Gabbai, E.M.L. Oliveira (Săo Paulo, BR)
15:30 - 17:00 Immunomodulation
Therapeutic treatment with an anti-mouse CD52 antibody reverses disease symptoms in a murine EAE model of multiple sclerosis P 908
M. Turner, N. Chretien, E. Havari, M. LaMorte, B. Roberts, J. Kaplan, W. Siders (Framingham, US)
15:30 - 17:00 Treatment of specific symptoms
An alternative approach to estimate the health economic value of a non-disease modifying therapy for patients with multiple sclerosis: a Swedish application P 1032
R.-L. Leskelä, M. Dahlman, J.A. Gaebler, B. Deniz, S. Sarda, F. Herse (Helsinki, FI; Copenhagen, DK; Weston, US)
15:30 - 17:00 Devic’s NMO spectrum
Genetic susceptibility of idiopathic acute transverse myelitis in Brazilian patients from Rio de Janeiro P 656
R. Papais-Alvarenga, M. Papais-Alvarenga, M. Alvarenga, L. Campanella, L. Levya, O. Fernandez (Rio de Janeiro, BR)
15:30 - 17:00 Diagnosis and differential diagnosis
Four-year evolution of multiple sclerosis lesions using diffusion tensor imaging P 654
D. Ontaneda, K. Sakaie, J. Lin, X. Wang, M. Lowe, M. Phillips, R. Fox (Cleveland, US)
15:30 - 17:00 Neuro-ophthalmology
The role of vitamin D status in optic neuritis P 1058
J.M. Burton, J. Trufyn, C. Tung, M. Eliasziw, F. Costello (Calgary, CA; Boston, US)
15:30 - 17:00 Immunomodulation
Integrin expression patterns on naive and memory CD4+ and CD8+ T-cells before and during natalizumab therapy P 943
A. Harrer, K. Oppermann, G. Pilz, B. Holl, P. Wipfler, S. Afazel, E. Haschke-Becher, E. Trinka, J. Kraus (Salzburg, AT)
15:30 - 17:00 Late Breaking News
Exploring the temporal evolution of structural and functional changes after acute optic neuritis: a prospective study with spectral-domain optical coherence tomography P 1108
F.E. Costello, Y.I. Pan, J. Burton, J. Trufyn, W. Hodge (Calgary, CA)
15:30 - 17:00 Adaptative and Innate immunology
Comparison of skin cell immunity in patients receiving treatment with fingolimod and healthy individuals P 812
S.M. Newman, P. Hays, N. Harrington, S. Chin, G. Lee, J. Kelemen, T.M. Harding (New York, US)
15:30 - 17:00 Pathology
Is there a functional role for KCNMA1 in multiple sclerosis? P 766
A. Vanheel, B. Brône, R. Daniels, P. Stinissen, J.P. Noben, N. Hellings (Diepenbeek, BE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Chronic cerebrospinal venous insufficiency and extracranial venous stenoses in Danish multiple sclerosis patients P 1094
M. Blinkenberg, P. Ĺkeson, H. Sillesen, S. Lövgaard, F. Sellebjerg, O.B. Paulson, H.B. Siebner, P.S. Sřrensen (Copenhagen, DK)
15:30 - 17:00 Long-term treatment monitoring
Clinical and MRI aspects of immune reconstitution after natalizumab interruption P 972
A. Guéguen, C. Bensa, R. Deschamps, R. Depaz, M. Obadia, A. Moulignier, O. Gout (Paris, FR)
15:30 - 17:00 Pregnancy and MS
Use of glatiramer acetate during pregnancy: offering women a choice P 733
A.E. Miller, S. Rustgi, C. Farrell (New York, US)
15:30 - 17:00 Epidemiology
Epidemiologic features of multiple sclerosis in south-western Iran P 701
N. Majdinasab, A. Nakhostin-Mortazavi, M.H. Alemzadeh-Ansari (Ahvaz, IR)
15:30 - 17:00 Clinical assessment tools
The effect of standardised EDSS re-training on the performance of EDSS raters P 757
M. D`Souza, O. Yaldizli, E. Lucassen, E. Kornyeyeva, L. Kappos (Basel, CH; East Hanover, US)
15:30 - 17:00 Pregnancy and MS
Neuromyelitis optica in pregnancy: treatment with intravenous immunoglobulin P 735
M. Houtchens, K.H. Vo, L. Stazzone, H. Weiner (Boston, US)
15:30 - 17:00 Risk management for disease modifying treatments
Management of natalizumab-related PML: a different approach P 998
C. Cordioli, C. Costanzi, N. De Rossi, S. Rasia, R. Capra (Brescia, IT)
15:30 - 17:00 Late Breaking News
Teriflunomide suppresses antigen induced T-cell expansion in a TCR avidity dependent fashion P 1107
V. Posevitz*, D. Chudyka*, F. Kurth, H. Wiendl (Münster, DE)
15:30 - 17:00 Immunomodulation
Disability improvement with alemtuzumab vs. interferon-beta-1a in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II) P 922
G. Giovannoni, D.L. Arnold, J. Cohen, A.J. Coles, C. Confavreux, E. Fox, H.-P. Hartung, E. Havrdova, K. Selmaj, H. Weiner, C.L. Twyman, T. Miller, S.L. Lake, D.H. Margolin, M. Panzara, D.A.S. Compston for the CARE-MS II investigators
15:30 - 17:00 Immunomodulation
Effect of teriflunomide on immune responses to seasonal influenza vaccination in patients with relapsing multiple sclerosis: results from the TERIVA study P 925
A. Bar-Or, M. S. Freedman, M. Kremenchutzky, F. Menguy-Vacheron, D. Bauer, S. Jodl, P. Truffinet, M. Benamor, P. O'Connor (Montreal, Ottawa, London, CA; Chilly Mazarin, FR; Bridgewater, US; Berlin, DE; Toronto, CA)
15:30 - 17:00 Biomarkers
Pharmacogenomic study in multiple sclerosis patients responders and non-responders to interferon-beta P 1083
M. Bustamante, C. Morcillo-Suárez, S. Malhotra, D. Brassat, R. Goertsches, J. Lechner-Scott, E. Urcelay, Ó. Fernández, J. Drulovic, A. García-Merino, F. Martinelli-Boneschi, A. Chan, K. Vandenbroeck, A. Navarro, J. Río, D. Akkad, G. Giacalone, A. Sánchez, L. Leyva, R. Álvarez-Lafuente, U. Zettl, A. Rodríguez-Antigüedad, J. Killestein, J. Oksenberg, X. Montalban, M. Comabella (Barcelona, ES; Toulouse, FR; Rostock, DE; Madrid, Málaga, ES; Belgrade, RS; Milan, IT; Bochum, DE; Leioa, ES; Bilbao, ES; Amsterdam, NL; San Francisco, US)
15:30 - 17:00 Treatment of specific symptoms
Comparison of different endurance trainings in advanced multiple sclerosis patients: a randomised, controlled pilot study P 1031
S. Briken, S. Gold, K. Schulz, D. Harbs, S. Patra, G. Ketels, C. Heesen (Hamburg, DE)
15:30 - 17:00 Experimental models
Characterization of the expression of semaphorin 3A and 7A and their receptors in experimental autoimmune encephalomyelitis P 781
A. Gutiérrez, H. Eixarch, C. Costa, M. Castillo, X. Montalban, C. Espejo (Barcelona, ES)
15:30 - 17:00 Clinical assessment tools
Assessment of prevalence and pathological response to orthostatic provocation in patients with relapsing-remitting multiple sclerosis in relapse and remitting phases P 742
I. Adamec, I. Bach, A.K. Barusic, A. Mismas, M. Habek (Zagreb, HR)
15:30 - 17:00 Biomarkers
Proteomics discovery of novel CSF biomarkers for disease progression in multiple sclerosis P 1085
C.E. Teunissen, M.J.A. Koel-Simmelink, S. Piersma, T. Pham, J. Killestein, H. Vrenken, F. Berven, C.R. Jimenez (Amsterdam, NL; Bergen, NO)
15:30 - 17:00 Pathology
CHI3L1 expression in chronic active multiple sclerosis lesions P 765
C. Costa, E. Cantó, A.C. Wing, L. Agulló, X. Montalban, M. Comabella (Barcelona, ES)
15:30 - 17:00 Adaptative and Innate immunology
CD5-positive B cell subsets in secondary-progressive multiple sclerosis P 805
M. Niino, T. Fukazawa, N. Minami, I. Amino, J. Tashiro, N. Fujiki, S. Doi, S. Kikuchi (Sapporo, JP)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Chronic cerebrospinal venous insufficiency in MS/CIS is not consistently observed with a blinded ultrasound protocol P 1088
K. Knox, J. Gitlin, S. Harvey, C. Hayward, S. Wiebe, C. Voll, P. Szkup, R. Otani (Saskatoon, CA)
15:30 - 17:00 MS and infections
Epstein-Barr virus seroprevalence in multiple sclerosis patients: a systematic review and meta-analysis P 818
J. Pakpoor, G. Disanto, U.C Meier, G. Giovannoni, S.V Ramagopalan (Oxford, London, GB)
15:30 - 17:00 Neuropsychology and fatigue
Survival analysis of the BRB-N supports SDMT as a sentinel test for cognitive deterioration in MS P 904
J. Van Schependom, M.B. D'hooghe, A. Symons, K. Cleynhens, M. D'hooghe, S. Neirinckx, M.C. Haelewyck, G. Nagels (Mons, Melsbroek, BE)
15:30 - 17:00 Immunosuppression
Reduced dosage treatment for the multiple sclerosis patients developing lymphopenia or neutropenia during the treatment with fingolimod P 954
M. Tanaka, K. Park, R. Motoyama, K. Tanaka (Kyoto, Uchinada, JP)
15:30 - 17:00 Experimental models
Pharmacological characterisation of HCA3551: a novel, orally active alpha4 integrin antagonist with a long duration of action P 788
S. Kageyama, A. Andou, H. Ito, Y. Shima, K. Sagi, T. Yamada, T. Okuzumi, M. Tokumasu, T. Koyama, Y. Okamatsu, T. Miyazawa, K. Fujita, H. Kihara, M. Shoji (Tokyo, JP)
15:30 - 17:00 Clinical assessment tools
Assessment of relapse activity in the CombiRx randomised clinical trial P 754
F. Lublin, S. Cofield, T. Gustafson, R. Conwit, J. Wolinsky, G. Cutter for the The CombiRx Investigators
15:30 - 17:00 Comprehensive care and rehabilitation
Evaluating the effects of functional electrical stimulation on ambulation in individuals with secondary progressive multiple sclerosis P 1043
S. Newsome, K. Zackowski, P. Calabresi, D. Becker (Baltimore, US)
15:30 - 17:00 Imaging
Brain distribution of BZM055, an analog of fingolimod (FTY720), in human P 839
G. Tamagnan, A. Tavares, O. Barret, D. Alagille, J. Seibyl, K. Marek, P.R Maguire, E. Briard, R. Schmouder, R. Behrje, D. Jennings (New Haven, US; Basel, CH)
15:30 - 17:00 Imaging
Inter-rater variability of new T2 determination in the clinic has implications for MS diagnosis and monitoring P 874
C. Elliott, J. Maranzano, D. Cadavid, N. Richert, P. Duda, E. Fisher, S. Narayanan, D.L. Collins, T. Arbel, D.L. Arnold (Montreal, CA; Cambridge, Cleveland, US)
15:30 - 17:00 Risk management for disease modifying treatments
Body mass and natalizumab concentration as potential risk stratification markers for drug-related PML P 987
J. Foley, A. Christensen, T. Hoyt (Salt Lake City, US)
15:30 - 17:00 Tools for detecting therapeutic response
Long-standing B cells depletion in MS patients treated with combination of rituximab and mitoxantrone P 1011
E. Evdoshenko, S. Lapin, A. Maslyanskiy, L. Zaslavsky, A. Totolian, A. Skoromets (Saint-Petersburg, RU)
15:30 - 17:00 Epidemiology
Causes of death in US patients with multiple sclerosis P 697
S. Reshef, H. Golub, D. Goodin, G. Cutter, D. Kaufman, D. Pleimes, M. Corwin (Montville, Boston, San Francisco, Birmingham, US)
15:30 - 17:00 Treatment of specific symptoms
Clinical efficacy of fampridin and the influence of physiotherapy in outpatient MS patients in Germany P 1033
S. Braune, A. Kornhuber, M. Lang, A. Bergmann on behalf of the NTD Study Group
15:30 - 17:00 Experimental models
BNN27, a neuroprotective neurosteroid derivative, induces IL-10-producing regulatory T-cells and treats established experimental autoimmune encephalomyelitis P 794
M. Aggelakopoulou, E. Kourepini, I. Lazarides, D.C.M. Simoes, N. Paschalidis, D. Kalavrizioti, I. Pediaditakis, A. Mouzaki, I. Charalampopoulos, A. Gravanis, V. Panoutsakopoulou (Athens, Heraklion, Patras, GR)
15:30 - 17:00 Diagnosis and differential diagnosis
A practical algorithm for differentiating neurosarcoidosis from multiple sclerosis with application to cases from NYU MS Centre P 639
L. Zhovtis Ryerson, J. Herbert, I. Kister (New York, US)
15:30 - 17:00 Imaging
Early pseudoatrophy on natalizumab is due to white matter volume changes P 879
Ŕ. Vidal-Jordana, J. Sastre-Garriga, C. Tur, F. Pérez-Miralles, A. Horga, M. Tintoré, C. Auger, J. Río, C. Nos, E. Huerga, J. Castilló, A. Rovira, X. Montalban (Barcelona, ES)
15:30 - 17:00 Epidemiology
Temporal trends in the prevalence of co-morbidity in MS P 694
R.A. Marrie, N. Yu, S. Leung, L. Elliott, P. Caetano, S. Warren, C. Wolfson, S. Patten, L. Svenson, J. Fisk, J. Blanchard, H. Tremlett on behalf of the CIHR Team in the Epidemiology and Impact of Comorbidity on MS
15:30 - 17:00 Risk management for disease modifying treatments
Treatment-associated risk acceptance in natalizumab-treated MS patients P 1002
C. Tur, M. Tintoré, Ŕ. Vidal-Jordana, D. Bichuetti, P. Nieto, M.J. Arévalo, G. Arrambide, E. Anglada, Í. Galán, J. Castilló, C. Nos, J. Río, I. Martín, M. Comabella, J. Sastre-Garriga, X. Montalban (Barcelona, ES)
15:30 - 17:00 Clinical assessment tools
Does OCT predict conversion to MS? A longitudinal study P 751
C. Oreja-Guevara, S. Noval, A. Royo, B. Chamorro, J. Moreno, J. Alvarez-Linera (Madrid, ES)
15:30 - 17:00 Clinical assessment tools
Early diagnosis of cognitive disorders in multiple sclerosis: the HV3 score P 744
M. Laffon, G. Malandain, M. Cohen, C. Lebrun (Nice, Sophia Antipolis, FR)
15:30 - 17:00 Diagnosis and differential diagnosis
A sound localisation test discriminates between controls and multiple sclerosis patients with no measurable disability P 638
J.H. Bacon, T.E. Bacon, I. Kister, Y. Strauchler, G. Tsikhanovski Bochner, M. Omari, A. Bochkanova, J. Herbert (New York, US)
15:30 - 17:00 Genetics / transcriptomics
Study of the TNFRSF1A polymorphisms rs4149584 and rs1800693 in patients with multiple sclerosis P 802
M. Comabella, A.B. Caminero, S. Malhotra, L. Agulló, F. Reverter, K. Vandenbroeck, O. Fernández, F. Matesanz, G. Izquierdo, A. López-Larios, E. Urcelay, A. Sánchez, A. Rodríguez-Antigüedad, S. Otero, M. Tintoré, X. Montalban (Barcelona, Leioa, Málaga, Granada, Sevilla, Madrid, Bilbao, ES)
15:30 - 17:00 Diagnosis and differential diagnosis
Cryopyrin-associated periodic syndrome (CAPS) in multiple sclerosis P 645
E. Schuh, P. Lohse, M. Braun-Falco, R. Hohlfeld, T. Kümpfel (Munich, Singen, DE)
15:30 - 17:00 Environmental risk factors
Smoking and alcohol are related to multiple sclerosis severity, a case-control study P 830
A. Lucenti, A. Ivashynka, O. Raymkulova, M. Leone, P. Naldi (Novara, IT)
15:30 - 17:00 Treatment of specific symptoms
Extensive semi-automated gait analysis by Zebris FDM during treatment of multiple Sclerosis associated gait disturbancies with fampridine-SR P 1034
G. Wewerka, B. Holl, H. Bartsch, M. Malisa, C. Illhardt, G. Wewerka, G. Pilz, P. Wipfler, E. Trinka, B. Iglseder, J. Kraus (Salzburg, AT)
15:30 - 17:00 Devic’s NMO spectrum
Ultra-high-field (7T) magnetic resonance imaging of brain lesions of neuromyelitis optica spectrum disorders and multiple sclerosis: a case-control study P 661
I. Kister, J. Herbert, Y. Zhou, Y. Ge (New York, US)
15:30 - 17:00 Comprehensive care and rehabilitation
Variation of muscle power after twelve weeks of resistance training in multiple sclerosis patients P 1036
C. Medina-Pérez, F. de Souza-Teixeira, R. Fernandez-Gonzalo, J.A. de Paz-Fernández (Leon, ES; Pelotas, BR; Stockholm, SE)
15:30 - 17:00 Epidemiology
Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study P 707
A. Gajofatto, A. Stefani, M. Turatti, M.R. Bianchi, M. Gomez Lira, A. Salviati, M.D. Benedetti (Verona, IT)
15:30 - 17:00 Quality of life
Depression and physical activity among adults with multiple sclerosis, muscular dystrophy, spinal cord injury, and post-polio syndrome P 1050
A.M. Verrall, H. Bombardier, R. Rosenberg, B. Artherholt, W. Motl, M. Jensen (Seattle, Urbana, US)
15:30 - 17:00 Immunomodulation
Bioequivalence of BG-12 administered as a single 240 mg capsule and two 120 mg capsules: findings from a randomised, two-period crossover study P 913
K.T. Dawson, I. Nestorov, R. Manchanda, D. Goldman, J. O'Gorman, H. Russell, M.A. Matson, M. Tighe, S.I. Sheikh (Weston, Cambridge, St Paul, US)
15:30 - 17:00 Clinical assessment tools
Plasma vitamin B12, uric acid levels and lipids profiles in multiple sclerosis patients P 756
A. Celebi, O. Tehneldere, E. Gursoy, M. Kolukisa, G. Babacan-Yildiz, A. Kocer (Istanbul, Adiyaman, TR)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
No evidence for impairment in venous haemodynamics in children or young adults with paediatric-onset multiple sclerosis P 1087
B. Banwell, S. Laughlin, J. Traubici, S. Khan, K.Y. Chan, R.A. Marrie, C.K. Macgowan (Toronto, Winnipeg, CA)
15:30 - 17:00 Tools for detecting therapeutic response
Use of emerging logistic and linear IRT methods to place common clinical measures of MS progression on a single scale of global neurological disability P 1017
E. Chamot, I. Kister, G.R. Cutter (Birmingham, New York, US)
15:30 - 17:00 Grey matter damage in MS
Imaging cortical lesions in multiple sclerosis brains – a combined post-mortem 7 Tesla MRI and histopathological study P 778
S. Hametner, B. Yao, P. van Gelderen, H. Merkle, H. Lassmann, F.K. Cantor, C. Chen, J. Duyn, F. Bagnato (Vienna, AT; Bethesda, US)
15:30 - 17:00 Biomarkers
Microglial microvesicles as a prognostic biomarker in CIS patients: a 2 years-prospective study P 1077
D. Dalla Libera, A. Bergami, C. Verderio, M. Rocca, V. Martinelli, G. Comi, M. Filippi, R. Furlan (Milan, IT)
15:30 - 17:00 Devic’s NMO spectrum
Seasonal pattern of variation in neuromyelitis optica relapses P 664
L. Elsone, S. Luppe, J. Kitley, P. Chater-Lea, K. Harding, K. Mutch, M.I. Leite, J. Palace, N. Robertson, A. Jacob (Liverpool, Cardiff, Oxford, GB)
15:30 - 17:00 Biomarkers
A lipidomic investigation for the characterisation of CSF lipid profile in patients with multiple sclerosis P 1074
M. di Ioia, D. Pieragostino, P. Del Boccio, C. Rossi, P. Sacchetta, A. Urbani, D. Farina, D. Travaglini, L. Mancinelli, A. Lugaresi (Chieti, Rome, IT)
15:30 - 17:00 Imaging
Assessment of disease activity in multiple sclerosis phenotypes using a combined gadolinium and iron oxide nanoparticles MR contrast P 878
S. Roggerone, T. Tourdias, B. Brochet, S. Molinier, J. Bocquet, S. Vukusic, F. Durand-dubief, C. Confavreux, D. Miller, J.-P. Pruvo, M. Dufour, M. Rovaris, M. Filippi, V. Dousset (Bron, Bordeaux, FR; London, GB; Lille, FR; Milan, IT)
15:30 - 17:00 Others
Symptomatic steroid induced osteonecrosis of distal femur in multiple sclerosis P 1021
S. La Gioia, M. Poloni, M. Rottoli (Milan, Bergamo, IT)
15:30 - 17:00 Diagnosis and differential diagnosis
Motor-evoked potentials and gait analysis in patients with clinically isolated syndrome P 649
I. López Gutiérrez, B. Rosado Peńa, L. Dinca Avarvarei, B. Heredia Camacho, A. Hochsprung, C. Menéndez De León, G. Izquierdo Ayuso (Madrid, Seville, ES)
15:30 - 17:00 Imaging
Quantitative susceptibility mapping in multiple sclerosis P 870
C. Langkammer, T. Liu, M. Khalil, C. Enzinger, M. Jehna, S. Fuchs, F. Fazekas, Y. Wang, S. Ropele (Graz, AT; New York City, US)
15:30 - 17:00 Paediatric MS
Application of the 2010 criteria on baseline MRI in a paediatric cohort: does positivity at onset associate with a more aggressive clinical disease course? P 678
S. Bigi, R.A. Marrie, B. Banwell (Toronto, Winnipeg, CA)
15:30 - 17:00 Tools for detecting therapeutic response
Relapsing-remitting multiple sclerosis: serial computerised assessment of cognitive changes with natalizumab therapy P 1018
M. Gudesblatt, M. Zarif, B. Bumstead, S. Thotam, M. Buhse, L. Fafard, G. Doniger (Patchogue, Stony Brook, Bellaire, US)
15:30 - 17:00 Diagnosis and differential diagnosis
Application of the revised version of the 2010 McDonald diagnostic criteria: retrospective comparison using the BENEFIT clinical study dataset P 648
X. Montalbán, L. Kappos, M.S. Freedman, H.-P. Hartung, G. Edan, D.H. Miller, C.H. Polman, F. Barkhof, B. Stemper, J. Herrmann, C. Stolz, R. Sandbrink, C. Pohl, D. Pleimes (Barcelona, ES; Basel, CH; Ottawa, CA; Düsseldorf, DE; Rennes, FR; London, GB; Amsterdam, NL; Berlin, DE; Montville, US)
15:30 - 17:00 MS and infections
Progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients in Spain: more than expected? P 821
T. Castillo-Trivino, R. Arroyo, C. De Andres, R. Fernandez-Bolańos, A. Garcia-Merino, L. Landete, M. Menendez, P. Oliva, A. Oterino, M.D. Paramo, A. Saiz, J. Olascoaga (San Sebastian, Madrid, Sevilla, Valencia, Mieres, Oviedo, Santander, Barcelona, ES)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Cerebral venous outflow in multiple sclerosis studied by transcranial brain photoplethysmography P 1093
S. Viola, P. Viola, P. Litterio, M.P. Buongarzone, L. Fiorelli (Vasto, Atessa, IT)
15:30 - 17:00 Grey matter damage in MS
Is the development of T2 hypointensity a global process? P 773
R. Kane, V. Ikonomidou, J. Ohayon, F. Cantor, S. Stern, A. Gallo, S. Pellegrini, M. Ehrmantraut, F. Bagnato (Washington DC, Fairfax, Atlanta, US)
15:30 - 17:00 Long-term treatment monitoring
A two-year, observational study of patients with relapsing-remitting multiple sclerosis to assess the outcome of switching between disease-modifying therapy class in routine UK clinical practice P 971
D. Rog, J. O'Riordan, J.P. Mottershead, D. Croft (Salford, Aylesbury, GB)
15:30 - 17:00 Risk management for disease modifying treatments
Suppression of humoral responses after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab P 991
W. Kim, S.H. Kim, S.Y. Huh, J.Y. Cho, S.Y. Kong, Y.J. Choi, W.J. Kim, H.J. Kim (Seoul, Goyang, KR)
15:30 - 17:00 Clinical assessment tools
Knowledge, attitude assessment of Iranian patients with MS receiving interferon-beta P 758
R. Abolfazli, A. Elyasi, M. Javadi, K. Gholami, H. Torkamandi (Tehran, IR)
15:30 - 17:00 Tools for detecting therapeutic response
Single cell Stats activation in immune cells reveals NAb effects in vivo P 1010
S. Gavasso, T. Marřy, E. Mosleth, K. Jřrgensen, B.-T. Gjertsen, K.-M. Myhr, C. Vedeler (Bergen, Ĺs, NO)
15:30 - 17:00 Others
Time trends in baseline characteristics and eligibility criteria in trials in relapsing mutliple sclerosis - a systematic review and meta-analysis P 1022
S.M. Steinvorth, R. Nicholas, C. Röver, S. Schneider, S. Straube, T. Friede (Göttingen, DE; London, GB)
15:30 - 17:00 Epidemiology
High body mass index before age 20 is associated with increased risk for MS in both men and women: results from the Epidemiological Investigation of Multiple Sclerosis (EIMS) P 714
L. Alfredsson, A.K. Hedström, J. Hillert, T. Olsson (Stockholm, SE)
15:30 - 17:00 Environmental risk factors
Immune system modulation by UV radiation in multiple sclerosis: effects of urocanic acid P 833
J. Correale, M. Farez (Buenos Aires, AR)
15:30 - 17:00 Imaging
Deformation based MRI analysis of deep grey matter structures in MS P 872
S. Magon, M. Chakravarty, M. Amann, K. Weier, Y. Naegelin, M. Andelova, E.-W. Radue, C. Stippich, J. Lerch, L. Kappos, T. Sprenger (Basel, CH; Toronto, CA)
15:30 - 17:00 Imaging
High-field phase contrast imaging in multiple sclerosis P 864
V. Ovtcharov, M. Matzke, E. Stadler, K. Zhong, O. Speck, M. Sailer (Magdeburg, DE)
15:30 - 17:00 Imaging
Diffusional kurtosis imaging in relapsing-remitting MS: towards a more specific characterisation of white matter damage P 843
M. Inglese, J. Jensen, E. Fieremans (New York, Charleston, US)
15:30 - 17:00 Environmental risk factors
Smoking as a risk factor for multiple sclerosis P 828
J. Salzer, M. Nyström, G. Hallmans, H. Stenlund, G. Wadell, P. Sundström (Umeĺ, SE)
15:30 - 17:00 Grey matter damage in MS
The relative contribution of cortical versus white matter lesions to cognitive dysfunction in MS: evidence from an MRI study with double inversion recovery imaging P 775
A. Papadopoulou, N. Müller-Lenke, Y. Nägelin, G. Kalt, K. Bendfeldt, P. Kuster, A. Gass, T. Sprenger, E.-W. Radue, L. Kappos, I.K. Penner (Basel, CH; Mannheim, DE)
15:30 - 17:00 Databases and Pharmacoepidemiology
The clinical outcomes associated with adherence to and discontinuation of disease-modifying treatments P 716
J. Burks, E. Malangone, M. Jhaveri, S. Zhou, L. Stern, S. Bhurke, R. Casciano (Cherry Hill, New York, Bridgewater, US)
15:30 - 17:00 Others
A novel oral medical nutrition formula (PLP10) for the treatment of relapsing-remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial P 1019
M.C. Pantzaris, G.N. Loukaides, E.E. Ntzani, I.S. Patrikios (Nicosia, CY; Ioannina, GR)
15:30 - 17:00 Risk management for disease modifying treatments
How does risk tolerance to MS therapies change with time: survey results from the NARCOMS registry P 986
R. Fox, J. Alster, N. Dawson, M. Kattan, D. Miller, S. Ramesh, A. Salter, T. Tyry, B. Wells, G. Cutter (Cleveland, Birmingham, Phoenix, US)
15:30 - 17:00 Imaging
Reproducibility of surface-based laminar measures of T2* relaxation decay in the cortex at 7 Tesla MRI P 838
S.T. Govindarajan, M.P. Sormani, J. Cohen-Adad, C. Mainero (Charlestown, US; Genoa, IT)
15:30 - 17:00 Economic burden
Multiple Sclerosis Severity Scale: cognition and employment correlates P 760
M. Gudesblatt, M. Zarif, O. Gorbatsevych, B. Bumstead, M. Buhse, L. Fafard, I. Topalli, G. Doniger (Patchogue, Stony Brook, Cambridge, Bellaire, US)
15:30 - 17:00 Pathology
Fractalkine its receptor (CX3CR1) expression in the spinal cord associated with MS-induced neuropathic pain P 768
M.P. Namaka, W. Zhu, C.M.R. Acosta, B. MacNeil, E.E. Frost (Winnipeg, CA)
15:30 - 17:00 Devic’s NMO spectrum
Pain in neuromyelitis optica spectrum disease: a cross-sectional study in an English cohort P 663
H.A.C. Leonard, J. Revis, L.A.E. Matthews, J. Kitley, M.I. Leite, J. Palace (Oxford, GB)
15:30 - 17:00 Imaging
Assessment of myelin content by positron emission tomography with [methyl-ąąC]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole in relapsing-remitting MS P 865
B. Bodini, L. Bottin, L. Freeman, A. Chardain, M. Battaglini, O. Ciccarelli, C. Papeix, D. Galanaud, B. Zalc, D. García-Lorenzo, S. Lehéricy, C. Lubetzki, M. Bottlaender, B. Stankoff (Paris, FR; Siena, IT; London, GB; Orsay, FR)
15:30 - 17:00 Neuroprotection
The effects of glatiramer acetate on the retinal nerve fibre layer in patients with a first episode of acute optic neuritis P 964
M. Kupersmith, R. Sergott, D. Hurtukova, P. Calabresi, G. Cutter, M. Kupersmith (New York, Philadelphia, Kansas City, Baltimore, Birmingham, US)
15:30 - 17:00 Epidemiology
Multiple Sclerosis Registry in Catalonia: results after 3 years P 706
S. Otero, J. Sastre-Garriga, E. Simón, C. Nos, L. Ramió-Torrentŕ, H. Perkal, A. Saiz, S. Llufriu, A. Escartín, C. Ramo, M. Marco, L. Brieva, E. Muteis, E. Bufill, M. Fragoso, I. Bonaventura, I. Pericot, A. Cano, A. Boltes, O. Carmona, G. Martín, J. Hernández, V. González, J. Bello, E. Moral, M. Tintoré, X. Montalban (Barcelona, Girona, Badalona, Lleida, Mataró, Figueras, Tortosa, Vilanova i la Geltrú, Esplugues de Llobregat, Sant Joan Despí, ES)
15:30 - 17:00 Risk management for disease modifying treatments
Lyme neuroborreliosis during natalizumab treatment in multiple sclerosis – a case presentation P 993
K. Thomas, T. Schultheiß, T. Ziemssen (Dresden, DE)
15:30 - 17:00 Devic’s NMO spectrum
Use of rituximab in Devic´s disease, two-year follow-up. Mexican experience P 673
J. Flores, L. Aguirre, L. Salinas, Y. Rito, T. Corona (Mexico City, MX)
15:30 - 17:00 Immunomodulation
Studying the SAfety, tolerability and efficacy of Boswellic Acids in multiple sclerosis (SABA Trial) P 930
K.H. Stürner, P. Stellmann, F. Paul, M. Sospedra, R. Martin, C. Heesen (Hamburg, Berlin, DE; Zurich, CH)
15:30 - 17:00 Epidemiology
Immunomodulatory treatment of multiple sclerosis in Switzerland - a nationwide follow-up of 8’046 patients, 1995 - 2010 P 704
C. Lienert, A. Schoetzau, S. Beer, L. Kappos, O. Yaldizli (Basel, Valens, CH)
15:30 - 17:00 Clinical assessment tools
FAME - FAmpyra outcome MEasure Study - an ongoing study P 745
H.B. Jensen, U. Dalgas, M.H. Ravnborg, E. Stenager (Sřnderborg, Aarhus, Odense, DK)
15:30 - 17:00 Grey matter damage in MS
Grey matter microstructural and volumetric short-term changes in early relapsing and progressive MS P 770
B. Bodini, M. Battaglini, M.L. Stromillo, A. Eshaghi, C. Gasperini, C. Pozzilli, A.J. Thompson, N. De Stefano, O. Ciccarelli (London, GB; Siena, IT; Tehran, IR; Rome, IT)
15:30 - 17:00 Experimental models
The envelope of human endogenous retrovirus mediates neuro-inflammation in mice P 783
H-L. Reynaud-Dougier, C. Lomparski, C.L. Villiers, E. Jouvin-Marche, H. Perron, P.N. Marche (Grenoble, Lyon, FR)
15:30 - 17:00 Neurophysiology
Evoked potentials may predict response to immunomodulating treatment in multiple sclerosis P 881
L. Leocani, M. Bianco, G. Di Maggio, A. Nuara, S. Medaglini, J. Gonzalez Rosa, R. Chieffo, U. Del Carro, V. Martinelli, L. Moiola, G. Comi (Milan, IT)
15:30 - 17:00 Imaging
Ganglion cells loss in non-optic neuritis eyes of MS patients P 846
P. Sriram, N. Saakova, C. Wang, H. Arvind, S. Graham, C. Yiannikus, R. Garrick, M.H. Barnett, J. Parratt, A. Klistorner (Sydney, AU)
15:30 - 17:00 Neuroprotection
Neuroprotective role of fumarate therapy in chronic EAE P 969
S. Demir, S. Heckers, R. Scannevin, A. Chan, R. Gold (Bochum, DE; Cambridge, US)
15:30 - 17:00 Environmental risk factors
Vitamin A not associated with exacerbations in multiple sclerosis P 826
T.F. Runia, W.C.J. Hop, Y.B. De Rijke, D. Buljevac, R.Q. Hintzen (Rotterdam, NL)
15:30 - 17:00 Environmental risk factors
Epstein-Barr virus and vitamin D as risk factors for multiple sclerosis P 829
J. Salzer, M. Nyström, G. Hallmans, H. Stenlund, G. Wadell, P. Sundström (Umeĺ, SE)
15:30 - 17:00 Grey matter damage in MS
Grey matter changes in relapsing-remitting multiple sclerosis: a meta-analysis of voxel-based morphometry studies P 772
J.A. Lansley, M. Grau, J. Radua, D. Mataix-Cols, J. Sastre-Garriga (Norwich, London, GB; Barcelona, ES)
15:30 - 17:00 Environmental risk factors
High dietary salt aggravates autoimmune neuroinflammation via induction of Th17 cells P 827
A. Manzel, M. Kleinewietfeld, J. Titze, D. Hafler, D. Müller, R. Linker (Erlangen, DE; New Haven, Nashville, US)
15:30 - 17:00 Risk management for disease modifying treatments
Fingolimod following natalizumab in RRMS: clinical and MRI findings P 999
F. Rinaldi, D. Seppi, M. Calabrese, P. Perini, P. Gallo (Padua, IT)
15:30 - 17:00 Risk management for disease modifying treatments
Monitoring of expression of two CD49d epitopes as biomarker during natalizumab therapy P 988
R. Johanson, T. Leist (Philadelphia, US)
15:30 - 17:00 Long-term treatment monitoring
Long-term efficacy and safety of repeated treatment with rituximab in neuromyelitis optica spectrum disorder: a 4-year follow-up study P 973
S.-H. Kim, W. Kim, S.-Y. Huh, S.J. Lee, A.-R. Joung, G.J. Wolbink, D. van der Kleij, P.P. Tak, H.J. Kim (Goyangsi, KR; Amsterdam, NL)
15:30 - 17:00 Quality of life
Summary scores for patient-reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC) P 1052
M. Cascione, D. Wynn, N. Agashivala, K. McCague, L. Pestreich, L. Schofield, E. Kim, L. Barbato (Tampa, Northbrook, East Hanover, US)
15:30 - 17:00 Neuropsychology and fatigue
Difficulties in planning among MS patients: a relative consequence of deficits in information processing speed P 889
E. Owens, D. Denney, S. Lynch (Lawrence, Kansas City, US)
15:30 - 17:00 Immunomodulation
Increase in proportion of patients free from disease activity following 1 year of treatment with daclizumab high-yield process in relapsing-remitting multiple sclerosis: results from the SELECT study P 921
G. Giovannoni, D. Stefoski, K. Umans, S. Greenberg, S. Glyman, J. Elkins (London, GB; Chicago, Cambridge, Redwood City, US)
15:30 - 17:00 Imaging
SWI phase values of the whole grey and white matter in patients with multiple sclerosis and neuromyelitis optica: a comparative study with controls P 848
V. Itagiba, E. Gasparetto, F. Lopes-Rueda, T. Doring, P. Bahia, R. Domingues (Rio de Janeiro, BR)
15:30 - 17:00 Imaging
Resting-state functional magnetic resonance imaging in the assessment of patients with neuromyelitis optica P 847
F. Rueda-Lopes, F. Miraldi, F. Malfetano, I. Meira, S. Alves-leon, R. Domingues, E. Gasparetto (Rio de Janeiro, BR)
15:30 - 17:00 Immunomodulation
RPC1063, a potent, selective S1P1 receptor modulator, is active in a therapeutic EAE model and exhibits favourable PK/PD properties in healthy volunteers P 915
J. Brooks, R. Peach, F. Scott, G. Timony, J. Hartung, M. Boehm, H. Rosen, S. Gujrathi (San Diego, US)
15:30 - 17:00 Imaging
Myelin water imaging changes in primary progressive multiple sclerosis brain P 876
S. Kolind, A. Seddigh, N. Sibtain, S. Deoni, G.J. Barker, A. Traboulsee, S.C.R. Williams, P.A. Brex (Vancouver, CA; London, GB; Providence, US)
15:30 - 17:00 Quality of life
Is the impact of relapsing-remitting multiple sclerosis on carers different between early and older stages of the disease? - REPIT survey in France P 1044
P. Clavelou, A. Creange, M. Debouverie, C. Donze, P. Hautecoeur, C. Mekies, M. Montreuil,, T. Moreau, S. Pittion-Vouyovitch, A.L. Ramelli, M.S. Behier, I. Bourdeix, G. Thual, K. Rerat on behalf of the REPIT STUDY GROUP
15:30 - 17:00 Risk management for disease modifying treatments
Dynamics of the peripheral blood CD4 cell counts of JCV Ab positive patients at the different phases of natalizumab treatment P 989
R. Berkovich, D. Togasaki, D. Subhani, L. Steinman (Los Angeles, Stanford, US)
15:30 - 17:00 Economic burden
Symptoms and quality of life of adults with multiple sclerosis by employment status P 759
K. Johnson, D. Amtmann, A. Verrall, V. Weir, R. Salem (Seattle, US)
15:30 - 17:00 Biomarkers
Paraoxonase1 (an antioxidant): a marker of disease activity in multiple sclerosis? P 1071
L. Racz, J. Padra, Z. Mezei, G. Paragh, L. Csiba, I. Seres, T. Csepany (Debrecen, HU)
15:30 - 17:00 Quality of life
Rationale for and design of the ENABLE study: an open-label, multicentre, phase 4 study to assess the effect of long-term treatment with prolonged-release fampridine on health-related quality of life in patients with multiple sclerosis P 1053
J.A. Gaebler, J. Potts, D. Paes (Weston, US)
15:30 - 17:00 Experimental models
Intranasal HHV-6A infection accelerates EAE in the common marmoset P 786
E. Leibovitch, P. Maggi, S. Cummings Macri, G. Brunetto, K. Motanic, J. Wohler, S. Westmoreland, A. Silva, D. Reich, S. Jacobson (Bethesda, Southborough, US)
15:30 - 17:00 Imaging
Diffusion tensor imaging of cervical spinal cord tracts is specific to clinical function in demyelinating disease P 842
R.T. Naismith, J. Xu, E.C. Klawiter, N.T. Tutlam, S. Lancia, K. Trinkaus, S.K. Song, A.H. Cross (Saint Louis, US)
15:30 - 17:00 Paediatric MS
Support for the relapse disability paradox: higher relapse rates persist in paediatric compared to adult onset multiple sclerosis at six year follow-up P 683
L. Benson, B. Healy, M. Gorman, N. Baruch, T. Gholipour, A. Musallam, T. Chitnis (Boston, US)
15:30 - 17:00 Neuro-ophthalmology
Correlation between structural and functional measures of optic nerve myelination P 1057
C. Yiannikas, A. Van Der Walt, P. Mitchell, Y. Wang, S. Kolbe, T. Kilpatrick, H. Butzkueven, G. Egan, H. Arvind, S. Graham, M. Paine, A. Klistorner (Sydney, Melbourne, AU)
15:30 - 17:00 Epidemiology
Causes of death in multiple sclerosis patients from British Columbia, Canada P 700
E. Kingwell, C. Evans, T. Duggan, F. Zhu, J. Oger, H. Tremlett (Vancouver, CA)
15:30 - 17:00 Immunomodulation
A multinational, multicentre, randomised, parallel-group study to assess efficacy, safety, and tolerability of glatiramer acetate 40 mg injection three times a week in subjects with RRMS: baseline patient characteristics of the GALA study P 912
O. Khan, P. Rieckmann, A. Boyko, K. Selmaj, R. Zivadinov (Detroit, US; Bamberg, DE; Moscow, RU; Lodz, PL; Buffalo, US)
15:30 - 17:00 Quality of life
Impact on health-related quality of life by cutaneous adverse events associated with long-term disease-modifying therapy in multiple sclerosis: the derMiS study P 1048
D.M.W. Balak, G.J.D. Hengstman, E. Hajdarbegovic, R.J.P. van den Brule, R.M.M. Hupperts, H.B. Thio (Rotterdam, Eindhoven, Badhoevedorp, Sittard-Geleen, NL)
15:30 - 17:00 Imaging
Cortical reorganisation and white matter tracts structural features matching in relapse-remitting multiple sclerosis during the relapse with motor disorders P 868
S. Kulikova, V. Bryukhov, A. Peresedova, O. Trifonova, M. Krotenkova, I. Zavalishin (Moscow, RU)
15:30 - 17:00 Neuropsychology and fatigue
''Benign'' multiple sclerosis: long disease duration and low EDSS is not cognitively benign P 888
M. Gudesblatt, M. Zarif, B. Bumstead, M. Buhse, L. Fafard, J. Cruz, O. Gorbatsevych, G. Thippeswamy, L. Strober, J. DeLuca, G. Doniger (Patchogue, Stony Brook, West Orange, Bellaire, US)
15:30 - 17:00 Epidemiology
Anti-body titres against Epstein-Barr virus are associated with increased risk of multiple sclerosis in Mexico City P 699
J. Massa, K. Simon, R. Lopez-Ridaura, J Rivera-Flores, O. Silverman-Retana, I. Kagan, A. Ascherio (Boston, US; Mexico City, MX; Georgia, US)
15:30 - 17:00 Comprehensive care and rehabilitation
Multiple sclerosis: cognitive reserve and disease impact P 1038
M. Gudesblatt, M. Pardini, M. Zarif, B. Bumstead, S. Thotam, M. Buhse, L. Fafard, G. Thippeswamy, L. Strober, J. DeLuca, G. Doniger, I. Topalli, M.P. Sormani (Patchogue, US; Genoa, IT; Stony Brook, West Orange, Bellaire, Cambridge, US)
15:30 - 17:00 Experimental models
The regulatory function of B-cells in protection against EAE by a human commensal bacteria polysaccharide P 796
Y. Wang, K. Telesford, S. Begum-Haque, J. Ochoa-Repáraz, D.L. Kasper, L.H. Kasper (Lebanon, Boston, US)
15:30 - 17:00 Natural history
Predictors of disease progression in a large cohort of primary-progressive MS P 690
J.-P. Stellmann, A Neuhaus, C Lederer, M Daumer, C Heesen (Hamburg, Munich, DE)
15:30 - 17:00 Devic’s NMO spectrum
Long-term follow-up of patients with neuromyelitis optica treated with rituximab P 666
T. Kümpfel, J. Havla, E. Schuh, H. Pellkofer, L.A. Gerdes, I. Meinl, R. Hohlfeld (Munich, DE)
15:30 - 17:00 Imaging
Evidence for a neuroprotective effect of oral laquinimod in relapsing-remitting multiple sclerosis P 861
M. Filippi, M.A. Rocca, N. De Stefano, D. Jeffery, L. Kappos, X. Montalban, A.N. Boyko, G. Comi on behalf of the ALLEGRO Study Group
15:30 - 17:00 Epidemiology
Comparative effectiveness of long-term users of disease-modifying therapy P 698
A. Salter, Y. Tang, L. Hornung, S. Kolodny, D. Hurtukova, S. Glenski, S. Cofield, X. Zhang, G. Cutter (Birmingham, Kansas City, US)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Prevalence, sensitivity and specificity of chronic cerebrospinal venous insufficiency in paediatric multiple sclerosis P 1090
R. Zivadinov, E.A. Yeh, K. Marr, V. Valnarov, C. Kilanowski, M. Karpinski, E. Carl, C. Kennedy, B. Weinstock-Guttman (Buffalo, US)
15:30 - 17:00 Immunomodulation
The effect of daclizumab HYP on sustained disability progression in the SELECT trial P 949
E. Havrdova, R. Gold, G. Giovannoni, K. Umans, S. Glyman, J. Elkins (Prague, CZ; Bochum, DE; London, GB; Cambridge, US)
15:30 - 17:00 Devic’s NMO spectrum
Outcome of repeated rituximab treatment in 81 patients with neuromyelitis optica spectrum disorder P 670
S.-H. Kim, W. Kim, S.-Y. Huh, S.J. Lee, A.-R. Joung, H.J. Kim (Goyangsi, KR)
15:30 - 17:00 Neuropsychology and fatigue
Pattern of cognitive impairment and related factors in clinically isolated syndrome P 895
S. Özakbas, B. Piri Cinar, A. Gürkan, O. Öztürk, E. Idiman (Izmir, TR)
15:30 - 17:00 MS and infections
Study of the JC virus presence in multiple sclerosis patients treated with natalizumab P 822
M.I. Dominguez-Mozo, M. García-Montojo, V. De las Heras, M.A. García-Martínez, A. Arias-Leal, I. Casanova, R. Álvarez-Lafuente, R. Arroyo (Madrid, ES)
15:30 - 17:00 Risk management for disease modifying treatments
Interferon-beta-1a (Avonex®) as treatment option for untreated MS patients (AXIOM) P 1007
C. Kleinschnitz, G. Niemczyk, K. Rehberg-Weber, C. Wernsdörfer for the AXIOM Study Group
15:30 - 17:00 Neuroprotection
Selective oestrogen receptor beta agonist as a possible neuroprotective intervention of multiple sclerosis P 958
M.K. Österlund, P. Fagergren, A. Ökvist, M. Sjöberg (Huddinge, SE)
15:30 - 17:00 Adaptative and Innate immunology
Effector CD8+ T-cells recognise cognate and cross-reactive peptides presented in non-inflamed CNS tissue P 807
E. Zindler, N. Boldakowa, J. Herz, F. Zipp, V. Siffrin (Mainz, Berlin, Essen, DE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
A prospective follow-up of the venous haemodynamics in patients with MS: the fluctuating natural course of CCSVI P 1092
L.H. Visser, L. van den Berg, A. van der Zande, G. van den Berg, B. Westerhuis (Tilburg, Maassluis, NL)
15:30 - 17:00 Risk management for disease modifying treatments
A Swiss best practice experience in three different clinical settings of the 6 hour fingolimod first dose observation procedure P 1003
S.P. Ramseier, S. Roth, A. Czaplinski (Aarau, Carouge, Zurich, CH)
15:30 - 17:00 Biomarkers
Proteomic and red-ox proteomic analysis of serum proteins in relapsing-remitting multiple sclerosis patients P 1075
T. Koudriavtseva, E. Onesti, E. Bucaj, A. Fiorini, E. Sbardella, M. Mingoia, F. De Marco, M. Perluigi (Rome, IT)
15:30 - 17:00 Devic’s NMO spectrum
Three cases of neuromyelitis optica spectrum disorders with interstitial pneumonia P 671
M. Sakamaki, T. Kanamaru, Y. Takayama, M. Kobayashi, A. Nogami, T. Kumagai, H. Nagayama, M. Yamazaki, Y. Katayama (Tokyo, JP)
15:30 - 17:00 Immunomodulation
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergic respiratory diseases P 937
G. Mallucci, L. La Mantia, P.A. Confalonieri, S. Galgani, S. Haggiag, A. Lugaresi, G. De Luca, C. Solaro, E. Trabucco, G. Meola, M. Robotti, G. Cavaletti, B. Frigeni, R. Clerici, L. Chiveri, G. Bono, P. Banfi, E. Ambrosoni, L. Mancardi, F. Della Cava, R. Balgera, R. Bergamaschi (Pavia, Milan, Rome, Chieti, Genoa, Monza, Como, Varese, Lecco, IT)
15:30 - 17:00 Comprehensive care and rehabilitation
Is virtual reality a useful tool in multiple sclerosis neurorehabilitation? A pilot study P 1040
A. Tacchino, M.A. Battaglia, G. Brichetto (Genoa, IT)
15:30 - 17:00 Clinical assessment tools
A new path for the MS Walking Scale: MSWS-12 version 2 P 748
J. Hobart, S. Cano, W. Ingram, J. Zajicek (Plymouth, GB)
15:30 - 17:00 Immunomodulation
Ponesimod is a potent S1P1 receptor modulator causing efficient receptor internalisation, degradation and functional antagonism P 926
J. Gatfield, L. Monnier, O. Nayler (Allschwil, CH)
15:30 - 17:00 Diagnosis and differential diagnosis
Antibodies against neuronal and non-neuronal autoantignes existing in inflammatory demyelinating disorders in Japan P 652
M. Watanabe, T. Kageyama, A. Ozaki, K. Murakata, S. Matsumoto, T. Kondo (Osaka, JP)
15:30 - 17:00 Devic’s NMO spectrum
Human aquaporin 4 281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01 – Relevance for diagnosing and monitoring patients with neuromyelitis optica P 658
B. Arellano, R. Hussain, T. Zacharias, J. Yoon, C. David, S. Zein, L. Steinman, T. Forsthuber, B. Greenberg, D. Lambracht-Washington, A. Ritchie, J. Bennet, O. Stuve (Dallas, Palo Alto, Rocherster, San Antonio, Denver, US)
15:30 - 17:00 Immunomodulation
Intravenous administration of human MultiStem® cells provides functional benefit through immunomodulation in rodent models of multiple sclerosis P 916
J. Hamilton, R. Cutrone, J. Hecker, C. Wylie, J. Krasno, K. Wyatt, S. Busch, L. Bai, R. Deans, R. Miller, R. Mays (Cleveland, US)
15:30 - 17:00 Epidemiology
Artificial neural network predicts paediatric-onset multiple sclerosis incidence rate P 702
N. Latif-ol-tojar, P. Heydarpour, K. Mohammad, S.-R. Elhami, M-A. Sahraian (Tehran, IR)
15:30 - 17:00 Immunomodulation
Effect of switching from intramuscular interferon beta-1a to fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS P 909
G. Cutter, X. Meng, P. Chin, R. Hashmonay, M.Z. Islam (Birmingham, East Hanover, US)
15:30 - 17:00 Risk management for disease modifying treatments
Safety of fingolimod in patients with relapsing forms of multiple sclerosis: subgroup analyses from the 4-month, open-label, multi-centre FIRST study P 1009
R. Gold, G. Comi, T. Ziemssen, J. Haas, A. Sinha, F. Dahlke, P. von Rosenstiel, D. Tomic, L. Kappos (Bochum, DE; Milan, IT; Dresden, Berlin, DE; Hyderabad, IN; Basel, CH)
15:30 - 17:00 Clinical assessment tools
A novel method of measuring subclinical neurological deficit in patients with a clinically isolated syndrome P 750
M. Clough, J. Fielding, A. Ng, G. Egan, O. White (Clayton, Parkville, AU)
15:30 - 17:00 Imaging
Longitudinal changes of cerebral glutathione levels in patients with secondary progressive multiple sclerosis may reflect the clinical course of disease progression P 841
I.-Y. Choi, P. Lee, D. Denney, S. Lynch (Kansas City, Lawrence, US)
15:30 - 17:00 Devic’s NMO spectrum
Recurrent hyperCKemia preceding neuromyelitis optica exacerbations P 659
C.K. Grouse, R. Balabanov (Chicago, US)
15:30 - 17:00 Biomarkers
Pharmacogenomics biomarkers in multiple sclerosis: transcriptional profiling of the B cell response to interferon-beta P 1072
R. Khsheibun, T. Paperna, N. Avidan, A. Volkovitz, A. Miller (Haifa, IL)
15:30 - 17:00 Experimental models
Preferential decrease in Th1 and Th17 cells within the CNS of EAE mice in response to oral laquinimod P 795
S. Begum-Haque, M. Christy, K. Telesford, Y. Wang, A. Haque, L.H. Kasper (Lebanon, US)
15:30 - 17:00 Genetics / transcriptomics
Conventional and non-conventional MRI characteristics of familial and sporadic multiple sclerosis patients P 801
A. Tipirneni, B. Weinstock-Guttman, M. Ramanathan, N. Abdelrahman, S. Hussein, J. Hagemeier, J. Durfee, B. Teter, D. Hojnacki, M. Dwyer, F. Munschauer, R. Zivadinov (Buffalo, US)
15:30 - 17:00 Adaptative and Innate immunology
Laquinimod's effects on innate immunity directs adaptive T-cell modulation P 813
U. Schulze-Topphoff, M. Varrin-Doyer, A. Shetty, P.A. Nelson, S.S. Zamvil (San Francisco, US)
15:30 - 17:00 Immunomodulation
Correlation between EDSS and MSFC in the FREEDOMS study P 917
R.A. Rudick, R. Hashmonay, X. Meng, P. Chin, G. Cutter (Cleveland, East Hanover, Birmingham, US)
15:30 - 17:00 Biomarkers
Clinical characterisation of interferon inhibitory activity in multiple sclerosis patients treated with IFN-beta-1a P 1079
B. Weinstock-Guttman, M. Ramanathan, R. Zivadinov, A. Khan, M. Dillon, K. Patrick, M.W Masud, D. Hojnacki, K. Chadha (Buffalo, US)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Prevalence, sensitivity and specificity of chronic cerebrospinal venous insufficiency in other neurologic diseases. A case-control study P 1089
R. Zivadinov, K. Marr, V. Valnarov, C. Kilanowski, C. Kennedy, T. Guttuso, D. Lichter, N. Silvestri, L. Fugoso, E.A. Yeh, M. Ramanathan, R. Benedict, E. Carl, D. Hojnacki, B. Weinstock-Guttman (Buffalo, US)
15:30 - 17:00 Treatment of specific symptoms
Office-based single-bolus intrathecal Baclofen trials in MS patients: a call to action P 1025
J. Nicholas, M. Bartoszek, C. O’Connell, B. Morgan-Followell, D. Pitt, A. Boster (Columbus, US)
15:30 - 17:00 Epidemiology
Clinical and radiological characteristics of Korean patients with autoimmunity to Aquaporin-4 at onset P 710
O. Kwon, H. J. Kim, W. J. Kim, B. J. Kim, B. J. Kim, J. H, Min, M. S. Park, K. S. Lee, J. Y. An, K. K. Kim, Y. M. Lim, S. M. Kim, H. Y. Shin, S. M. Cheon, J. G. Kim, S. Y. Kim, M. S. Park, B. S. Shin, J. S. Bae, J. Y. Cho, S. S. Lee, S. W. Ahn, E. H. Sohn, G. J. Park, J. G. Lim, J. Y. Oh, Y. H. Hong, K. H. Lee on behalf of the Korean MS Investigators Group
15:30 - 17:00 Risk management for disease modifying treatments
Evaluating results of blood serum anti-JCV antibodies of natalizumab treated multiple sclerosis patients P 990
T. Kalamatas, N. Protopapas, A. Lafionati, A. Nella, A. Graigos, K. Karageorgiou (Athens, GR)
15:30 - 17:00 Long-term treatment monitoring
Long-term glatiramer acetate therapy in every-day practice: comparison of MS course in continued 10 years therapy and in cases with treatment stop P 985
A. Boyko on behalf of neurologists at the Moscow MS Center
15:30 - 17:00 Environmental risk factors
The association between sunlight hours and month of birth in multiple sclerosis patients across UK regions P 832
L.A.E. Matthews, M. Oppenheimer, A. Cavey, N. Evangelou, C. Constantinescu, N. Robertson, J. Zajicek, R. Nicholas, M. Boggild, G. Giovannoni, O. Gray, S. Hawkins, P. Rothwell, J. Palace (Oxford, GB)
15:30 - 17:00 Immunomodulation
Development of anti-CXCL13 monoclonal antibody for the treatment of multiple sclerosis P 911
E. Klimatcheva, T. Pandina, C. Reilly, J. Decker, A. Jonason, M. Scrivens, H. Huang, C. Cornelius, M. Doherty, J. Veeraraghavan, R. Kirk, J. Caplan, A. Howell, P. Kenney, G. Seigel, S. Torno, T. Richards, T. Fisher, E. Evans, M. Paris, J. Leonard, R. Watkins, P. Foster, W. Bowers, M. Zauderer, E. Smith (Rochester, US)
15:30 - 17:00 Long-term treatment monitoring
Multiple sclerosis and natalizumab: “between the dose symptoms” P 982
M. Gudesblatt, M. Zarif, B. Bumstead, S. Thotam, L. Fafard, G. Thippeswamy, J. Cruz, L. Cruz, S. Fahie, J. Bohuslaw, M. Buhse (Patchogue, Stony Brook, US)
15:30 - 17:00 Paediatric MS
Psychological distress in parents of children with multiple sclerosis P 685
M. Messmer Uccelli, S. Traversa, M. Trojano, R.G. Viterbo, A. Ghezzi, A. Signori (Genoa, Bari, Gallarate, IT)
15:30 - 17:00 Experimental models
Dual roles of adenosine 2a receptor in experimental autoimmune encephalomyelitis P 791
J. Ingwersen, B. Wingerath, K. Lepka, M. Hofrichter, J. Graf, F. Schröter, S. Burghoff, H.-P. Hartung, J. Schrader, T. Prozorovski, O. Aktas (Düsseldorf, DE)
15:30 - 17:00 Imaging
All Gd lesions are not the same: impact of protocol sensitivity on lesion detection assessed using quantitative dynamic contrast-enhanced MRI P 873
I.R. Leppert, S. Narayanan, D. Araújo, R. Arnaoutelis, I.O. Jelescu, D.L. Arnold, G.B. Pike (Montreal, CA)
15:30 - 17:00 Devic’s NMO spectrum
Characterisation of NMO and HRS patients with a late onset P 674
N. Collongues, R. Marignier, A. Jacob, A. Siva, F. Paul, H. Zephir, M.I. Leite, G. Akman-Demir, L. Elsone, S. Jarius, C. Papeix, K. Mutch, S. Saip, B. Wildemann, J. Kitley, R. Karabudak, O. Aktas, D. Kuscu, A. Altintas, J. Palace, J. de Seze on behalf on the EDEN project (including NOMADMUS, LNMO Turkish group, the UK cohort and German datasets)
15:30 - 17:00 Biomarkers
Analysis of autoantibody signatures of multiple sclerosis- and clinically Isolated syndrome patients using protein arrays P 1073
A. Lueking, H. Goehler, J. Schwermann, M. Gamer, P. Schulz-Knappe, K. Marquart, D. Chamrad, S. Schimrigk, M. von Darl (Dortmund, Lüdenscheid, DE)
15:30 - 17:00 Neuroprotection
Therapeutic laquinimod treatment restores axon myelination and callosal conduction in a chronic mouse model of multiple sclerosis P 966
S. Moore, G. Hannsun, M. Sasidhar, J. Yoon, T. Yoo, S. Tiwari-Woodruff (Los Angeles, US)
15:30 - 17:00 Experimental models
Development of a high-content screening assay to identify and evaluate remyelination therapeutics for multiple sclerosis P 784
B. Bai, R. Avila, S. Medicetty, B. Trapp (Cleveland, US)
15:30 - 17:00 Adaptative and Innate immunology
Peripheral blood depletion-kinetics after S1P-receptor blockade allow better understanding of lymph node access-hierarchy and homing-frequency of human T-cells in MS P 810
M. Mehling, V. Brinkmann, A.-V. Burgener, P. Gubser, L. Kappos, C. Hess (Basel, CH)
15:30 - 17:00 Quality of life
Disability in multiple sclerosis: patients’ perceptions and needs from an Italian survey P 1056
T. Sacco, C. Collicelli, K. Vaccaro, T. Manacorda, C. Pozzilli, M.A. Battaglia (Rome, Genoa, IT)
15:30 - 17:00 Immunomodulation
Analysis of lymph node dendritic cells induced in multiple sclerosis patients after transdermal immunisation with myelin peptides P 944
M. Jurynczyk, A. Jurewicz, A. Walczak, K. Wodz, K. Selmaj (Lodz, PL)
15:30 - 17:00 Grey matter damage in MS
Morphology of cortical grey matter lesions – a possible diagnostic role? P 771
V. Sethi, T. Yousry, N. Muhlert, M. Ron, X. Golay, C. Wheeler-Kingshott, D. Miller, D. Chard (London, GB)
15:30 - 17:00 Imaging
Quantification of independent cervical spinal cord atrophy measures correlate to motor and sensory deficits in MS P 869
E. Garde, H. Lundell, A.-M. Dogonowski, S. Gude, H. Schmidt, P. Soelberg Sorensen, M. Blinkenberg, H.R. Siebner (Hvidovre, Copenhagen, DK)
15:30 - 17:00 Comprehensive care and rehabilitation
Rehabilitation induces brain structural plasticity in multiple sclerosis P 1042
E. Robinet, W. Zaaraoui, A. Rico, J. Raillard, S. Tisserand, A. Faivre, F. Reuter, I. Malikova, E. Soulier, S. Confort-Gouny, P. Cozzone, P. Asquinazi, P. Bardot, J. Pelletier, J.P. Ranjeva, B. Audoin (Marseille, Hyčres, FR)
15:30 - 17:00 Diagnosis and differential diagnosis
Proteomic investigations on differential post-translational modifications of transthyretin in multiple sclerosis P 640
D. Pieragostino, P. Del Boccio, M. di Ioia, L. Pieroni, V. Greco, G. De Luca, C. Di Ilio, D. Centonze, P. Sacchetta, A. Lugaresi, A. Urbani (Chieti, Rome, IT)
15:30 - 17:00 Immunomodulation
Trial design and baseline data of the INFORMS (fingolimod in patients with primary progressive multiple sclerosis) study P 951
C.H. Polman, B. Cree, A. de Vera, M.S. Freedman, H.-P. Hartung, F. Holdbrook, L. Kappos, E. Kornyeyeva, C. Lubetzki, F.D. Lublin, D.H. Miller, X. Montalban, C. Pirozzi, P. von Rosenstiel, H.L. Weiner, J.S. Wolinsky (Amsterdam, NL; San Francisco, US; Basel, CH; Ottawa, CA; Düsseldorf, DE; East Hanover, US; Paris, FR; New York, US; London, GB; Barcelona, ES; Bosten, Houston, US)
15:30 - 17:00 Experimental models
Siponimod (BAF312) (and/or its metabolites) penetrates into the CNS and distributes to white matter areas P 792
V. Aslanis, T. Faller, E. Van de Kerkhof, A. Schubart, E. Wallström, A. Beyerbach (Basel, CH)
15:30 - 17:00 Immunomodulation
A randomised, double-blind, ascending multiple-dose study with ponesimod, a selective S1P1 receptor modulator: safety, pharmacokinetics, pharmacodynamics P 927
P. Brossard, H. Maatouk, A. Halabi, M. Cavallaro, J. Dingemanse (Allschwil, CH; Kiel, DE)
15:30 - 17:00 Risk management for disease modifying treatments
TYSTART: monitoring and management of MS patients starting natalizumab treatment in Germany P 994
B. Kallmann, R. Hoffmann, U. Walter, C. Wernsdörfer, V. Zingler, A. Chan (Bamberg, Berlin, Fulda, Ismaning, Bochum, DE)
15:30 - 17:00 Immunomodulation
Pharmacodynamic effect, safety and tolerability of ponesimod, a selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis P 919
O. Fernandez, C. Pozzilli, M.S. Freedman, T. Olsson, M. Melanson, D. Bach, O. Berkani, M. Mueller, T. Sidorenko, A. Boster (Malaga, ES; Rome, IT; Ottawa, CA; Stockholm, SE; Cincinnati, US; Allschwil, CH; Columbus, US)
15:30 - 17:00 Paediatric MS
Quality of life in paediatric and juvenile multiple sclerosis and its clinical correlations P 688
R. Lanzillo, V. Magri, A. Napolitano, R. Liuzzi, G. Vacca, M. Ottobre, A. Filla, P. Valerio, A. Chiodi, V. Brescia Morra (Naples, IT)
15:30 - 17:00 Immunomodulation
Preventive laquinimod treatment shifts pro-inflammatory to regulatory T-cells and reduces myeloid dendritic cells in experimental autoimmune encephalomyelitis P 932
M. Ott, C. Wegner, S. Nessler, W. Brück (Göttingen, DE)
15:30 - 17:00 Neuroprotection
Mesenchymal stem cells exert their therapeutic effect by inducing microglia to acquire a neuroprotective phenotype P 959
A. Uccelli, B. Parodi, C. Usai, L. Vergani, S. Bruzzone, G. Mancardi, D. Giunti (Genoa, IT)
15:30 - 17:00 Epidemiology
Evidence for sub-clinical malnutrition in Kuwaiti patients with multiple sclerosis: relationship with clinical phenotypes, disease activity and outcome P 711
S. Al-Shammri, A. Bhattacharya, R. Mathew, M. Girgis, C. Madala, A. Akanji (Kuwait, KW)
15:30 - 17:00 Imaging
Short-term evolution of spinal cord damage in multiple sclerosis: a diffusion tensor MRI study P 866
M. Théaudin, G. Saliou, B. Ducot, C. Denier, K. Deiva, D. Adams, D. Ducreux (Kremlin-Bicętre, FR)
15:30 - 17:00 Long-term treatment monitoring
Observational program Tysabri 24 plus: evaluating efficacy and safety of natalizumab therapy beyond two years P 980
M. Mäurer, H. Wiendl, C. Heesen, A. Gass, C. Wernsdörfer, V. Zingler, B.C. Kieseier (Bad Mergentheim, Münster, Hamburg, Mannheim, Ismaning, Düsseldorf, DE)
15:30 - 17:00 Immunomodulation
Dose-dependent effect of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, on magnetic resonance imaging outcomes in patients with relapsing-remitting multiple sclerosis P 923
M.S. Freedman, T. Olsson, M. Melanson, O. Fernandez, A. Boster, D. Bach, O. Berkani, M. Mueller, T. Sidorenko, C. Pozzilli (Ottawa, CA; Stockholm, SE; Cincinnati, US; Malaga, ES; Columbus, US; Allschwil, CH; Rome, IT)
15:30 - 17:00 Economic burden
Assessing prognostic factors of severe relapse requiring hospitalisation and/or IV methylprednisolone in RRMS treated with placebo or laquinimod: pooled analysis from the ALLEGRO and BRAVO trials P 762
C.A. Carroll, P. Lindgren, A. Lang on behalf of the Allegro & BRAVO Study Group
15:30 - 17:00 Immunomodulation
EARLIMS Study methodology: open-label, non-randomised trial to assess the efficacy of fingolimod in treatment-naďve patients with RRMS vs. fingolimod in patients previously treated with interferons or glatiramer acetate, based on the presence of relapses P 953
X. Montalbán, O. Fernández, H. Butzkueven, M.H. Barnett, A. Gobartt, D. Silva on behalf of the EARLIMS Study Investigators
15:30 - 17:00 Epidemiology
Disease course and oligoclonal band status among immigrants with multiple sclerosis in Oslo, Norway P 712
P. Berg-Hansen, C. Smestad, L. Sandvik, H.F. Harbo, E.G. Celius (Oslo , NO)
15:30 - 17:00 Imaging
Association between cognitive reserve and white matter integrity in multiple sclerosis P 844
J. Stojanovic-Radic, A. Das, P. Girgis, H. Genova, N. Chiaravalloti, J. DeLuca, J. Sumowski, G. Wylie (West Orange, US)
15:30 - 17:00 Neuropsychology and fatigue
Cognitive impairment in relapsing-remitting multiple sclerosis patients P 896
A. Altinkaya, E. Ozcan, D. Yandim-Kuscu, E. Kurt, A. Bingol, D. Kirbas, B. Topcular (Istanbul, TR)
15:30 - 17:00 Neuro-ophthalmology
Characterising disability in early onset MS patients: correlation of clinical parameters with retinal nerve fibre layer thickness P 1063
K. Huhn, R. Lämmer, F. Paul, A. Waschbisch, A. Lämmer, R.A. Linker, D.-H. Lee (Erlangen, Berlin, DE)
15:30 - 17:00 Databases and Pharmacoepidemiology
Towards personalised MS patient care - The Finnish MS Register P 718
N. Oksala, P. Hartikainen, K. Koivisto, M. Laaksonen, A. Remes, J. Ruutiainen, M. Soilu-Hänninen, M.-L. Sumelahti, P. Tienari, I. Elovaara (Turku, Kuopio, Seinäjoki, Masku, Tampere, Helsinki, FI)
15:30 - 17:00 Imaging
Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis P 867
A. Faivre, A. Rico, W. Zaaraoui, L. Crespy, F. Reuter, D. Wybrecht, E. Soulier, I. Malikova, S. Confort-Gouny, P.J. Cozzone, J. Pelletier, J.-P. Ranjeva, B. Audoin (Marseille, FR)
15:30 - 17:00 Neuropsychology and fatigue
Memory and attention disorders in a large sample of out-patients with multiple sclerosis P 906
G. Adler, Y. Lembach, M. Feger, M. Bektas, N. Baumgart, Y. Ko-Inoshishi (Mannheim, DE)
15:30 - 17:00 Databases and Pharmacoepidemiology
Comparison of time to discontinuation among multiple sclerosis patients receiving fingolimod and other first-line disease-modifying treatments P 717
N. Agashivala, N. Wu, Y. Wu, E. Kim, L. Boulanger, D. Brandes (East Hanover, Lexington, Knoxville, US)
15:30 - 17:00 Adaptative and Innate immunology
Follicular T-helper cell activation in progressive multiple sclerosis P 814
J. Romme Christensen, L. Börnsen, R. Ratzer, F. Piehl, M. Khademi, T. Olsson, P. Soelberg Sorensen, F. Sellebjerg (Copenhagen, DK; Stockholm, SE)
15:30 - 17:00 Economic burden
Clinical audit: establishing reasons and patterns of non-elective admissions of patients with multiple sclerosis in a UK centre P 761
S. Binks, W. Rashid (Brighton, GB)
15:30 - 17:00 Epidemiology
Sickness absence and disability pension among multiple sclerosis patients in Sweden P 713
P. Tinghög, L. Kjeldgĺrd, J. Hillert, K. Alexanderson (Stockholm, SE)
15:30 - 17:00 Devic’s NMO spectrum
Brainstem manifestations in neuromyelitis optica P 665
L. Kremer, M. Mealy, A. Jacob, I. Nakashima, P. Cabre, S. Bigi, P. Friedemann, S. Jarius, O. Aktas, M. Levy, Y. Takai, N. Collongues, B. Banwell, K. Fujihara, J. de Seze (Strasbourg, FR; Baltimore, US; Liverpool, GB; Tohoku, JP; Fort De France, FR; Toronto, CA; Berlin, Heidelberg, Düsseldorf, DE)
15:30 - 17:00 Devic’s NMO spectrum
Interleukin-6 receptor blockade in neuromyelitis optica resistant to anti-CD20 therapy P 667
I. Kleiter, I. Ayzenberg, A. Schröder, K. Hellwig, A. Chan, R. Gold (Bochum, DE)
15:30 - 17:00 MS and infections
Ex vivo and in vitro expression of the neuroinflammatory endogenous protein MSRV-Env (Envelope protein of Multiple Sclerosis Associated Retrovirus) from human endogenous type W elements and interaction with Epstein-Barr virus in multiple sclerosis P 825
N. Morel, R. Germi, O. Casez, O. Epaulard, L. Grossi, L. Morand, M. Zaccaria, H. Perron, P. Morand (Grenoble, FR; Geneva, CH)
15:30 - 17:00 Clinical assessment tools
Longitudinal measures of instrumented gait and balance in multiple sclerosis over 18 months P 740
R. Spain, M. Mancini, R. St. George, D. Bourdette, F. Horak (Portland, US)
15:30 - 17:00 Paediatric MS
Brain growth rate is reduced in paediatric-onset multiple sclerosis P 680
B. Aubert-Broche, V. Fonov, N. Guizard, B. Banwell, S. Narayanan, D.L. Arnold, D.L. Collins on behalf of the Canadian Pediatric Demyelinating Disease Network
15:30 - 17:00 Neuroprotection
Oligodendrocyte precursor cell resistance to excitotoxic death through inhibition of a prostaglandin E2 receptor P 965
N. Carlson, J. Redd, S. Bellamkonda, B. Wood, T. Maruyama, J. Rose (Salt Lake City, US; Osaka, JP)
15:30 - 17:00 Diagnosis and differential diagnosis
Prediction of conversion from clinically isolated syndrome to multiple sclerosis according to baseline characteristics P 646
B. Piri Cinar, S. Ozakbas, E. Idiman (Izmir, TR)
15:30 - 17:00 Immunomodulation
From natalizumab to fingolimod: an observational study of 32 patients P 938
A. Ghezzi, D. Baroncini, P.O. Annovazzi, A. Bianchi, G. Minonzio, G. Comi (Gallarate, IT)
15:30 - 17:00 Neuropsychology and fatigue
Prediction of vocational status 10 years after the MS diagnosis by early information processing speed assessment P 899
A. Ruet, M. Deloire, J.C. Ouallet, B. Brochet (Bordeaux, FR)
15:30 - 17:00 Diagnosis and differential diagnosis
Spinal cord lesions in CIS patients: a pivotal role in diagnosis and prognosis P 653
M.H. Sombekke, M.P. Wattjes, L.J. Balk, J.M. Nielsen, H. Vrenken, B.M.J. Uitdehaag, C.H. Polman, F. Barkhof (Amsterdam, NL)
15:30 - 17:00 Tools for detecting therapeutic response
Sample sizes for lesion magnetisation transfer ratio outcome measures in remyelination trials for multiple sclerosis P 1013
D.R. Altmann, T. Button, K. Schmierer, K. Hunter, D. Tozer, C. Wheeler-Kingshott, A. Coles, D.H. Miller (London, Cambridge, GB)
15:30 - 17:00 Experimental models
Astrocytes are essential for activation of microglia to clear myelin debris in cuprizone induced demyelination P 789
T Skripuletz, D. Hackstette, K. Bauer, V. Gudi, R. Pul, E. Voss, M. Kipp, W. Baumgärtner, M. Stangel (Hannover, Aachen, DE)
15:30 - 17:00 Devic’s NMO spectrum
Good response to ofatumumab in a child with severe relapsing neuromyelitis optica P 675
S. Sedani, M. Absoud, D. Milford, M.I. Leite, M.G. Pike, A. Vincent, J. Palace, E. Wassmer (Birmingham, Oxford, GB)
15:30 - 17:00 Clinical assessment tools
Deciphering distance-induced deceleration of gait and ataxia in people with multiple sclerosis P 755
R. Phan-Ba, S. Pierard, G. Moonen, M. Vandroogenbroeck, S. Belachew (Ličge, BE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
A systematic review of the association between chronic cerebrospinal venous insufficiency and multiple sclerosis P 1086
J.M. Burton on behalf of the Canadian CCSVI Systematic Review Group
15:30 - 17:00 Immunomodulation
Risk of infections and malignancies after treatment with anti-CD20 monoclonal antibodies: ocrelizumab and rituximab in rheumatoid arthritis and multiple sclerosis P 929
L. Kappos, D. Leppert, J. Tinbergen, M. Gerber, S.L. Hauser (Basel, CH; San Francisco, US)
15:30 - 17:00 Clinical assessment tools
Assessing Relapse in Multiple Sclerosis (ARMS) questionnaire: initial pilot data P 739
A. Williamson, J. Smrtka, T. Flemming Tracy, C. Saunders, C. Easterling, A. Perrin Ross, J. Niewoehner, N. Mutschler (Fairfax, Pompano Beach, Birmingham, Oceanside, Orlando, Maywood, Hayward, US)
15:30 - 17:00 Imaging
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis P 858
C. Tortorella, R. Romano, V. Direnzo, L. Fazio, P. Taurisano, S. Zoccolella, P. Iaffaldano, R.G. Viterbo, T. Popolizio, G. Blasi, A. Bertolino, M. Trojano (Bari, IT)
15:30 - 17:00 Devic’s NMO spectrum
In-vivo identification of a novel retinal pathology in neuromyelitis optica P 657
E.S. Sotirchos, S. Saidha, G. Byraiah, M.A. Mealy, M.A. Ibrahim, Y.J. Sepah, S.D. Newsome, J.N. Ratchford, E.M. Frohman, L.J. Balcer, Q.D. Nguyen, M. Levy, P.A. Calabresi (Baltimore, Dallas, Philadelphia, US)
15:30 - 17:00 Risk management for disease modifying treatments
Annual rate of JCV seroconversion in a French Cohort of MS Patients under Natalizumab P 996
A. Etxeberria, O. Outteryck, J.C. Ongagna, H. Zéphir, N. Collongues, A. Lacour, F. Blanc, M. Giroux, M.-C. Fleury, P. Vermersch, J. de Sčze (Lille, Strasbourg, FR)
15:30 - 17:00 Comprehensive care and rehabilitation
WalkAide® FES device improves gait function and quality of life for people with multiple sclerosis on Ampyra P 1037
L. Mayer, T. Warring, S. Agrella, E.J. Fox (Austin, US)
15:30 - 17:00 Risk management for disease modifying treatments
Cancer and disease-modifying therapy in multiple sclerosis: an audit of the Tayside DMT Register P 997
K. Grieve, B. Waddell, P. Walker, J. O'Riordan (Dundee, GB)
15:30 - 17:00 Neurophysiology
Brain atrophy correlates with cognitive impairment and event-related potentials P300 in multiple sclerosis P 885
N. Tevzadze, M. Janelidze (Tbilisi, GE)
15:30 - 17:00 Risk management for disease modifying treatments
Frequency of John Cunningham virus (JCV) DNA and of antibodies against JCV in patients affected by multiple sclerosis and their relationship with natalizumab therapy P 1000
V. Lo Re, F. Cardinale, S. De Grazia, S. Alessi, V. Cusimano, M.A. Mazzola, M. Lo Re, S. Realmuto, P. Ragonese, G. Salemi, P. Conaldi, G. Savettieri (Palermo, IT)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
A prospective study comparing ultrasonography and angiography of internal jugular veins in multiple sclerosis patients P 1091
M. Simka (Katowice, PL)
15:30 - 17:00 Neuropsychology and fatigue
Neuroanatomical substrates of mentalisation: a multimodal MRI study in multiple sclerosis P 893
A. Mike, E. Strammer, M. Aradi, G. Orsi, G. Perlaki, R. Herold, A. Hajnal, M. Banati, E. Illes, C. Guttmann, Z. Illes (Pecs, HU; Boston, US)
15:30 - 17:00 Neuropsychology and fatigue
HYPNOSEP : Brief Hypnotherapy Treating Chronic Fatigue for Multiple Sclerosis Patients P 898
R. Devy, P. Cormier, O. Anne, I. Devy-Gourdon, G. Chedeau, G. Edan (Saumur, Laval, La Rochelle, FR; Geneva, CH; Rennes, FR)
15:30 - 17:00 Quality of life
Interim analysis of AMETYST: a phase 4 observational study of the impact of intramuscular interferon beta-1a on quality of life, disability, and cognition in patients with clinically isolated syndrome/clinically definite multiple sclerosis P 1047
P. Stourac, D. Horakova, M. Tyblova, E. Klimova, J. Szilasiova, I. Fenclova, A. Svorenova, X. You, P. Turcani (Brno, Prague, CZ; Presov, Kosice, SK; Bratislava, SK; Weston, US)
15:30 - 17:00 Pregnancy and MS
Final results from the Avonex(R) (intramuscular interferon-beta-1a) pregnancy exposure registry P 732
S. Tomczyk, S. Richman, K. Wallace, S. Liu, B. Sperling (Weston, US)
15:30 - 17:00 MS and infections
Anti-JC virus antibody prevalence in the JCV Epidemiology in MS trial P 824
C. Bozic, M. Subramanyam, D. Paes, S. Richman, T. Plavina, A. Zhang, B. Ticho (Weston, US)
15:30 - 17:00 Adaptative and Innate immunology
Interferon-b therapy differently modulates Toll-like receptor 7 and 9- induced differentiation of B lymphocytes in multiple sclerosis patients P 817
M. Severa, E. Giacomini, F. Rizzo, V. Annibali, M.E. Remoli, S. Romano, A. Fornasiero, V. Riccieri, M. Salvetti, E.M. Coccia (Rome, IT)
15:30 - 17:00 Biomarkers
Subclinical demyelinating disease activity assessed by 7T MRI scanning and peripheral cytokine concentrations P 1068
L. Edwards, S.Y Lim, A. Al-Radaideh, P. Gowland, C. Constantinescu (Nottingham, GB)
15:30 - 17:00 Natural history
Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time? P 692
B.R. Quaranto, B.C. Healy, T.L. Vollmer, R.H.B. Benedict, C.E. Schwartz (Concord, Boston, Denver, Buffalo, US)
15:30 - 17:00 Immunomodulation
Laquinimod regulates inflammatory gene induction in a human model of reactive astrogliosis P 914
T. Pham, J. Zhang, J. Seto, B. Hartmann, L. Hayardeny, G. John (New York, US; Netanya, IL)
15:30 - 17:00 Neuro-ophthalmology
Multicentre reliability of intra-retinal layer segmentation P 1064
T. Oberwahrenbrock, I. Gabilondo, R. Nolan, C. Songster, G.L. Traber, L. Balk, F. Paul, A. Petzold, S. Schippling, P. Villoslada, A.U. Brandt, A. Green (Berlin, DE; Barcelona, ES; San Francisco, US; Zurich, CH; Amsterdam, NL)
15:30 - 17:00 Neuroprotection
The neuroprotective effects of BG-12 on malonate-induced striatal lesion volume are dependent upon Nrf2 P 962
H.M. Arnold, C. Huang, R. Huang, T.M. Engber, M. Yamamoto, K.J. Rhodes, R.H. Scannevin (Weston, US; Sendai, JP)
15:30 - 17:00 Pregnancy and MS
Pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database P 737
B. Kieseier, M. Benamor, H. Benzerdjeb, O. Stüve (Düsseldorf, DE; Chilly Mazarin, FR; Dallas, US)
15:30 - 17:00 Experimental models
Systemic treatment with hepatocyte growth factor suppresses the development of experimental autoimmune encephalomyelitis and induces the differentiation of regulatory dendritic cells P 793
M. Benkhoucha, N. Molnarfi, M.-L. Santiago-Raber, G. Schneiter, P.H. Lalive (Geneva, CH)
15:30 - 17:00 Neurophysiology
The response of the blink reflex test in a group of Brazilian patients with multiple sclerosis P 883
J.B.B. Brooks, Y.D. Fragoso, C.L.S. Oliveira, M.R. Kai, C.A.C. Silva (Santos, Săo Paulo, BR)
15:30 - 17:00 Experimental models
Ameliorating effects of anti-alpha v integrin mAb on Theiler's Murine encephalomyelitis virus-induced demyelinating disease P 787
H. Tomiki, T. Kaneyama, S. Tsugane, I. Nakashima, M. Ichikawa, H. Yagita, B.S. Kim, C.S. Koh (Matsumoto, Tokyo, JP; Chicago, US)
15:30 - 17:00 Neuropsychology and fatigue
Self-reported behavioural changes and executive function impairment P 903
M. López-Góngora, A. Martínez-Domeńo, A. Escartín (Barcelona, ES)
15:30 - 17:00 Neuropsychology and fatigue
A process approach to letter fluency performance in multiple sclerosis - evidence for derailed temporal gradients P 890
A. Tart-Zelvin, J. Eppig, C. Nieves, D. Libon, J. DeLuca, M. Williams (Philadelphia, West Orange, US)
15:30 - 17:00 Neuropsychology and fatigue
Longitudinal change in PASAT performance following immunoablative therapy and haematopoietic stem cell transplant in MS P 886
L.A.S. Walker, J. Berard, M. Bowman, H.L. Atkins, H. Lee, M.S. Freedman (Ottawa, Montreal, CA)
15:30 - 17:00 Immunomodulation
No beneficial effect of minocycline as add-on therapy to interferon-beta-1a for the treatment of relapsing-remitting multiple sclerosis: results of a large double-blind, randomised, placebo-controlled trial P 941
P.S. Sorensen, F. Sellebjerg, J. Lycke, M. Färkkila, A. Creange, C. Lund, M. Schluep, J. L. Frederiksen, E. Stenager, C. Pfleger, E. Garde, K. Marhardt on behalf of the RECYCLINE Study Investigators
15:30 - 17:00 Neuropsychology and fatigue
Personality and capacity for coping with stress in patients with MS P 892
A. Ožura, S. Šega, A. Horvat Ledinek, U. Rot, A. Noc (Ljubljana, SI)
15:30 - 17:00 Clinical assessment tools
Information processing in multiple sclerosis: a comparison of the paced serial addition test and Tens test P 746
J. Silversteen, G. Greenberg, M. O'Neill, K. Greenbaum (Newark, US)
15:30 - 17:00 Devic’s NMO spectrum
Predictors of the effectiveness of plasma exchange in NMO-IgG seropositive neuromyelitis optica spectrum disorders P 668
Y.M. Lim, S.Y. Pyun, J. Kim, S.M. Kim, K.S. Park, K.K. Kim (Seoul, KR)
15:30 - 17:00 Neuroprotection
A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis P 961
R.E. Raftopoulos, S. Hickman, A. Toosy, C.A. Wheeler-Kingshott, D. Altmann, K. Schmierer, B. Sharrack, R. Sheridan, G. Giovannoni, D.H. Miller, R. Kapoor (London, Sheffield, GB)
15:30 - 17:00 Neuro-ophthalmology
High-resolution spectral domain optical coherence tomography in multiple sclerosis, Part II - the Total Macula Volume. The first follow-up study over two years P 1060
N. Serbecic, F. Aboul-Enein, S.C. Beutelspacher, C. Vass, W. Kristoferitsch, H. Lassmann, A. Reitner, U. Schmidt-Erfurth (Vienna, AT; Mannheim, DE)
15:30 - 17:00 Diagnosis and differential diagnosis
Diffusion tensor imaging evaluations of visual pathways in multiple sclerosis patients with acute and chronic optic neuritis P 647
A.O. Keskin, F. Idiman, A Ada, O. Alatas, E. Idiman, S. Ozakbas, A.O. Saatci (Izmir, TR)
15:30 - 17:00 Others
Consequences of different definitions of confirmed disability progression across randomised trials of MS therapies P 1020
N. Bergvall, N. Sfikas, J. Alsop, P. Chin, P. von Rosensteil, L. Kappos (Basel, CH; Berkshire, GB; New Jersey, US)
15:30 - 17:00 Neurobiology
Microglia responses during early pathological changes in the cuprizone animal model for multiple sclerosis P 835
S. Diederichs, T. Clarner, J. Goldberg, T. Reiss, K. Berger, M. Viktor, C. Beyer, M. Kipp (Aachen, DE)
15:30 - 17:00 Clinical assessment tools
The Arm Function in Multiple Sclerosis Questionnaire (AMSQ): development and validation of a new tool P 743
L.B. Mokkink, D.L. Knol, J.M. Sonder, F.A. van der Linden, M. D'Hooghe, B.M.J. Uitdehaag (Amsterdam, NL; Melsbroek, BE)
15:30 - 17:00 Adaptative and Innate immunology
Non-classical and intermediate monocytes in relapsing-remitting multiple sclerosis P 809
S.D. Schröder, D.H. Lee, S. Pfeifenbring, C. Stadelmann, R.A. Linker, A. Waschbisch (Erlangen, Göttingen, DE)
15:30 - 17:00 Economic burden
Economic costs, utility and social participation of patients with multiple sclerosis treated by natalizumab P 763
A. Kwiatkowski, M. Puyfaucon, J. Pelzer, JP. Marissal, B. Dervaux, P. Vermersch, P. Hautecoeur (Lille, FR)
15:30 - 17:00 Epidemiology
Co-morbidities previous to multiple sclerosis P 705
A. Fromont, C. Binquet, F. Rollot, R. Despalins, A. Weill, L. Clerc, C. Bonithon-Kopp, T. Moreau (Dijon, Paris, FR)
15:30 - 17:00 Neuropsychology and fatigue
Working memory training in patients treated with INFB-1b – Effects on cognitive performance, functional MRI and resting state networks P 900
M. Hubacher, K. Weier, K. Opwis, M. Stoecklin, L. Kappos, T. Sprenger, I.K. Penner (Basel, CH)
15:30 - 17:00 Neuro-ophthalmology
Characterising neuronal damage in multiple sclerosis using optic nerve head volume P 1065
H. Zimmermann, E.M. Kadas, A. Freing, F. Kaufhold, F. Paul, A.U. Brandt (Berlin, DE)
15:30 - 17:00 Natural history
Impact of menopause on disease course in women with multiple sclerosis: a pilot study P 693
R. Bove, A. Musallam, B. C. Healy, B. Glanz, M. Houtchens, P.L. De Jager, T. Chitnis (Boston, US)
15:30 - 17:00 Risk management for disease modifying treatments
Low immunogenicity but reduced bioavailability of an interferon-beta-1a biosimilar: results of MATRIX, a cross-sectional, multicentre phase 4 study P 1006
C. Cuevas, F. Deisenhammer, X. You, M. Scolnik, R. Buffels, B. Sperling on behalf of the MATRIX study group
15:30 - 17:00 Imaging
Natural history of MRI lesion accrual in children with MS: a national prospective cohort study of children with acute CNS demyelination P 875
L.H. Verhey, D.L. Arnold, H.M. Branson, M.M. Shroff, S. Narayanan, J.G. Sled, A. Bar-Or, A.D. Sadovnick, R.A. Marrie, B. Banwell on behalf of the Canadian Paediatric Demyelinating Disease Network
15:30 - 17:00 Epidemiology
MSIF Atlas of MS database update: multiple sclerosis resources in the world 2013 P 708
A. J. Thompson, P. O. Browne, B. V. Taylor, M. A. Battaglia, L. Pandit, H. Tremlett, B. M. Uitdehaag, E. Holloway (London, GB; Hobart, AU; Genoa, IT; Mangalore, IN; Vancouver, CA; Amsterdam, NL)
15:30 - 17:00 Risk management for disease modifying treatments
Severe multiple sclerosis relapse under fingolimod therapy P 992
E. Meluzinova, M. Bojar, E. Havrdova, P. Liskova, L. Kappos (Prague, CZ; Basel, CH)
15:30 - 17:00 Immunomodulation
Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing–remitting multiple sclerosis: results from the phase 3 FREEDOMS II study P 952
T. Vollmer, D. Goodin, D. Jeffery, L. Kappos, E.-W. Radue, K. Rammohan, A.T. Reder, M.A. Agius, L. Cappiello, T. Stites, B.B. Li, M. Malhotra, P. von Rosenstiel, P.A. Calabresi (Aurora, San Francisco, North Carolina, US; Basel, CH; Miami, Chicago, Davis, East Hanover, US; Baltimore, US)
15:30 - 17:00 Long-term treatment monitoring
Five years impact of subcutaneous interferon-beta-1a on cognitive impairment in mildly disabled patients with relapsing-remitting multiple sclerosis: the COGIMUS study group P 984
F. Patti, V. Brescia Morra, M.P. Amato, S. Bastianello, M. Tola, S. Cottone, R. Lanzillo, M. Trojano, D. Centonze, L.M.E. Grimaldi, C. Gasperini on behalf of the Cogimus study Group
15:30 - 17:00 Biomarkers
Dual role of response gene to complement-32 in multiple sclerosis P 1078
C. Tegla, C. Cudrici, P. Azimzadeh, A. Singh, R. Trippe, A. Khan, H. Chen, M. Andrian-Albescu, W. Royal, C. Bever, V. Rus, H. Rus (Baltimore, US)
15:30 - 17:00 Neuropsychology and fatigue
Symptom overlap in anxiety and multiple sclerosis: on the need for caution P 902
S. Ó Donnchadha, T. Burke, J. Bramham, M.C. O'Brien, R. Whelan, R. Reilly, H. Kiiski, R. Lonergan, K. Kinsella, S.B. Kelly, C. McGuigan, M. Hutchinson, N. Tubridy (Dublin, IE; Burlington, US)
15:30 - 17:00 Imaging
Increased functional connectivity of multiple resting state networks after motor training in multiple sclerosis P 856
N. Petsas, V. Tomassini, E. Sbardella, F. Tona, C. Pozzilli, R.G. Wise, P. Pantano (Rome, IT; Cardiff, GB)
15:30 - 17:00 Long-term treatment monitoring
TYSEDMUS: observational prospective follow-up study of patients with MS and treated with natalizumab in France using the French EDMUS (European Database for Multiple Sclerosis) network – Five-year results P 974
S. Vukusic, N. Passante, M. Dufour, F. Rocher, E. Van Ganse, M. Clanet, E. Falip, C. Confavreux on behalf of the TYSEDMUS group
15:30 - 17:00 Diagnosis and differential diagnosis
A Pilot Reproducibility Evaluation of CoSMo Study (PREP Study): methodological aspects P 642
G Malferrari, M.L. Zedde, S. Sanguigni, D. Ciampanelli, P. Prati, C. Baracchini, N. Carraro, M. Del Sette, E. Stolz, L. Motti, G. Comi, G. Mancardi, M.A. Battaglia on behalf of CoSMo Study
15:30 - 17:00 Paediatric MS
Natalizumab therapy in active paediatric multiple sclerosis P 686
B. Kornek, F. Aboul-Enein, I.-R. Milos, I. Steiner, K. Rostasy, J. Penzien, K. Hellwig, K. Pitarokoili, K. Storm van's Gravesande, M. Karenfort, A. Blaschek, A. Meyer, D. Debelic, R. Seidl, D. Prayer, K. Vass, W. Kristoferitsch, A. Bayas (Vienna, Innsbruck, AT; Augsburg, Bochum, DE; Düsseldorf, Munich, Ravensburg, DE; Mistelbach, AT)
15:30 - 17:00 Databases and Pharmacoepidemiology
www.msregistry.eu: interactive online registry for self-monitoring by people with multiple sclerosis and clinically isolated syndrome P 719
P. Jongen, M. Heerings, A. Kool, E. Van Noort, A. Van der Zande (Nijmegen, Maassluis, Geertruidenberg, NL)
15:30 - 17:00 Devic’s NMO spectrum
A qualitative study investigating the experiences of affected persons and family members living with neuromyelitis optica P 662
K.P. Mutch, A. Methley, J. Boot, A. Jacob (Liverpool, GB)
15:30 - 17:00 Diagnosis and differential diagnosis
Early clinical remission as a prognosis factor for medium term disability progression in multiple sclerosis P 643
T. Moreau, M. Debouverie, C. Lebrun-Frenay, P. Clavelou, D. Brassat, O. Gout, D. Laplaud, J. De Sčze, B. Stankoff, P. Vermersch, S. Millot, F. Rollot, C. Bonithon-Kopp, C. Binquet (Dijon, Nancy, Nice, Clermont-Ferrand, Toulouse, Paris, Nantes, Strasbourg, Lille, FR)
15:30 - 17:00 Immunosuppression
Daclizumab-induced side effects in multiple organ systems in multiple sclerosis P 956
J. Oh, S. Saidha, P. Calabresi, S. Newsome (Baltimore, US)
15:30 - 17:00 Immunomodulation
Biological basis of fluctuations in total peripheral lymphocyte counts in patients receiving FTY720 therapy P 924
L. Galleguillos, D. Henault, L.R. Feldman, T.A. Johnson, A. Bar-Or, J.P. Antel (Montreal, CA)
15:30 - 17:00 Treatment of specific symptoms
Dalfampridine effects on visual-evoked potentials P 1028
R. Schmeck, M. Korsen, U. Runge, U. Schminke, A. Dressel (Greifswald, DE)
15:30 - 17:00 Tools for detecting therapeutic response
Predicting the response status to natalizumab in relapsing-remitting multiple sclerosis P 1012
L. Prosperini, C.R. Mancinelli, C. Gianně, V. Barletta, F. Fubelli, G. Borriello, C. Pozzilli (Rome, IT)
15:30 - 17:00 Immunomodulation
Interferon-b therapy targets memory B cells of multiple sclerosis patients: investigation of the mechanisms P 939
F. Rizzo, E. Giacomini, M. Severa, V. Annibali, R. Mechelli, G. Ristori, M. Salvetti, E.M. Coccia (Rome, IT)
15:30 - 17:00 Neuropsychology and fatigue
Developing paperless, portable cognitive applications for smartphones P 894
D. Langdon, J. Hujol, N. Chiaravalloti, M.C. Botfield, R.K. Ramachandran, G. Giovannoni, P.L. De Jager on behalf of the MSCODES3 Consortium
15:30 - 17:00 Neuropsychology and fatigue
Emotional and neutral verbal memory impairment in multiple sclerosis P 901
P. Iaffaldano, R.G. Viterbo, B. Goretti, E. Portaccio, M.P. Amato, M. Trojano (Bari, Florence, IT)
15:30 - 17:00 Long-term treatment monitoring
A comparison of extreme profiles of disability change in beta-interferon treated multiple sclerosis patients: findings from British Columbia, Canada P 981
A. Shirani, Y. Zhao, J. Oger, BC MS Clinic Neurologists, H. Tremlett (Vancouver, CA)
15:30 - 17:00 Grey matter damage in MS
Thalamic lesion analysis on 7-Tesla MRI as a surrogate for cortical demyelination P 774
D. Harrison, J. Oh, M. Seigo, J. Aquino, C. Jones, P. van Zijl, D. Reich, P. Calabresi (Baltimore, US)
15:30 - 17:00 Neuro-ophthalmology
Initiation of fingolimod in MS leads to increased macular volume P 1062
J.M. Gelfand, R. Nolan, A.J. Green (San Francisco, US)
15:30 - 17:00 Comprehensive care and rehabilitation
Predictors of changes in work productivity and activity impairment scores P 1035
M. Tullman, T. Leist, H. Zwibel, B. Cohen, P.K. Coyle, M. Lage on behalf of the TOP MS Study Steering Committee
15:30 - 17:00 Natural history
Monocentric long-term follow-up of a cohort of patients with clinically isolated syndrome: descriptive data at baseline P 691
N. Moll, I. Malikova, A. Rico, L. Crespy, A. Faivre, E. Robinet, L. Durante, D. Wybrecht, F. Reuter, W. Zaaraoui, P. Cozzone, J.-P. Ranjeva, B. Audoin, J. Pelletier (Marseille, FR)
15:30 - 17:00 Imaging
MTR analysis of inner and outer cortical bands in multiple sclerosis P 850
R.S. Samson, M.J. Cardoso, N. Muhlert, V. Sethi, C.A.M. Wheeler-Kingshott, S. Ourselin, T. Yousry, M. Ron, D.H. Miller, D.T. Chard (London, GB)
15:30 - 17:00 MS and infections
An alternative assay to assess the anti-JC virus status in MS patients P 823
C. Warnke, M. Pawlita, T. Dehmel, H.-P. Hartung, H. Wiendl, B.C. Kieseier, O. Adams (Düsseldorf, Heidelberg, Münster, DE)
15:30 - 17:00 Clinical assessment tools
Is the Epworth Sleepiness Scale valid in multiple sclerosis? P 749
R.J. Mills, C.A. Young (Preston, Liverpool, GB)
15:30 - 17:00 Neuro-ophthalmology
The King-Devick test as a rapid global visual performance measure in MS P 1061
S.L. Galetta, S. Moster, R.E. Sakai, J.A. Wilson, G.R. Cutter, L.J. Balcer (Philadelphia, Birmingham, US)
15:30 - 17:00 Experimental models
Laquinimod enhances the frequency of regulatory T-cells in peripheral lymphoid organs after EAE induction P 790
F. Lühder, D. Lodygin, T. Borchert, S. Michanski, A. Flügel (Göttingen, DE)
15:30 - 17:00 Immunomodulation
ONO-4641, a potent and selective sphingosine 1-phosphate receptor-1 and -5 agonist, ameliorates relapses in a preclinical model of multiple sclerosis P 928
F. Bernard, A. Soares, A. Spill, A. Attinger, V. Eligert, S. Laustela, T. Seabrook, A. Nichols, F. Beltram, T. Martin, H. Kurata, H. Habashita, S. Nakade, P. Smith, U. Boschert (Geneva, CH; Osaka, JP)
15:30 - 17:00 Genetics / transcriptomics
Natalizumab treatment impacts on deregulated expression profile of miRNAs in CD4+ T-cells of patients with relapsing-remitting MS P 799
M. Meira, C. Sievers, F. Hoffmann, J. Kuhle, L. Kappos, R.L.P. Lindberg (Basel, CH)
15:30 - 17:00 Biomarkers
Serum sPECAM-1 and sVCAM-1 could be useful biomarkers in idiopathic optic neuritis, correlating with progression to multiple sclerosis and with presence of NMO-IgG P 1084
A. Kalinowska-Lyszczarz, J. Losy, S. Michalak, A. Styszynski, W. Kozubski (Poznan, PL)
15:30 - 17:00 Epidemiology
Month of birth does not seem to interfere with the prevalence or disease progression in multiple sclerosis for South American patients, irrespectively of the latitude P 709
Y. Fragoso, T. Adoni, F. Barbagelata-Aguero, S. Almeida, S. Alves-Leon, W. Arruda, J. Brooks, A. Carra, R. Claudino, E. Comini-Frota, E. Correa, A. Damasceno, B. Damasceno, E. Dias, D. Vizcarra-Escobar, A. Fiore, C. Franco, M. Giacomo, S. Gomes, M. Goncalves, A. Grzesiuk, J. Inojosa, D. Kaimen-Maciel, K. Lin, G. Lourenco, A. Martinez, M. Melcon, N. Morales, R. Morales, M. Moreira, S. Moreira, C. Oliveira, F. Oliveira, J. Ribeiro, S. Ribeiro, C. Rodriguez, L. Russo, J. Safanelli, K. Shearer, F. Siquineli (Santos, Săo Paulo, BR; Lima, PE; Rio de Janeiro, Curitiba, BR; Buenos Aires, AR; Florianópolis, Belo Horizonte, Brasilia, Campinas, BR; Santiago, CL; Recife, Sao Bernardo do Campo, Joinville, Cuiaba, Londrina, BR; Uberlandia, Juiz de Fora, Uberaba, BR; Aberdeen, GB; Blumenau, BR)
15:30 - 17:00 Grey matter damage in MS
Phenotyping multiple sclerosis; clinical relevance of combining MRI features of inflammation and degeneration P 780
E.M.M. Strijbis, J.J.G. Geurts, Y. Naegelin, L. Kappos, E.W. Radue, F. Barkhof, B.M.J. Uitdehaag, C.H. Polman (Amsterdam, NL; Basel, CH)
15:30 - 17:00 Genetics / transcriptomics
Multiple sclerosis risk genotypes correlate with elevated cerebrospinal fluid levels of the suggestive prognostic marker CXCL13 P 798
M. Lindén, M. Khademi, I. Lima Bomfim, F. Piehl, M. Jagodic, I. Kockum, T. Olsson (Stockholm, SE)
15:30 - 17:00 Diagnosis and differential diagnosis
A novel mutation of adult-onset Alexander disease mimics CNS demyelinating disease P 641
C. Costanzi, N. De Rossi, R. Capra (Brescia, IT)
15:30 - 17:00 Immunomodulation
The selective sphingosine 1-phosphate receptor modulator siponimod (BAF312): magnetic resonance imaging lesion and lymphocyte relationship in a phase 2 study in relapsing-remitting multiple sclerosis P 934
H.-P. Hartung, E. Pigeolet, D. Li, B. Hemmer, L. Kappos, M.S. Freedman, O. Stüve, P. Rieckmann, X. Montalban, T. Ziemssen, L. Zhang-Auberson, E. Wallström, K. Selmaj (Düsseldorf, DE; Basel, CH; Vancouver, CA; Munich, DE; Ottawa, CA; Dallas, US; Bamberg, DE; Barcelona, ES; Dresden, DE; Lodz, PL)
15:30 - 17:00 Experimental models
Magnetic resonance imaging characterisation of the therapeutic effect of glatiramer acetate in different models of experimental autoimmune encephalomyelitis P 782
R. Aharoni, E. Sason, T. Katzir, M. Sela, Y. Asssaf, R. Arnon (Rehovot, Ramat Gan, Tel Aviv, IL)
15:30 - 17:00 Paediatric MS
Subcutaneous interferon-beta-1a in paediatric patients with multiple sclerosis: regional outcomes in an international retrospective study (REPLAY) P 677
L.B. Krupp, D. Pohl, A. Ghezzi, A. Boyko, S. Tenembaum, M. Meinel, M. Stam Moraga, C. McIIroy, L. Lehr, B. Banwell on behalf of the REPLAY Study Group
15:30 - 17:00 Immunosuppression
Mycophenolate mofetil – an underestimated MS rescue treatment? P 955
I. Marques, S. Batista, J. Sargento-Freitas, C. Macário, F. Matias, L. Sousa (Coimbra, PT)
15:30 - 17:00 Neuropsychology and fatigue
Longitudinal assessment of attention and cognitive functions related to fronto-temporal circuits in relapsing-remitting multiple sclerosis 6-year follow-up P 891
A. Fuchs, S. Schlegel, M. Lang, M. Freidel, W. Hofmann, W. Elias, G. Reifschneider, S. Ries, B. Bühler, A. Bergmann, I. Uttner, C. Ring, I.K. Penner, H. Schreiber on behalf of the NTD Study Group on Multiple Sclerosis
15:30 - 17:00 Biomarkers
Cerebrospinal fluid levels of IL-1beta correlate with inflammatory cortical lesions in early stages of multiple sclerosis P 1076
P. Gallo, M. Puthenparampil, L. Federle, D. Seppi, S. Miante, V. Poretto, S. Alessio, M. Calabrese (Padua, IT)
15:30 - 17:00 Neuro-ophthalmology
Optical coherence tomography in MS: correlation with proton magnetic resonance spectroscopy P 1059
M. Siger, K. Dziegielewski, J. Nawrocki, K. Selmaj (Lodz, PL)
15:30 - 17:00 Epidemiology
A 10-year population-based cohort of patients from Brittany (France) having started Putative Incident Multiple Sclerosis (PIMS) in 2000-2001 P 696
A. Kerbrat, J. Yaouanq, E. Leray, S. Hamonic, I. Tron, G. Edan on behalf of the Collčge InterRégional des Neurologues de l’Ouest (CIRNO) and Association des Neurologues Libéraux de Langue Française (ANLLF)
15:30 - 17:00 Comprehensive care and rehabilitation
Blind randomised controlled study of the efficacy of attentional cognitive rehabilitation in multiple sclerosis as measured by fMRI P 1041
G. Mangone, A. Cerasa, P. Valentino, M.C. Gioia, C. Chiriaco, D. Pirritano, R. Nisticň, M. Trotta, F. Rocca, P. Perrotta, A. Augimeri, T. Talarico, G. Bilotti, A. Quattrone (Catanzaro, IT)
15:30 - 17:00 Grey matter damage in MS
Deficits in memory and spatial cognition correlate with regional hippocampal atrophy in multiple sclerosis P 777
M.A. Rocca, G. Longoni, E. Pagani, G. Riccitelli, B. Colombo, M. Rodegher, G. Comi, M. Filippi (Milan, IT)
15:30 - 17:00 Long-term treatment monitoring
Efficacy of DMD in reducing the accumulation of cortical damage. A 4-year longitudinal study P 978
M. Calabrese, F. Rinaldi, V. Poretto, S. Alessio, S. Miante, A. Favaretto, M. Puthenparampil, L. Federle, P. Perini, P. Gallo (Padua, IT)
15:30 - 17:00 Long-term treatment monitoring
Phase III FREEDOMS study extension: fingolimod (FTY720) efficacy in patients with relapsing–remitting multiple sclerosis receiving continuous or placebo-fingolimod switched therapy for up to 4 years P 979
L. Kappos, E.W. Radue, P. O'Connor, C.H. Polman, R. Hohlfeld, K. Selmaj, C. Agoropoulou, F. Holdbrook, P. von Rosenstiel, L. Zhang-Auberson (Basel, CH; Toronto, CA; Amsterdam, NL; Munich, DE; Lodz, PL)
15:30 - 17:00 Imaging
Regional hippocampal involvement differs across multiple sclerosis clinical phenotypes: evidences from a radial mapping MR-based study P 860
M. Filippi, M.A. Rocca, G. Longoni, E. Pagani, B. Colombo, M. Rodegher, G. Comi (Milan, IT)
15:30 - 17:00 Genetics / transcriptomics
Gene variants in interferon regulatory factor 5 regulate the endogenous type 1 interferon-response in multiple sclerosis P 800
H.B. Sřndergaard, A.B. Oturai, P. Soelberg Sřrensen, F. Sellebjerg (Copenhagen, DK)
15:30 - 17:00 Immunomodulation
MEDI-551, a novel antibody that depletes CD19+ B-cells: rationale for clinical development In multiple sclerosis P 910
L. Carter, V. Knappertz, Y. Wang, C. Groves, E. Ward, S. Gallagher, I. Yusuf, J. Karnell, B. Rajan, R. Ettinger, R. Herbst (Gaithersburg, US)
15:30 - 17:00 Imaging
Relation of baseline cortical blood flow and whole-brain volume reduction over five years P 871
M. Amann, K. Weier, Y. Naegelin, J. G. Hirsch, J. Reinhardt, J. Gregori, M. Günther, E.W. Radue, L. Kappos, A. Gass, C. Stippich, T. Sprenger (Basel, CH; Bremen, DE)
15:30 - 17:00 Neuro-ophthalmology
Microcystic macular oedema in multiple sclerosis P 1066
L. Balk, J. Killestein, B. Uitdehaag, C. Polman, A. Petzold (Amsterdam, NL)
15:30 - 17:00 Neuropsychology and fatigue
Relationship between self-efficacy and cognitive performance in clinically isolated syndrome and early relapsing-remitting multiple sclerosis P 907
P. Jongen, K. Wesnes, B. Van Geel, P. Pop, E. Sanders, H. Schrijver, L. Visser, J. Gilhuis, O. Sinnige, A. Brands (Nijmegen, NL; Goring, GB; Alkmaar, Venray, Breda, Hoorn, Tilburg, Delft, Leeuwarden, Utrecht, NL)
15:30 - 17:00 Imaging
Detecting evolving white matter MS lesions in serial brain MRI studies: analysis of a subtraction approach P 853
O. Ganiler, X. Lladó, A. Oliver, Y. Díez, J. Freixenet, J.C. Vilanova, A. Quiles, G. Laguillo, L. Ramió-Torrentŕ, D. Pareto, A. Rovira (Girona, Barcelona, ES)
15:30 - 17:00 Neurophysiology
Clinical disability in MS correlates with resting-state oscillatory brain activity: an MEG source-space study P 882
M.L. vd Meer, P. Tewarie, M.M. Schoonheim, L. Douw, F. Barkhof, C.H. Polman, C.J. Stam, A. Hillebrand (Amsterdam, NL)
15:30 - 17:00 Imaging
Registration of serial brain MRI scans from multiple sclerosis patients. Analysis of 3D intensity-based methods P 852
Y. Díez, X. Lladó, A. Oliver, R. Martí, E. Roura, M. Cabezas, O. Ganiler, J. Freixenet, J.C. Vilanova, L. Valls, L. Ramió-Torrentŕ, D. Pareto, A. Rovira (Girona, Barcelona, ES)
15:30 - 17:00 Immunomodulation
Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis P 946
L. Börnsen, J. Romme Christensen, R. Ratzer, A. Bang Oturai, P. Soelberg Sřrensen, H. Bach Sřndergaard, F. Sellebjerg (Copenhagen, DK)
15:30 - 17:00 Comprehensive care and rehabilitation
Effects of different physical activities on the walking capacity for people with MS P 1039
C. Jolk, R. Alcantara, L. Bernhardt, P. Platen, M. Marziniak, K. Weßling (Münster, DE)
15:30 - 17:00 Grey matter damage in MS
Cortical pathology in Caucasian multiplex MS families of the Veneto region, Italy P 776
M. Calabrese, V. Bernardi, E. Cocco, D. Seppi, V. Poretto, A. Favaretto, S. Alessio, S. Miante, F. Rinaldi, P. Perini, P. Gallo (Padua, Cagliari, IT)
15:30 - 17:00 Neurobiology
Functional genomic analysis of cuprizone-induced demyelination reveals the importance of oligodendrocytes for MS lesion formation P 836
K. Berger, B. Krauspe, W. Baumgartner, M. Rickert, T. Clarner, J.-P. Buschmann, C. Beutner, B. Linnartz, H. Neumann, L. Valliéres, C. Beyer, M. Kipp (Aachen, Bonn, DE; Quebec, CA)
15:30 - 17:00 Immunomodulation
Teriflunomide treatment of human monocyte-derived dendritic cells in vitro does not impair their maturation or ability to induce allogeneic T -cell responses P 950
L. Li, J. Liu, D. Zhang, C. Jones (Bridgewater, US)
15:30 - 17:00 Tools for detecting therapeutic response
Magnetic resonance imaging as a surrogate for clinical endpoints in multiple sclerosis P 1014
M.P. Sormani, J.S. Wolinksy, L. Wang, P. Truffinet, P.A. Narayana, F. Nelson, P. O'Connor for the TEriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group
15:30 - 17:00 Risk management for disease modifying treatments
Effect of teriflunomide on lymphocyte and neutrophil levels in patients with relapsing multiple sclerosis: results from the TEMSO study P 995
G. Comi, H. Benzerdjeb, L. Wang, P. Truffinet, P. O'Connor (Milan, IT; Chilly Mazarin, FR; Bridgewater, US; Toronto, CA)
15:30 - 17:00 Imaging
A Voxel-based assessment of cervical cord damage in MS patients P 859
M.A. Rocca, P. Valsasina, D. Damjanovic, S. Mesaros, M.A. Horsfield, T. Stosic-Opincal, J. Drulovic, G. Comi, M. Filippi (Milan, IT; Belgrade, RS; Leicester, GB)
15:30 - 17:00 Imaging
Longitudinal prediction of cognition in multiple sclerosis P 845
M.M. Schoonheim, V. Popescu, H. Vrenken, C.H. Polman, J.J.G. Geurts, F. Barkhof (Amsterdam, NL)
15:30 - 17:00 Imaging
Alterated resting state fMRI connectivity in thalamic networks correlates with cognitive impairment in multiple sclerosis P 857
F. Tona, N. Petsas, E. Sbardella, L. Prosperini, M. Carmellini, C. Pozzilli, P. Pantano (Rome, IT)
15:30 - 17:00 Adaptative and Innate immunology
Inflammatory response of endothelial cells to an endogenous retrovirus associated to MS is mediated by TLR4 P 806
D. Barbe, G. Raguenez, H. Perron, P.N. Marche, A. Duperray (Grenoble, Lyon, FR)
15:30 - 17:00 Tools for detecting therapeutic response
Early development of natalizumab antibodies in MS patients P 1016
B. Oliver-Martos, P. Urbaneja, T. Órpez- Zafra, C. Arnaiz, M.-J. Pinto-Medel, C. López- Gómez, J.-A. García-León, M. Suardíaz, C. Bańasco, R. Maldonado-Sánchez, L. Leyva, Ó. Fernández (Malaga, ES)
15:30 - 17:00 Immunomodulation
The “Immunomodulation and Multiple Sclerosis Epidemiology” (IMSE) study; A Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of natalizumab (Tysabri) P 945
C. Holmén, F. Piehl, J. Hillert, P. Nilsson, C. Dahle, N. Feltelius, A. Svenningsson, J. Lycke, J. Fagius, F. Wallentin, C. Martin, T. Olsson (Stockholm, Lund, Linköping, Uppsala, Umeĺ, Gothenburg, Örebro, SE)
15:30 - 17:00 Epidemiology
Aquaporin-4 antibodies in Korean patients with idiopathic inflammatory demyelinating diseases of the central nervous system P 715
H.R. Yang, S.M. Kim, P. Waters, M. Woodhall, S.W. Ahn, K.K. Kim, S.Y. Pyun, J.E. Kim, J.S. Kim, J.J. Sung, K.S. Park, K.W. Lee (Gyeonggi-do, Seoul, KR; Oxford, GB)
15:30 - 17:00 Neuroprotection
KATP channel opener NT-KO-003 mediates neuroprotection by a novel mechanism of action and induces beneficial effects in a murine model of multiple sclerosis P 960
N. Virgili, P. Mancera, A. Pastén-Zamorano, B. Wappenhans, G. Sorrosal, M. De Frias, C. Campŕs, J. Bustos, M. Pugliese, J.F. Espinosa-Parrilla (Barcelona, ES)
15:30 - 17:00 Adaptative and Innate immunology
Regulatory T-cells unequally inhibit Ca2+ signalling in conventional T-cells: nonsuppressors determine the treg defect in multiple sclerosis P 808
A. Schwarz, J. Haas, M. Schumacher, D. Pfaff, K. Schumacher, S. Jarius, B. Wildemann (Heidelberg, DE)
15:30 - 17:00 Clinical assessment tools
Do motor impairments detected on onset of multiple sclerosis suggest an early second attack? P 741
A. Kalron, Z. Dvir, A. Achiron (Tel-Hashomer, Tel-Aviv, IL)
15:30 - 17:00 Imaging
Cortical-juxtacortical lesions in clinically isolated syndromes: distribution and diagnostic value P 854
D. Pareto, C. Auger, A. Pla, R. Mitjana, M. Tintoré, J.F. Corral, X. Montalban, A. Rovira (Barcelona, ES)
15:30 - 17:00 Experimental models
DMF treatment prevents cellular infiltration and reduces the frequency of IFN[gamma]-positive CD4-T-lymphocytes in EAE spinal cords P 797
B.T. Wipke*, P. Bista*, A. Thomas, W. Zeng, K. Fu, M.N. Shackett, D. Huss, R.H. Scannevin, M. Lukashev (Weston, US)
15:30 - 17:00 Immunomodulation
Modulation of dendritic cell chemokine secretion and migration by laquinimod P 933
F. Luessi, S. Kraus, V. Jolivel, M. Hubo, V. Siffrin, H. Jonuleit, A. Waisman, F. Zipp (Mainz, DE)
15:30 - 17:00 Risk management for disease modifying treatments
Natalizumab discontinuation in clinical practice: a systematic observational study from the national TYSEDMUS cohort of 577 multiple sclerosis patients treated with natalizumab in France P 1004
C. Papeix, S. Vukusic, N. Passante, I. Ionescu, B. Frangoulis, B. Stankoff, S. Oporto, S. Mrejen, E. Van ganse, F. Rocher, A. Castot, M. Clanet, C. Lubetzki, C. Confavreux on behalf of the TYSEDMUS Group
15:30 - 17:00 Immunomodulation
Bradycardia induced by intravenous methylprednisolone treatment in relapsing-remitting multiple sclerosis patients during acute relapse P 948
M. Dolev, D. Elian, D. Magalashvili, H. Raz, A. Achiron (Rama-Gan, IL)
15:30 - 17:00 Imaging
Regional changes in tissue sodium concentration in relapsing-remitting and secondary progressive MS P 851
D. Paling, B. Solanky, F. Riemer, C. Wheeler-Kingshott, X. Golay, R. Kapoor, D. Miller (London, GB)
15:30 - 17:00 Quality of life
Correlation between quality of life and spasticity in Spanish patients with multiple sclerosis using two different spasticity scales: The CANDLE Study P 1045
R. Arroyo, D. González-Segura, M. Viladrich on behalf of the CANDLE Study Collaborative Group
15:30 - 17:00 Databases and Pharmacoepidemiology
Propensity score matching in large observational databases: a virtual trial comparing two doses of interferon-beta-1a SC in MSBase P 720
T. Kalincik, T. Spelman, H. Butzkueven on behalf of the MSBase Investigators
15:30 - 17:00 Treatment of specific symptoms
Drug treatment of spasticity in multiple sclerosis – a cross-sectional survey in Germany P 1029
P. Flachenecker, U. Zettl, U. Essner, T. Henze (Bad Wildbad, Rostock, Reinbek, Nittenau, DE)
15:30 - 17:00 Immunomodulation
Clinical efficacy of anti-IL-6 receptor monoclonal antibody tocilizumab in three patients with neuromyelitis optica P 918
M. Araki, T. Aranami, T. Matsuoka, M. Nakamura, T. Okamoto, M. Murata, S. Miyake, T. Yamamura (Kodaira, Tokyo, JP)
15:30 - 17:00 Quality of life
Dynamics of happiness and personal growth in multiple sclerosis patients treated with interferon-beta-1a compared with healthy subjects P 1046
D. Mazeh, Y. Barak, A. Achiron (Tel Hashomer, IL)
15:30 - 17:00 Devic’s NMO spectrum
Anti-Ro/SSA antibody and anti-aquaporin4-antibody in neuromyelitis optica spectrum disorder P 669
J.H. Park, J. Hwang, D. Lee, J.H. Min, B.J. Kim, E.S. Kang, K.H. Lee (Seoul, KR)
15:30 - 17:00 Clinical assessment tools
Does inclusion of visual contrast acuity testing increase the informative value of the Multiple Sclerosis Functional Composite (MSFC)? P 752
A.U. Brandt, J. Schinzel, K. Stoesslein, F. Paul, J. Dörr (Berlin, DE)
15:30 - 17:00 Long-term treatment monitoring
Second-line use of Fingolimod in RRMS is as effective as natalizumab P 975
S. Braune on behalf of the NTD Study Group
15:30 - 17:00 Immunomodulation
Effects of BG-12 on magnetic resonance imaging outcomes in relapsing–remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies P 920
D. H. Miller, R. Gold, R. J. Fox, D. MacManus, T. Yousry, A. Bar-Or, R. Zhang, V. Viglietta, M. Stephan, K. T. Dawson, D. L. Arnold (London, GB; Bochum, DE; Cleveland, US; Montreal, CA; Weston, US)
15:30 - 17:00 Imaging
Perfusion and permeability MR imaging in differentiating tumefactive demyelinating lesions from high-grade gliomas P 855
A. Rovira, S. Cavalletto, P. Alcaide, C. Auger, J. Sastre-Garriga, E. Huerga, X. Montalban (Barcelona, ES)
15:30 - 17:00 Biomarkers
CSF neural cell adhesion molecule in relation to 3T MRI-metrics in early multiple sclerosis P 1070
M. Khalil, C. Enzinger, C. Langkammer, S. Ropele, A. Mader, M. Wallner-Blazek, G. Bachmaier, J. Archelos-Garcia, S. Fuchs, M.A. Blankenstein, F. Fazekas, C.E. Teunissen (Graz, AT; Amsterdam, NL)
15:30 - 17:30 MS symptoms
PIEVII 59/69: semiology of urinary tracts infections in MS patients who don’t use clean intermittent catheterisation P 731
C. Donzé, S. Demaille, P. Hautecoeur, V. Neuville, S. Vukusic, M.C. Scheiber Nogueira (Lomme, Lille, Maubeuge, Lyon, FR)
15:30 - 17:30 MS symptoms
Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing–remitting multiple sclerosis: results from the phase 3 FREEDOMS II study P 724
E.-W. Radue, D. Goodin, D. Jeffery, L. Kappos, F.D. Lublin, K. Rammohan, A.T. Reder, T. Vollmer, M.A. Agius, L. Cappiello, T. Stites, B.B. Li, M. Malhotra, P. von Rosenstiel, P.A. Calabresi (Basel, CH; San Francisco, North Carolina, US; New York, Miami, Chicago, Aurora, Davis, East Hanover, US; Baltimore, US)
15:30 - 17:30 MS symptoms
Symptom profiles of individuals with multiple sclerosis grouped by levels of social support P 722
K. Johnson, D. Amtmann, A. Verrall, V. Weir, A. Smith (Seattle, US)
15:30 - 17:30 MS symptoms
Impact of spasticity on healthcare resource utilisation: results of a cross-sectional study in the USA P 721
R. Schapiro, D. Wynn, D. Lissin, A. AL-Sabbagh, E. Jones, J. Pike (Eagle, Northbrook, Santa Clara, US; Macclesfield, GB)
15:30 - 17:30 MS symptoms
The clinical characteristics of multiple sclerosis in Maori are homogeneous with that of the national cohort P 728
S. Alla, J. Pearson, G. Clarke, B. Taylor, D. Mason (Christchurch, NZ; Tasmania, AU)
15:30 - 17:30 MS symptoms
A survey of patients with multiple sclerosis in Japan P 723
T. Ohashi, S. Kurata, M. Kobayashi (Chiba, JP)
15:30 - 17:30 MS symptoms
Brain MRI correlates of cognitive function in early treated MS and clinically isolated syndrome P 729
M. Cohen, H. Joly, B. Brochet, P. Clavelou, E. Lepage, P. Vermersch, C. Lebrun on behalf of Qualicis Study Group
15:30 - 17:30 MS symptoms
Sexual disorders evaluation among people with multiple sclerosis: features and clinical correlations P 725
C. Cornut-Chauvinc, M. Lauxerois, P. Clavelou on behalf of the Reseau SEP Auvergne
15:30 - 17:30 MS symptoms
PIEVII 59/69: semiology of urinary tracts infections in MS patients with clean intermittent catheterisation P 727
M.C. Scheiber-Nogueira, C. Donzé, H. Hautecoeur, V. Neuville, S. Vukusic, S. Demaille (Lyon, Lomme, Lille, Maubeuge, FR)
15:30 - 17:30 MS symptoms
Interest of a programme of rehabilitation training on bicycle ergometer at home on fatigue in MS P 726
R. Colamarino, P. Givron, F. Taithe, B. Pereira, A. Vieuxrochas, C. Collange, E. Coudeyre (Vichy, Clermont-Ferrand, Chamaliéres, Beaumont, FR)
15:30 - 17:30 MS symptoms
Disability scale in multiple sclerosis and gait profile: a direct correlation P 730
B. Heredia Camacho, A. Hochsprung, M. Castillo, G. Izquierdo (Seville, ES)
17:00 - 17:15 Imaging and cognition (Auditorium Lumičre)
Morphological imaging 154
N. De Stefano (Siena, IT)
17:00 - 17:15 Paediatric MS (Forum 2 & 3)
The spectrum of paediatric MS and related disorders 157
Y. Mikaeloff (Paris, FR)
17:00 - 17:15 Symptomatic treatments (Amphitheatre)
Pitfalls in assessing symptomatic treatments 160
B. Uitdehaag (Amsterdam, NL)
17:15 - 17:30 Symptomatic treatments (Amphitheatre)
Cannabinoids, symptomatic or disease modifying? 161
J.P. Zajicek (Plymouth, GB)
17:15 - 17:30 Paediatric MS (Forum 2 & 3)
Disease-modifying treatments in paediatric MS 158
B. Banwell (Toronto, CA)
17:30 - 17:45 Paediatric MS (Forum 2 & 3)
Multiple sclerosis genetic susceptibility factors rs4648356 and rs11154801 are associated with relapse rate in paediatric patients 159
J. Graves, L. Barcellos, L. Krupp, A. Belman, E. Waubant (San Francisco, Berkeley, Stony Brook, US)
17:30 - 17:45 Imaging and cognition (Auditorium Lumičre)
Relative contribution of thalamus volume and diffusion tensor metrics to cognitive impairment in multiple sclerosis 156
R. Benedict, H.E. Hulst, N. Bergland, M. Schoonheim, M. Dwyer, B. Weinstock-Guttman, J. Geurts, R. Zivadinov (Buffalo, US; Amsterdam, NL)
17:30 - 17:45 Symptomatic treatments (Amphitheatre)
Walking improvement after deep rTMS with H-coil associated with rehabilitation in patients with progressive multiple sclerosis: a randomised, controlled, double-blind study 162
L. Leocani, A. Formenti, A. Nuara, P. Rossi, F. Martinelli Boneschi, A. Zangen, M. Comola, G. Comi (Milan, IT)
18:20 - 18:35 Biogen Idec: Committed to MS (Amphitheatre)
Targeting the demyelinated axons in MS 164
H.-P. Hartung (Düsseldorf, DE)
18:35 - 18:55 Biogen Idec: Committed to MS (Amphitheatre)
Current treatments and new perspectives for MS treatment 165
D. Miller (London, GB)

Saturday, October 13, 2012

08:30 - 08:45 Late Breaking News II (Forum 2 & 3)
A phase 3 trial to assess the efficacy and safety of glatiramer acetate injections 40mg administered 3 times a week compared to placebo 166
O. Khan, P. Rieckmann, A. Boyko, K. Selmaj, R. Zivadinov (Detroit, US; Bamberg/Erlangen, DE; Moscow, RU; Lodz, PL; Buffalo, US)
08:45 - 09:00 Late Breaking News II (Forum 2 & 3)
Chronic Cerebro-Spinal Venous Insufficiency (CCSVI) and global venous haemodynamics in multiple sclerosis: the CoSMo study 167
G. Comi, M.A. Battaglia, A. Bertolotto, M. Del Sette, A. Ghezzi, G. Malferrari, M. Salvetti, M. Sormani, E. Stolz, L. Tesio, G.L. Mancardi on behalf of the CoSMo study group
09:00 - 09:15 Late Breaking News II (Forum 2 & 3)
Positive proof of concept of AIN457, an antibody against interleukin-17A, in relapsing-remitting multiple sclerosis 168
E. Havrdová, A. Belova, A. Goloborodko, A. Tisserant, I. Jones, H. Garren, D. Johns , AIN457 for MS Study Group
09:15 - 09:30 Late Breaking News II (Forum 2 & 3)
Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis 169
G. Giovannoni, R. Gold, K. Selmaj, E. Havrdova, X. Montalban, E.-W. Radue, D. Stefoski, M. McNeill, J. Rana, J. Elkins, G. O’Neill (London, GB; Bochum, DE; Lodz, PL; Prague, CZ; Barcelona, ES; Basel, CH; Chicago, US; Maidenhead, GB; Cambridge, US)
09:30 - 09:45 Late Breaking News II (Forum 2 & 3)
Natalizumab treatment of progressive multiple sclerosis reduces inflammation and tissue damage - results of a phase 2A proof-of-concept study 170
J. Romme Christensen, R. Ratzer, L. Börnsen, E. Garde, M. Lyksborg, H.R. Siebner, T.B. Dyrby, P.S. Sřrensen, F. Sellebjerg (Copenhagen, Hvidovre, DK)
09:45 - 10:00 Late Breaking News II (Forum 2 & 3)
Efficacy and safety of oral contraceptives as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a multicenter, randomized investigator-run clinical trial 171
C. Pozzilli, L. De Giglio, V. Barletta, F. Marinelli, F. De Angelis, V. Gallo, V.A. Pagano, M.A. Bassano, M.C. Piattella, V. Tomassini, P. Pantano (Rome, IT)
10:30 - 10:50 Closing Session (Forum 2 & 3)
Devic’s neuromyelitis optica: What it is, what it isn’t and why it’s hard to be sure 172
B.G. Weinshenker (Rochester, US)
10:50 - 11:10 Closing Session (Forum 2 & 3)
Treatments highlights 173
G. Giovannoni (London, GB)
11:30 - 12:25 Closing Session (Forum 2 & 3)
Presentation of selected poster awards, awards for best oral presentations by young researchers and the MSIF award 175
M. Clanet, M. Trojano (Toulouse, FR; Bari, IT)
12:25 - 12:30 Closing Session (Forum 2 & 3)
Welcome to Copenhagen 176
P. Soelberg-Sřrensen (Copenhagen, DK)